Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 1342 articles:
HTML format



Single Articles


    July 2021
  1. LIU G, Wang N, Zhang C, Li M, et al
    ALDOB depletion promotes hepatocellular carcinogenesis through activating insulin receptor signaling and lipogenesis.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32064.
    PubMed     Abstract available


  2. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
    Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
    PubMed     Abstract available


  3. HU M, Zhang D, Xu H, Zhang Y, et al
    Salidroside activates the AMP-activated protein kinase pathway to suppress non-alcoholic steatohepatitis.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32066.
    PubMed     Abstract available


  4. HE Q, Liu M, Huang W, Chen X, et al
    IL-1beta-induced Elevation of SLC7A11 Promotes Hepatocellular Carcinoma Metastasis through Upregulating PD-L1 and CSF1.
    Hepatology. 2021 Jul 20. doi: 10.1002/hep.32062.
    PubMed     Abstract available


  5. YANG Q, Chen X, Zhang Y, Hu S, et al
    The E3 ubiquitin ligase RNF5 ameliorates nonalcoholic steatohepatitis via ubiquitin-mediated degradation of HRD1.
    Hepatology. 2021 Jul 17. doi: 10.1002/hep.32061.
    PubMed     Abstract available


  6. PIANO S, Cardenas A
    Metabolomics to predict acute kidney injury in cirrhosis.
    Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
    PubMed     Abstract available


  7. MILLER BM, Oderberg IM, Goessling W
    The Hepatic Nervous System in Development, Regeneration, and Disease.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32055.
    PubMed     Abstract available


  8. ZHENG J, Daniel CR, Hatia RI, Stuff J, et al
    Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A US-Based Study.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32046.
    PubMed     Abstract available


  9. LAI JC, Tandon P, Bernal W, Tapper EB, et al
    Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
    PubMed     Abstract available


  10. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    PubMed     Abstract available


  11. CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
    Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
    PubMed     Abstract available


    June 2021
  12. FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
    NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
    Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
    PubMed     Abstract available


  13. GARATE-RASCON M, Recalde M, Jimenez M, Elizalde M, et al
    SLU7 prevents oxidative stress-mediated HNF4alpha degradation preserving hepatic differentiation and protecting from liver damage.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32029.
    PubMed     Abstract available


  14. HIRAO H, Ito T, Kadono K, Kojima H, et al
    Donor Hepatic Occult Collagen Deposition Predisposes to Peri-transplant Stress and Impacts Human Liver Transplantation.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32030.
    PubMed     Abstract available


  15. KRIEGERMEIER A, Hyon A, Sommars M, Hubchak S, et al
    Hepatic X-box binding protein 1 and unfolded protein response is impaired in weanling mice with resultant hepatic injury.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32031.
    PubMed     Abstract available


  16. CHOLANKERIL G, Kanwal F
    Nonalcoholic fatty liver disease and Hepatocellular Carcinoma: Time to Bridge the Gap.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32025.
    PubMed     Abstract available


  17. TORRENS L, Montironi C, Puigvehi M, Mesropian A, et al
    Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma.
    Hepatology. 2021 Jun 22. doi: 10.1002/hep.32023.
    PubMed     Abstract available


  18. LIU H, Lee SS
    Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
    Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
    PubMed     Abstract available


  19. JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
    Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
    Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
    PubMed     Abstract available


  20. SHI YF, Xie WZ
    Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
    PubMed     Abstract available


  21. MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
    Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
    PubMed     Abstract available


  22. LEE YT, Wang JJ, Luu M, Noureddin M, et al
    Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
    PubMed     Abstract available


  23. JINDAL A, Sharma S
    Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
    PubMed     Abstract available


  24. SOLIPURAM V, Baretti M, Kim AY, Chen LX, et al
    Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31998.
    PubMed     Abstract available


  25. SHAH V, Iwakiri Y, Boyer JL
    Obituary for Roberto J. Groszmann - the Father of Portal Hypertension.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31996.
    PubMed     Abstract available


  26. KOZUMI K, Kodama T, Murai H, Sakane S, et al
    Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31995.
    PubMed     Abstract available


  27. CHO K, Ro SW, Lee HW, Moon H, et al
    YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation.
    Hepatology. 2021 Jun 8. doi: 10.1002/hep.32000.
    PubMed     Abstract available


  28. CHEN B, Wu JX, Cheng SH, Wang LM, et al
    Phase II study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31993.
    PubMed     Abstract available


  29. JINDAL A, Jagdish RK
    Response to terlipressin plus albumin in Hepatorenal syndrome - Need a closer look!
    Hepatology. 2021 Jun 6. doi: 10.1002/hep.31990.
    PubMed     Abstract available


  30. WONG TC, Lee VH, Law AL, Pang HH, et al
    Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
    Hepatology. 2021 Jun 6. doi: 10.1002/hep.31992.
    PubMed     Abstract available


  31. YANG W, He H, Wang T, Su N, et al
    Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis.
    Hepatology. 2021 Jun 5. doi: 10.1002/hep.31987.
    PubMed     Abstract available


  32. MUHAMMAD KHAN M, Alejandra Luna-Cuadros M, Lau DTY, Sehrawat TS, et al
    Hepatology Highlights.
    Hepatology. 2021;73:2085-2088.
    PubMed    


    May 2021
  33. VIVEIROS A, Schaefer B, Panzer M, Henninger B, et al
    MRI-based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of non-HFE Hemochromatosis Genes.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31982.
    PubMed     Abstract available


  34. LEPORE A, Choy PM, Lee NC, Carella MA, et al
    Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
    PubMed     Abstract available


  35. JOHNSTON ME 2ND, Rivas MP, Nicolle D, Gorse A, et al
    Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient Derived Xenograft Models.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31919.
    PubMed     Abstract available


  36. YI C, Chen L, Ling Z, Liu L, et al
    Lenvatinib Targets FGFR4 to Enhance Antitumor Immune Response of Anti-PD-1 in Hepatocellular Carcinoma.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31921.
    PubMed     Abstract available


  37. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    PubMed     Abstract available


  38. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    PubMed     Abstract available


  39. MEHTA G, Jalan R
    The 'Alter Ego' of Albumin in Cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
    PubMed     Abstract available


  40. BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
    Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
    PubMed     Abstract available


  41. JANSSON H, Sparrelid E
    Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
    PubMed     Abstract available


  42. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
    Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
    PubMed     Abstract available


  43. PEISELER M, Tacke F
    An unexpected line of defense: hepatoprotective eosinophils in ischemia-reperfusion injury.
    Hepatology. 2021 May 11. doi: 10.1002/hep.31895.
    PubMed     Abstract available


  44. VALSAN A, Verma N, Singh V
    Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
    Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
    PubMed     Abstract available


  45. ELKRIEF L, Lazareth M, Rautou PE
    Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
    Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
    PubMed     Abstract available


  46. DICHTEL LE
    The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis.
    Hepatology. 2021 May 6. doi: 10.1002/hep.31886.
    PubMed     Abstract available


  47. BIGGINS SW, Angeli P, Garcia-Tsao G, Gines P, et al
    Diagnosis, evaluation, and management of ascites and hepatorenal syndrome.
    Hepatology. 2021 May 3. doi: 10.1002/hep.31884.
    PubMed     Abstract available


  48. LIU Y, Dou X, Zhou WY, Ding M, et al
    Hepatic SENP2 Controls Systemic Metabolism via SUMOylation-dependent Regulation of Liver-Adipose Tissue Crosstalk.
    Hepatology. 2021 May 2. doi: 10.1002/hep.31881.
    PubMed     Abstract available


  49. BUCKHOLZ A, Jesudian A, Sehrawat TS, Sehrawat O, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1627-1630.
    PubMed    



  50. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    PubMed    


    April 2021
  51. SHENG J, Kohno S, Okada N, Okahashi N, et al
    Treatment of RB1-intact hepatocellular carcinoma with CDK4/6 inhibitor combination therapy.
    Hepatology. 2021 Apr 30. doi: 10.1002/hep.31872.
    PubMed     Abstract available


  52. BUCKARMA E, Smoot R
    Hepatocytes Induce Change in Their Neighbors by YAP-ing at Them.
    Hepatology. 2021 Apr 30. doi: 10.1002/hep.31874.
    PubMed     Abstract available


  53. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
    Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
    Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
    PubMed     Abstract available


  54. LUO Y, Gao Y, Liu W, Yang Y, et al
    MYC-Protein Arginine Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
    Hepatology. 2021 Apr 25. doi: 10.1002/hep.31864.
    PubMed     Abstract available


  55. YANG X, Sun D, Xiang H, Wang S, et al
    Hepatocyte SH3RF2 Deficiency is a Key Aggravator for Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021 Apr 24. doi: 10.1002/hep.31863.
    PubMed     Abstract available


  56. LIU D, Pang J, Shao W, Gu J, et al
    Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge.
    Hepatology. 2021 Apr 13. doi: 10.1002/hep.31856.
    PubMed     Abstract available


  57. XU X, Ye L, Zhang Q, Shen H, et al
    Group-2 Innate Lymphoid Cells Promote Hepatocellular Carcinoma Progression via CXCL2-Neutrophil Induced Immunosuppression.
    Hepatology. 2021 Apr 8. doi: 10.1002/hep.31855.
    PubMed     Abstract available


  58. SUN D, Yang X, Wu B, Zhang XJ, et al
    Therapeutic Potential of G Protein-Coupled Receptors against Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Apr 7. doi: 10.1002/hep.31852.
    PubMed     Abstract available


  59. WING-SUM CHEU J, Chak-Lui Wong C
    Mechanistic Rationales guiding Combination Hepatocellular Carcinoma Therapies involving Immune Checkpoint Inhibitors.
    Hepatology. 2021 Apr 3. doi: 10.1002/hep.31840.
    PubMed     Abstract available


  60. KOVALIC AJ, Huang G, Thuluvath PJ, Satapathy SK, et al
    Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis.
    Hepatology. 2021;73:1521-1530.
    PubMed     Abstract available


  61. FU Y, Zhu R, Bai T, Han P, et al
    Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study.
    Hepatology. 2021;73:1509-1520.
    PubMed     Abstract available


  62. KAUR SP, Trivedi H, Lau DTY, Bamidele AO, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1245-1247.
    PubMed    



  63. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    PubMed    


    March 2021
  64. NINA KIM H, Newcomb CW, Carbonari DM, Roy JA, et al
    Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31839.
    PubMed     Abstract available


  65. BOERNER T, Drill E, Pak LM, Nguyen B, et al
    Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
    PubMed     Abstract available


  66. DOURTHE C, Julien C, Di Tommaso S, Dupuy JW, et al
    Proteomic profiling of hepatocellular adenomas paves the way to new diagnostic and prognostic approaches.
    Hepatology. 2021 Mar 23. doi: 10.1002/hep.31826.
    PubMed     Abstract available


  67. BLOOM PP, Matherly S, Kumar S, Koh C, et al
    Professional Use of Social Media by Hepatology Providers.
    Hepatology. 2021 Mar 20. doi: 10.1002/hep.31824.
    PubMed     Abstract available


  68. SALEM R, Johnson GE, Kim E, Riaz A, et al
    Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
    PubMed     Abstract available


  69. YASUDO H, Ando T, Maehara A, Ando T, et al
    A possible association between a novel NLRP1 mutation and an autoinflammatory disease involving liver cirrhosis.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31818.
    PubMed     Abstract available


  70. ZHAO Y, Wang J, Liu WN, Fong SY, et al
    Analysis and validation of human targets and treatments using a hepatocellular carcinoma-immune humanized mouse model.
    Hepatology. 2021 Mar 18. doi: 10.1002/hep.31812.
    PubMed     Abstract available


  71. LEE YT, Wang JJ, Luu M, Tseng HR, et al
    State-Level Hepatocellular Carcinoma Incidence and Association with Obesity and Physical Activity in the United States.
    Hepatology. 2021 Mar 17. doi: 10.1002/hep.31811.
    PubMed     Abstract available


  72. WADA Y, Shimada M, Yamamura K, Toshima T, et al
    A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
    PubMed     Abstract available


  73. SANO A, Kakazu E, Hamada S, Inoue J, et al
    Steatotic hepatocytes release mature VLDL via methionine and tyrosine metabolism in a Keap1-Nrf2 dependent manner.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31808.
    PubMed     Abstract available


  74. ALEXOPOULOS AS, Crowley MJ, Wang Y, Moylan CA, et al
    Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31806.
    PubMed     Abstract available


  75. MEUNIER L, Hirsch TZ, Caruso S, Imbeaud S, et al
    DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes.
    Hepatology. 2021 Mar 13. doi: 10.1002/hep.31796.
    PubMed     Abstract available


  76. WU H, Xu X, Zheng A, Wang W, et al
    TIPE1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of ASK1.
    Hepatology. 2021 Mar 13. doi: 10.1002/hep.31801.
    PubMed     Abstract available


  77. BALDASSARRE M, Naldi M, Zaccherini G, Bartoletti M, et al
    Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications.
    Hepatology. 2021 Mar 12. doi: 10.1002/hep.31798.
    PubMed     Abstract available


  78. SATHIYAPALAN A, Legault K, van der Pol CB, Meyers BM, et al
    Paraneoplastic Polyarthritis in Hepatocellular Carcinoma Treated with Lenvatinib.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31794.
    PubMed     Abstract available


  79. SONG M, He J, Pan QZ, Yang J, et al
    Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression.
    Hepatology. 2021 Mar 8. doi: 10.1002/hep.31792.
    PubMed     Abstract available


  80. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    PubMed     Abstract available



  81. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    PubMed    


  82. HANIF H, Ali MJ, Chen HW, Lau DTY, et al
    Hepatology Highlights.
    Hepatology. 2021;73:877-880.
    PubMed    


  83. BLOOM PP, Meyerowitz EA, Reinus Z, Daidone M, et al
    Liver Biochemistries in Hospitalized Patients With COVID-19.
    Hepatology. 2021;73:890-900.
    PubMed     Abstract available


    February 2021
  84. NEWBERRY EP, Hall Z, Xie Y, Molitor EA, et al
    Liver specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis and hepatocellular cancer.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31771.
    PubMed     Abstract available


  85. CHIU M, Garabon J, Chen L, Karp N, et al
    Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
    PubMed     Abstract available


  86. SHIOTA J, Samuelson LC, Razumilava N
    Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
    PubMed     Abstract available


  87. SU T, Huang M, Liao J, Lin S, et al
    Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis through m(6) A mRNA Methylation Dependent Mechanism.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31766.
    PubMed     Abstract available


  88. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    PubMed     Abstract available


  89. HUANG DQ, Yeo YH, Nguyen MH
    Letter to the Editor: HCC surveillance in cirrhosis patients: Is the real-world situation even worse than reported?
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31760.
    PubMed     Abstract available


  90. RICH NE, Parikh ND, Singal AG
    HCC Surveillance in Cirrhosis Patients: Room for Improvement.
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31762.
    PubMed     Abstract available


  91. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
    Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
    PubMed     Abstract available


  92. BARROW F, Khan S, Fredrickson G, Wang H, et al
    Microbiota-Driven Activation of Intrahepatic B Cells Aggravates Nonalcoholic Steatohepatitis through Innate and Adaptive Signaling.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31755.
    PubMed     Abstract available


  93. QU C, He L, Yao N, Li J, et al
    Myofibroblast-specific Msi2 knockout inhibits hepatocellular carcinoma progression in a mouse model.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31754.
    PubMed     Abstract available


  94. LAN T, Yu Y, Zhang J, Li H, et al
    Cordycepin Ameliorates Nonalcoholic Steatohepatitis via Activation of AMP-Activated Protein Kinase Signaling Pathway.
    Hepatology. 2021 Feb 12. doi: 10.1002/hep.31749.
    PubMed     Abstract available


  95. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
    6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
    Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
    PubMed     Abstract available


  96. YOU Z, Li Y, Wang Q, Zhao Z, et al
    The Clinical Significance of Hepatic CD69(+) CD103(+) CD8(+) Resident Memory T Cells in Autoimmune Hepatitis.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31739.
    PubMed     Abstract available


  97. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
    PubMed     Abstract available


  98. ROSENTHAL SB, Liu X, Ganguly S, Dhar D, et al
    Heterogeneity of hepatic stellate cells in a mouse model of non-alcoholic steatohepatitis (NASH).
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31743.
    PubMed     Abstract available


  99. ZHANG XF, Lv Y, Pawlik TM
    Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
    Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
    PubMed     Abstract available


  100. KE W, Cai De L, Jian Nan S, Chun Nian W, et al
    Primary Hepatic Squamous Cell Carcinoma With MSI-H Shows Good Response to PD-1 Inhibitor as Adjuvant Therapy.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31737.
    PubMed     Abstract available


  101. TAO J, Krutsenko Y, Moghe A, Singh S, et al
    Nrf2 and beta-catenin coactivation in hepatocellular cancer: Biological and therapeutic implications.
    Hepatology. 2021 Feb 2. doi: 10.1002/hep.31730.
    PubMed     Abstract available


  102. SANSOE G, Aragno M, Wong F
    Covid-19 and liver cirrhosis: focus on the non-classical renin-angiotensin system and implications for therapy.
    Hepatology. 2021 Feb 1. doi: 10.1002/hep.31728.
    PubMed     Abstract available



  103. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:1.
    PubMed    


  104. BUCKHOLZ A, Brown RS Jr, Parthasarathy G, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2021;73:475-478.
    PubMed    


  105. KARDASHIAN A, Wilder J, Terrault NA, Price JC, et al
    Addressing Social Determinants of Liver Disease During the COVID-19 Pandemic and Beyond: A Call to Action.
    Hepatology. 2021;73:811-820.
    PubMed     Abstract available


    January 2021
  106. KALASEKAR SM, Garrido-Laguna I, Evason KJ
    Immune Checkpoint Inhibitors in Novel Combinations for Hepatocellular Carcinoma.
    Hepatology. 2021 Jan 12. doi: 10.1002/hep.31706.
    PubMed     Abstract available


  107. CARACENI P, Vargas V, Sola E, Alessandria C, et al
    The use of Rifaximin in Patients with Cirrhosis.
    Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708.
    PubMed     Abstract available


  108. LUCE E, Messina A, Duclos-Vallee JC, Dubart-Kupperschmitt A, et al
    Advanced techniques and awaited clinical applications for human pluripotent stem cell differentiation into hepatocytes.
    Hepatology. 2021 Jan 8. doi: 10.1002/hep.31705.
    PubMed     Abstract available


  109. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    PubMed     Abstract available


  110. SATIYA J, Kaur SP, Lau DTY, Hejazifar N, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1-3.
    PubMed    


  111. JAESCHKE H, Ramachandran A
    Letter to the Editor: Does c-Jun N-Terminal Kinase Regulate Acetaminophen Hepatotoxicity by Modulating Nuclear Factor Erythroid 2-Related Factor 2-Dependent Genes or Mitochondrial Oxidant Stress?
    Hepatology. 2021;73:467-468.
    PubMed    


  112. TANG X, Wang XJ
    REPLY.
    Hepatology. 2021;73:468-469.
    PubMed    


  113. CHOI J, Lim YS
    REPLY.
    Hepatology. 2021;73:467.
    PubMed    


  114. CASEY L, Aday A, Rule J, Lee WM, et al
    Letter to the Editor: Response to Letter Concerning Our Pregnancy Manuscript.
    Hepatology. 2021;73:465.
    PubMed    


  115. NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
    Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:366-413.
    PubMed    


  116. SARKAR M, Brady CW, Fleckenstein J, Forde KA, et al
    Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:318-365.
    PubMed    


  117. DE JONGHE S, Weinstock D, Aligo J, Washington K, et al
    Biopsy Pathology and Immunohistochemistry of a Case of Immune-Mediated Drug-Induced Liver Injury With Atabecestat.
    Hepatology. 2021;73:452-455.
    PubMed    


  118. LEONIS MA, Miethke AG, Fei L, Maynor S, et al
    Four Biomarkers Linked to Activation of Cluster of Differentiation 8-Positive Lymphocytes Predict Clinical Outcomes in Pediatric Acute Liver Failure.
    Hepatology. 2021;73:233-246.
    PubMed     Abstract available


  119. LI YJ, Phillips EJ, Dellinger A, Nicoletti P, et al
    Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.
    Hepatology. 2021;73:268-281.
    PubMed     Abstract available


  120. MORENO E, Toussaint MJM, van Essen SC, Bongiovanni L, et al
    E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.
    Hepatology. 2021;73:303-317.
    PubMed     Abstract available


  121. GU L, Zhu Y, Lin X, Lu B, et al
    The IKKbeta-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis.
    Hepatology. 2021;73:160-174.
    PubMed     Abstract available


  122. ZHOU B, Liu C, Xu L, Yuan Y, et al
    N(6) -Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes.
    Hepatology. 2021;73:91-103.
    PubMed     Abstract available


  123. CABALLERO-CAMINO FJ, Rivilla I, Herraez E, Briz O, et al
    Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
    Hepatology. 2021;73:186-203.
    PubMed     Abstract available


    December 2020
  124. PINATO DJ, Fessas P, Sapisochin G, Marron TU, et al
    Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma.
    Hepatology. 2020 Dec 28. doi: 10.1002/hep.31697.
    PubMed     Abstract available


  125. ELKRIEF L, Lazareth M, Chevret S, Paradis V, et al
    Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension.
    Hepatology. 2020 Dec 21. doi: 10.1002/hep.31688.
    PubMed     Abstract available


  126. ANANIA FA, Dimick-Santos L, Mehta R, Toerner J, et al
    Nonalcoholic Steatohepatitis: Current Thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration.
    Hepatology. 2020 Dec 19. doi: 10.1002/hep.31687.
    PubMed     Abstract available


  127. VIVEIROS A, Beliveau V, Panzer M, Schaefer B, et al
    Neurodegeneration in Hepatic and Neurologic Wilson Disease.
    Hepatology. 2020 Dec 14. doi: 10.1002/hep.31681.
    PubMed     Abstract available


  128. LIOU H, Mody K, Boyle AW, Keaveny AP, et al
    Neoadjuvant Radiation Lobectomy and Immunotherapy for Angioinvasive Hepatocellular Carcinoma Resulting in Complete Pathologic Response.
    Hepatology. 2020 Dec 7. doi: 10.1002/hep.31675.
    PubMed     Abstract available


  129. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
    Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
    Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
    PubMed     Abstract available


  130. KEISHAM A, Taneja S, Roy A, Singh V, et al
    ABIDE in NAFLD: A potential game changer in a select cohort of cirrhosis.
    Hepatology. 2020 Dec 4. doi: 10.1002/hep.31667.
    PubMed     Abstract available


  131. ANAND A, Pathak P, Shalimar
    Letter to the editor: ABIDE model for predicting decompensation in non-alcoholic fatty liver disease-related cirrhosis.
    Hepatology. 2020 Dec 3. doi: 10.1002/hep.31668.
    PubMed     Abstract available


  132. BUCKHOLZ A, Brown RS Jr, Trivedi H, Khan MM, et al
    Hepatology Highlights.
    Hepatology. 2020;72:1893-1896.
    PubMed    


  133. NOUREDDIN N, Alkhouri N, Brown KA, Noureddin M, et al
    Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights.
    Hepatology. 2020;72:2228-2230.
    PubMed    


  134. MEHTA N, Yao FY
    Reply.
    Hepatology. 2020;72:2243-2244.
    PubMed    


  135. SELCK TJ, Bok J, Amintavakoli R
    Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
    Hepatology. 2020;72:2239.
    PubMed    


  136. VENTURA-COTS M, Abraldes JG, Bataller R
    Reply.
    Hepatology. 2020;72:2239-2240.
    PubMed    


    November 2020
  137. SIMON TG, Chan AT, Huttenhower C
    Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis.
    Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660.
    PubMed     Abstract available


  138. HERNANDEZ-MEZA G, von Felden J, Gonzalez-Kozlova EE, Garcia-Lezana T, et al
    DNA methylation profiling of human hepatocarcinogenesis.
    Hepatology. 2020 Nov 25. doi: 10.1002/hep.31659.
    PubMed     Abstract available


  139. KHATUN M, Sur S, Steele R, Ray R, et al
    Inhibition of long noncoding RNA Linc-Pint by hepatitis C virus in infected hepatocytes enhances lipogenesis.
    Hepatology. 2020 Nov 24. doi: 10.1002/hep.31656.
    PubMed     Abstract available


  140. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
    Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
    PubMed     Abstract available


  141. SIMONETTO DA, Shah VH, Kamath PS
    Surgery in patients with cirrhosis: as much an art as science.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31643.
    PubMed     Abstract available


  142. IOANNOU GN, Liang PS, Locke E, Green P, et al
    Cirrhosis and SARS-CoV-2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31649.
    PubMed     Abstract available


  143. LI S, Liu Y, Bai Y, Chen M, et al
    RHOF promotes hepatocellular carcinoma metastasis by altering the metabolic status of cancer cells via RAB3D.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31641.
    PubMed     Abstract available


  144. RICH NE, Marrero JA, Singal AG
    Reply: Wang et al, "Should growth pattern of hepatocellular carcinoma be constant and homogenous?"
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31638.
    PubMed     Abstract available


  145. WANG H, Mao Y, Huang M
    Letter to the Editors: should growth pattern of hepatocellular carcinoma be constant and homogenous?
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31640.
    PubMed     Abstract available


  146. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    PubMed     Abstract available


  147. GU X, Sun R, Chen L, Chu S, et al
    Neutral ceramidase mediates nonalcoholic steatohepatitis by regulating monounsaturated fatty acids and gut IgA(+) B cells.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31628.
    PubMed     Abstract available


  148. KOKUDO T
    Evaluating Liver Function in Patients With Cirrhosis.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31626.
    PubMed     Abstract available


  149. LOOMBA R
    MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis.
    Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624.
    PubMed     Abstract available


  150. HUO TI, Liu PH, Hsu CY
    Using circulating biomarkers to stage hepatocellular carcinoma: Pitfalls and limitations.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31618.
    PubMed     Abstract available


  151. SUN L, Guan A, Liu M, Mao Y, et al
    Letter to the editor: Comment on "HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk".
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31621.
    PubMed     Abstract available


  152. LOOMBA R, Noureddin M, Kowdley KV, Kohli A, et al
    Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.
    PubMed     Abstract available


  153. GAO J, Wei B, Liu M, Hirsova P, et al
    Endothelial p300 promotes portal hypertension and hepatic fibrosis through CCL2-mediated angiocrine signaling.
    Hepatology. 2020 Nov 7. doi: 10.1002/hep.31617.
    PubMed     Abstract available


  154. KURODA H, Abe T, Fujiwara Y, Nagasawa T, et al
    Contrast-enhanced ultrasonography-based hepatic perfusion for early prediction of prognosis in acute liver failure.
    Hepatology. 2020 Nov 5. doi: 10.1002/hep.31615.
    PubMed     Abstract available


  155. KRISHNAN MS, Rajan Kd A, Park J, Arjunan V, et al
    Genomic analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive Biomarkers.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31614.
    PubMed     Abstract available


  156. RUSSO NW, Brown RS Jr, Parthasarathy G, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2020;72:1505-1508.
    PubMed    


  157. BANINI BA, P Kumar D, Cazanave S, Seneshaw M, et al
    Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.
    Hepatology. 2020 Nov 1. doi: 10.1002/hep.31609.
    PubMed     Abstract available


  158. ALKHOURI N, Kohli A, Loomba R, Harrison SA, et al
    Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome-Coronavirus 2 Pandemic.
    Hepatology. 2020;72:1509-1513.
    PubMed    


  159. BERTOLINI A, van de Peppel IP, Bodewes FAJA, Moshage H, et al
    Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.
    Hepatology. 2020;72:1864-1872.
    PubMed    


  160. CAVE MC
    Environmental Pollution and the Developmental Origins of Childhood Liver Disease.
    Hepatology. 2020;72:1518-1521.
    PubMed    


  161. JAESCHKE H, Ramachandran A
    Pleiotropic Roles of Platelets and Neutrophils in Cell Death and Recovery During Acetaminophen Hepatotoxicity.
    Hepatology. 2020;72:1873-1876.
    PubMed    


  162. SINGH S, Verma N, Singh V
    Letter to the Editor: MELD-Lactate-the New Kid on the Block.
    Hepatology. 2020;72:1883.
    PubMed    


    October 2020
  163. LONG MT, Zhang X, Xu H, Liu CT, et al
    Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: The Framingham Heart Study.
    Hepatology. 2020 Oct 30. doi: 10.1002/hep.31608.
    PubMed     Abstract available


  164. XU Y, Zhu Y, Hu S, Xu Y, et al
    Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
    Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
    PubMed     Abstract available


  165. STARLINGER P, Pereyra D, Hackl H, Ortmayr G, et al
    Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment during Hepatic Surgery.
    Hepatology. 2020 Oct 20. doi: 10.1002/hep.31601.
    PubMed     Abstract available


  166. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
    Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
    PubMed     Abstract available


  167. TAN HY, Wang N, Zhang C, Chan YT, et al
    LOXL4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis.
    Hepatology. 2020 Oct 17. doi: 10.1002/hep.31600.
    PubMed     Abstract available


  168. LI XJ, Li QL, Ju LG, Zhao C, et al
    Deficiency of histone methyltransferase SETD2 in liver leads to abnormal lipid metabolism and hepatocarcinoma.
    Hepatology. 2020 Oct 15. doi: 10.1002/hep.31594.
    PubMed     Abstract available


  169. BROWN SA, Izzy M, Watt KD
    Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underutilized Potential.
    Hepatology. 2020 Oct 12. doi: 10.1002/hep.31595.
    PubMed     Abstract available


  170. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    PubMed     Abstract available


  171. YUAN G, Yao J, Yu J, Xie X, et al
    Letter to the Editors: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Hepatology. 2020 Oct 5. doi: 10.1002/hep.31590.
    PubMed     Abstract available


  172. WONG TC, Yan-Yue Fung J, Pang HH, Leung CK, et al
    Analysis of survival benefits of living vs. deceased donor liver transplant in high MELD and hepatorenal syndrome.
    Hepatology. 2020 Oct 2. doi: 10.1002/hep.31584.
    PubMed     Abstract available


  173. ANTKOWIAK M, Green RM
    Telomeres, p53, Hepatocyte Nuclear Factor 4alpha, and Liver Disease.
    Hepatology. 2020;72:1166-1168.
    PubMed    


  174. LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
    Reply.
    Hepatology. 2020;72:1494-1495.
    PubMed    


  175. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    PubMed     Abstract available


    September 2020
  176. CALZADILLA-BERTOT L, Vilar-Gomez E, Wong VW, Romero-Gomez M, et al
    ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.
    PubMed     Abstract available


  177. CHANDLER RJ, Venturoni LE, Liao J, Hubbard BT, et al
    Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31570.
    PubMed     Abstract available


  178. OOSHIO T, Yamamoto M, Fujii K, Xin B, et al
    Hepatocyte MKK7 Contributes to Restoration of the Liver Parenchyma Following Injury.
    Hepatology. 2020 Sep 23. doi: 10.1002/hep.31565.
    PubMed     Abstract available


  179. ZHANG BH, Cai YS, Song JL, Lyu T, et al
    Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in CHB Patients.
    Hepatology. 2020 Sep 23. doi: 10.1002/hep.31563.
    PubMed     Abstract available


  180. GOH MJ, Sinn DH, Woo SY, Kim S, et al
    Statins and reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: Author's Reply.
    Hepatology. 2020 Sep 22. doi: 10.1002/hep.31567.
    PubMed     Abstract available


  181. CHEN D, Wu H, Feng X, Chen Y, et al
    DNA Methylation of CNRIP1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent PKM2 Ubiquitination.
    Hepatology. 2020 Sep 21. doi: 10.1002/hep.31561.
    PubMed     Abstract available


  182. MAHMUD N, Fricker Z, Hubbard RA, Ioannou GN, et al
    Novel Risk Prediction Models for Post-Operative Mortality in Patients with Cirrhosis.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31558.
    PubMed     Abstract available


  183. MARTIN N, Ziegler DV, Parent R, Bernard D, et al
    Hepatic Stellate Cell Senescence in Liver Tumorigenesis.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31556.
    PubMed     Abstract available


  184. MORRIS JS, Hassan MM, Zohner YE, Wang Z, et al
    HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31555.
    PubMed     Abstract available


  185. YAZDANI HO, Kaltenmeier C, Morder K, Moon J, et al
    Exercise training decreases hepatic injury via changes in immune response to liver ischemia/reperfusion in mice.
    Hepatology. 2020 Sep 14. doi: 10.1002/hep.31552.
    PubMed     Abstract available


  186. VERMA M, Younossi Z
    Integrating Patient Reported Outcomes within Routine Hepatology Care: A Prompt to Action.
    Hepatology. 2020 Sep 12. doi: 10.1002/hep.31550.
    PubMed     Abstract available


  187. THOMSON MJ, Lok AS, Tapper EB
    Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis.
    Hepatology. 2020 Sep 10. doi: 10.1002/hep.31548.
    PubMed     Abstract available


  188. ZHEN S, Cai X
    Letter to Editor: Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides.
    Hepatology. 2020 Sep 7. doi: 10.1002/hep.31543.
    PubMed     Abstract available


  189. PIANO S, Gambino C, Vettore E, Calvino V, et al
    Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
    Hepatology. 2020 Sep 1. doi: 10.1002/hep.31529.
    PubMed     Abstract available


  190. PHIPPS MM, Barraza LH, LaSota ED, Sobieszczyk ME, et al
    Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort.
    Hepatology. 2020;72:807-817.
    PubMed     Abstract available


  191. DA BL, Im GY, Schiano TD
    Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease.
    Hepatology. 2020;72:1102-1108.
    PubMed     Abstract available


  192. KAPLAN A, Rosenblatt R, Buckholz A, Kumar S, et al
    Hepatology Highlights.
    Hepatology. 2020;72:791-793.
    PubMed    


  193. JIANG X, Ding WX
    Acyl Coenzyme A Thioesterase 9: A Novel Target for Nonalcoholic Fatty Liver Disease by Shuttling Mitochondrial Short-Chain Fatty Acids?
    Hepatology. 2020;72:797-800.
    PubMed    


  194. GUICCIARDI ME, Nakao Y, Gores GJ
    The Metabolic Sensor Adenosine Monophosphate-Activated Protein Kinase Regulates Apoptosis in Nonalcoholic Steatohepatitis.
    Hepatology. 2020;72:1139-1141.
    PubMed    


  195. KUMAR M
    Reply.
    Hepatology. 2020;72:1160.
    PubMed    


  196. WEISS TS, Melter M, Dayoub R
    Letter to the Editor: Does Augmenter of Liver Regeneration Deficiency Pave the Way for Nonalcoholic Steatohepatitis Progression?
    Hepatology. 2020;72:1156-1157.
    PubMed    


  197. VERMA AK, Gandhi CR
    Reply.
    Hepatology. 2020;72:1157-1158.
    PubMed    


    August 2020
  198. SCHWANTES-AN TH, Darlay R, Mathurin P, Masson S, et al
    Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.
    Hepatology. 2020 Aug 27. doi: 10.1002/hep.31535.
    PubMed     Abstract available


  199. LOOMBA R, Ling L, Dinh DM, DePaoli AM, et al
    The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis.
    Hepatology. 2020 Aug 13. doi: 10.1002/hep.31523.
    PubMed     Abstract available


  200. BHUSHAN B, Molina L, Koral K, Stoops JW, et al
    Yap is crucial for CAR-driven hepatocyte proliferation, but not for induction of drug metabolism genes in mice.
    Hepatology. 2020 Aug 13. doi: 10.1002/hep.31521.
    PubMed     Abstract available


  201. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
    Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
    Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
    PubMed     Abstract available


  202. KULKARNI AV, Sharma M, Kumar P, Gupta R, et al
    Midodrine for Hepatic Hydrothorax.
    Hepatology. 2020 Aug 8. doi: 10.1002/hep.31513.
    PubMed     Abstract available


  203. BANINI BA, Alwatari Y, Ogden N, Gershman E, et al
    Letter to Editor: Response to Commentary "Midodrine for Hepatic Hydrothorax".
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31512.
    PubMed     Abstract available


  204. LU L, Jiang J, Zhan M, Zhang H, et al
    Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31502.
    PubMed     Abstract available


  205. DEGASPERI E, Galmozzi E, Pelusi S, D'Ambrosio R, et al
    Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs.
    Hepatology. 2020 Aug 6. doi: 10.1002/hep.31500.
    PubMed     Abstract available


  206. GINDIN Y, Chung C, Jiang Z, Zhou JZ, et al
    A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis.
    Hepatology. 2020 Aug 3. doi: 10.1002/hep.31488.
    PubMed     Abstract available


  207. VERNA EC, Serper M, Chu J, Corey K, et al
    Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation.
    Hepatology. 2020 Aug 2. doi: 10.1002/hep.31491.
    PubMed     Abstract available


  208. WANGENSTEEN KJ, Chang KM
    Multiple roles for hepatitis B and C viruses and the host in the development of hepatocellular carcinoma.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31481.
    PubMed     Abstract available


  209. TALAT A, Shah PA, Lau DTY, Russo NW, et al
    Hepatology Highlights.
    Hepatology. 2020;72:369-370.
    PubMed    


  210. SERPER M, Cubell AW, Deleener ME, Casher TK, et al
    Telemedicine in Liver Disease and Beyond: Can the COVID-19 Crisis Lead to Action?
    Hepatology. 2020;72:723-728.
    PubMed     Abstract available


  211. WEN Y, Ju C
    MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
    Hepatology. 2020;72:772-774.
    PubMed    


  212. SINHA RA, Bruinstroop E, Singh BK, Yen PM, et al
    Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
    Hepatology. 2020;72:770-771.
    PubMed    


  213. GAWRIEH S, Kleiner DE, Chalasani N, Vanderbeck S, et al
    Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;72:785.
    PubMed    


  214. WEI L, Chang PEJ, Anstee QM
    Reply.
    Hepatology. 2020;72:786.
    PubMed    


  215. KWON HM, Hwang GS
    Reply.
    Hepatology. 2020;72:784.
    PubMed    


  216. HUANG JF, Dai CY, Yu ML, Chuang WL, et al
    Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter.
    Hepatology. 2020;72:781.
    PubMed    


    July 2020
  217. LV Y, Wang Z, Li K, Wang Q, et al
    Risk Stratification based on CLIF Consortium Acute Decompensation score in Patients with Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2020 Jul 24. doi: 10.1002/hep.31478.
    PubMed     Abstract available


  218. SABERI B, Naik H, Overbey JR, Erwin AL, et al
    Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium.
    Hepatology. 2020 Jul 18. doi: 10.1002/hep.31460.
    PubMed     Abstract available


  219. LISMAN T
    Hemostatic Changes of Acute Kidney Injury in Patients With Cirrhosis: What Do They Mean?
    Hepatology. 2020 Jul 4. doi: 10.1002/hep.31451.
    PubMed     Abstract available


  220. ZANETTO A, Rinder HM, Campello E, Saggiorato G, et al
    Acute kidney injury in decompensated cirrhosis is associated with both hypo- and hyper-coagulable features.
    Hepatology. 2020 Jul 2. doi: 10.1002/hep.31443.
    PubMed     Abstract available


  221. WEI X, Zhao L, Ren R, Ji F, et al
    MiR-125b Loss Activated HIF1alpha/pAKT Loop, Leading to Trans-Arterial Chemoembolization Resistance in Hepatocellular Carcinoma.
    Hepatology. 2020 Jul 1. doi: 10.1002/hep.31448.
    PubMed     Abstract available


  222. WANG Y
    Letter to the Editor: Issues of Circular RNAs as MicroRNA Sponges.
    Hepatology. 2020;72:365.
    PubMed    


  223. LI L, Wei Y, Wang H
    REPLY.
    Hepatology. 2020;72:366.
    PubMed    


  224. HOOFNAGLE JH
    FXR Agonists as Therapy for Liver Disease.
    Hepatology. 2020;72:1-3.
    PubMed    


  225. MALLAT A, Lotersztajn S
    Glutamate Signaling in Alcohol-associated Fatty Liver: "Pas de Deux".
    Hepatology. 2020;72:350-352.
    PubMed    


  226. SU T, Iwakiri Y
    Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
    Hepatology. 2020;72:347-349.
    PubMed    


  227. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    Reply.
    Hepatology. 2020;72:364-365.
    PubMed    


  228. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    REPLY.
    Hepatology. 2020;72:362-363.
    PubMed    


  229. ARASE Y, Kagawa T, Tanaka A
    Reply.
    Hepatology. 2020;72:360-361.
    PubMed    


  230. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.
    PubMed    


    June 2020
  231. PAPATHEODORIDIS GV, Voulgaris T, Papatheodoridi M, Kim WR, et al
    Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine.
    Hepatology. 2020 Jun 30. doi: 10.1002/hep.31440.
    PubMed     Abstract available


  232. KIM BK, Kim SU
    Re: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Jun 29. doi: 10.1002/hep.31439.
    PubMed     Abstract available


  233. WU J, Gao W, Tang Q, Yu Y, et al
    M2 macrophage-derived exosomes facilitate hepatocarcinoma metastasis by transferring alphaM beta2 integrin to tumor cells.
    Hepatology. 2020 Jun 28. doi: 10.1002/hep.31432.
    PubMed     Abstract available


  234. XU M, Ge C, Zhu L, Qin Y, et al
    iRhom2 promotes hepatic steatosis by activating MAP3K7-dependent pathway.
    Hepatology. 2020 Jun 26. doi: 10.1002/hep.31436.
    PubMed     Abstract available


  235. BANINI BA, Alwatari Y, Stovall M, Ogden N, et al
    Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance.
    Hepatology. 2020 Jun 25. doi: 10.1002/hep.31434.
    PubMed     Abstract available


  236. AKBULUT S, Sahin TT, Yilmaz S
    Comment on Alpha-Fetoprotein Decrease from > 1.000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
    Hepatology. 2020 Jun 24. doi: 10.1002/hep.31433.
    PubMed     Abstract available


  237. KLOECKNER R, Galle PR, Bruix J
    Local and Regional Therapies for Hepatocellular Carcinoma.
    Hepatology. 2020 Jun 18. doi: 10.1002/hep.31424.
    PubMed     Abstract available


  238. KIM YS, Nam HJ, Han CY, Joo MS, et al
    LXRalpha activation inhibits autophagy and lipophagy in hepatocytes by dysregulating ATG4B and Rab-8B, reducing mitochondrial fuel oxidation.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31423.
    PubMed     Abstract available


  239. RUSSO MW, Fix OK, Koteish AA, Duggan K, et al
    Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31425.
    PubMed     Abstract available


  240. ZHANG J, Li Y, Liu Q, Huang Y, et al
    Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells.
    Hepatology. 2020 Jun 14. doi: 10.1002/hep.31418.
    PubMed     Abstract available


  241. ALFERINK LJ, Radjabzadeh D, Erler NS, Vojinovic D, et al
    Microbiomics, metabolomics, predicted metagenomics and hepatic steatosis in a population-based study of 1355 adults.
    Hepatology. 2020 Jun 12. doi: 10.1002/hep.31417.
    PubMed     Abstract available


  242. XIE C, Fang JH, Zhuang SM
    Reply to: Letter to the editor, "PDIA3P1 level could predict recurrence-free survival in hepatocellular carcinoma: reliable?" (HEP-20-0942).
    Hepatology. 2020 Jun 11. doi: 10.1002/hep.31300.
    PubMed     Abstract available


  243. MUNROE M, Niero EL, Fok WC, Vessoni AT, et al
    Telomere dysfunction activates p53 and represses HNF4alpha expression leading to impaired human hepatocyte development and function.
    Hepatology. 2020 Jun 9. doi: 10.1002/hep.31414.
    PubMed     Abstract available


  244. PFEIFFER RM, Rotman Y, O'Brien TR
    Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?
    Hepatology. 2020 Jun 7. doi: 10.1002/hep.31413.
    PubMed     Abstract available


  245. ZHAO N, Dang H, Ma L, Martin SP, et al
    Intratumoral gammadelta T-cell infiltrates, CCL4/5 protein expression and survival in patients with hepatocellular carcinoma.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31412.
    PubMed     Abstract available


  246. ABUD A, Maddur H, Salem R
    Management of symptomatic portal cavernoma cholangiopathy via transplenic portal vein recanalization and TIPS.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31411.
    PubMed     Abstract available


  247. PRABHU A, Cargill T, Roberts N, Ryan JD, et al
    Systematic review of the clinical outcomes of iron reduction in Hereditary Hemochromatosis.
    Hepatology. 2020 Jun 4. doi: 10.1002/hep.31405.
    PubMed     Abstract available


  248. KUMAR K, Kulkarni AV
    Sodium-Glucose Cotransporter-2(SGLT2-I) inhibitor are not the magic pills for control of ascites in cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31399.
    PubMed     Abstract available


  249. PATEL K, Chung C, Myers RP
    Reply to HEP-20-0871 Letter to the Editors: Cilofexor in patients with non-alcoholic steatohepatitis (NASH): Is it really effective?
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31402.
    PubMed     Abstract available


  250. PATOULIAS D, Katsimardou A, Papadopoulos C, Doumas M, et al
    Letter to the Editor: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31398.
    PubMed     Abstract available


  251. JINDAL A, Sarin SK
    Letter to the Editors: Cilofexor in Patients With Nonalcoholic Steatohepatitis (NASH): Is It Really Effective?
    Hepatology. 2020 Jun 2. doi: 10.1002/hep.31400.
    PubMed     Abstract available


  252. LUCEY MR, Singal AK
    Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
    Hepatology. 2020;71:1891-1893.
    PubMed    


    May 2020
  253. CALVISI DF
    Schistoma mansoni and Hepatocellular Carcinoma: is it all about c-Jun and STAT3?
    Hepatology. 2020 May 28. doi: 10.1002/hep.31392.
    PubMed     Abstract available


  254. HALL Z, Chiarugi D, Charidemou E, Leslie J, et al
    Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma.
    Hepatology. 2020 May 27. doi: 10.1002/hep.31391.
    PubMed     Abstract available


  255. SMITH JL, Rodriguez TC, Mou H, Kwan SY, et al
    YAP1 withdrawal in hepatoblastoma drives therapeutic differentiation of tumor cells to functional hepatocyte-like cells.
    Hepatology. 2020 May 26. doi: 10.1002/hep.31389.
    PubMed     Abstract available


  256. GUNASEKARAN G, Bekki Y, Lourdusamy V, Schwartz M, et al
    Surgical Treatments of Hepatobiliary Cancers.
    Hepatology. 2020 May 21. doi: 10.1002/hep.31325.
    PubMed     Abstract available


  257. LLOVET JM, Villanueva A, Marrero JA, Schwartz M, et al
    Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference.
    Hepatology. 2020 May 20. doi: 10.1002/hep.31327.
    PubMed     Abstract available


  258. DEVARBHAVI H
    RE: Acute Liver Failure (ALF) in Pregnancy: How Much Is Pregnancy-Related? Casey et al. Hepatology 2020 Jan 28[Online ahead of print DOI: 10.1002/hep.31144.
    Hepatology. 2020 May 17. doi: 10.1002/hep.31323.
    PubMed     Abstract available


  259. CHU S, Sun R, Gu X, Chen L, et al
    Inhibition of sphingosine-1-phosphate-induced Th17 cells ameliorates alcoholic steatohepatitis in mice.
    Hepatology. 2020 May 17. doi: 10.1002/hep.31321.
    PubMed     Abstract available


  260. NEWTON KP, Lavine JE, Wilson L, Behling C, et al
    Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
    Hepatology. 2020 May 16. doi: 10.1002/hep.31317.
    PubMed     Abstract available


  261. VANDEL J, Dubois-Chevalier J, Gheeraert C, Derudas B, et al
    Hepatic molecular signatures highlight the sexual dimorphism of Non-Alcoholic SteatoHepatitis (NASH).
    Hepatology. 2020 May 11. doi: 10.1002/hep.31312.
    PubMed     Abstract available


  262. WOLF E, Rich NE, Marrero JA, Parikh N, et al
    Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: A systematic review and meta-analysis.
    Hepatology. 2020 May 8. doi: 10.1002/hep.31309.
    PubMed     Abstract available


  263. FINN RS, Zhu AX
    Evolution of Systemic Therapy for Hepatocellular Carcinoma.
    Hepatology. 2020 May 7. doi: 10.1002/hep.31306.
    PubMed     Abstract available


  264. LI W
    Letter to the Editor: PDIA3P1 level could predict recurrence-free survival in hepatocellular carcinoma: reliable?
    Hepatology. 2020 May 7. doi: 10.1002/hep.31299.
    PubMed     Abstract available


  265. PISA JF, Brown RS Jr, Hirsova P, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2020;71:1527-1529.
    PubMed    


  266. KAPLOWITZ N, Than TA, Win S
    Acetaminophen Hepatotoxicity: Strong Offense and Weakened Defense.
    Hepatology. 2020;71:1530-1532.
    PubMed    


  267. RAEVENS S, Fallon MB
    PORTICO: First Randomized Controlled Trial of Vasomodulator Therapy in Portopulmonary Hypertension.
    Hepatology. 2020;71:1870-1872.
    PubMed    


  268. HENSON JB, Roden M, Targher G, Corey KE, et al
    Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart.
    Hepatology. 2020;71:1867-1869.
    PubMed    


  269. ABERG F, Farkkila M, Salomaa V, Jula A, et al
    REPLY.
    Hepatology. 2020;71:1888-1889.
    PubMed    


  270. GOW P, Testro AG, Hey P, Sinclair M, et al
    Letter to the Editor: Moderate Alcohol Use in Fatty Liver Disease: Don't Throw the Cabernet Out With the Bathwater.
    Hepatology. 2020;71:1887-1888.
    PubMed    


  271. MA Y, Brown PM, Rotman Y
    REPLY.
    Hepatology. 2020;71:1886-1887.
    PubMed    


  272. GALMOZZI E
    Letter to the Editor: Does the HSD17B13 rs72613567 Splice Variant Actually Yield a New Type of Alternative Splicing?
    Hepatology. 2020;71:1885-1886.
    PubMed    


  273. IZZY M, VanWagner LB, Lin G, Altieri M, et al
    Reply.
    Hepatology. 2020;71:1884-1885.
    PubMed    


  274. ZHOU J, Zhou F, Wang W, Zhang XJ, et al
    Epidemiological Features of NAFLD From 1999 to 2018 in China.
    Hepatology. 2020;71:1851-1864.
    PubMed     Abstract available


  275. CHEN Y, Liu K, Zhang J, Hai Y, et al
    c-Jun NH2 -Terminal Protein Kinase Phosphorylates the Nrf2-ECH Homology 6 Domain of Nuclear Factor Erythroid 2-Related Factor 2 and Downregulates Cytoprotective Genes in Acetaminophen-Induced Liver Injury in Mice.
    Hepatology. 2020;71:1787-1801.
    PubMed     Abstract available


  276. GAO W, Jia Z, Tian Y, Yang P, et al
    HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.
    Hepatology. 2020;71:1678-1695.
    PubMed     Abstract available


  277. FLEMING BD, Urban DJ, Hall MD, Longerich T, et al
    Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Hepatology. 2020;71:1696-1711.
    PubMed     Abstract available


  278. XIE C, Zhang LZ, Chen ZL, Zhong WJ, et al
    A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance.
    Hepatology. 2020;71:1660-1677.
    PubMed     Abstract available


    April 2020
  279. BEYLS C, Haustermans K, Deroose CM, Pans S, et al
    Could autoimmune disease contribute to the abscopal effect in metastatic hepatocellular carcinoma?
    Hepatology. 2020 Apr 29. doi: 10.1002/hep.31186.
    PubMed     Abstract available


  280. FONDEVILA MF, Fernandez U, Gonzalez-Rellan MJ, Da Silva Lima N, et al
    The L-alpha-lysophosphatidylinositol/GPR55 system induces the development of non-alcoholic steatosis and steatohepatitis.
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31290.
    PubMed     Abstract available


  281. CHOI J, Jo C, Lim YS
    Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31289.
    PubMed     Abstract available


  282. MCGLYNN KA, Petrick JL, El-Serag HB
    Epidemiology of Hepatocellular Carcinoma.
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
    PubMed     Abstract available


  283. KUMAR A
    Letter to the Editor: Role of Sorafenib in Liver Transplantation Outcomes of Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria?
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31285.
    PubMed     Abstract available


  284. KARDASHIAN A, Agopian V
    Reply to: "Role of Sorafenib in Liver Transplantation Outcomes of Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria?"
    Hepatology. 2020 Apr 20. doi: 10.1002/hep.31283.
    PubMed     Abstract available


  285. MAHMUD N, Asrani SK
    Defining (and refining) the role of the Model for End Stage Liver Disease-Lactate (MELD-LA) score in cirrhosis.
    Hepatology. 2020 Apr 20. doi: 10.1002/hep.31287.
    PubMed     Abstract available


  286. LU L, Jiang J, Zhan M, Zhang H, et al
    Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
    Hepatology. 2020 Apr 16. doi: 10.1002/hep.31279.
    PubMed     Abstract available


  287. FIX OK, Hameed B, Fontana RJ, Kwok RM, et al
    Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.
    Hepatology. 2020 Apr 16. doi: 10.1002/hep.31281.
    PubMed     Abstract available


  288. ZHANG L, Tian R, Yao X, Zhang XJ, et al
    Milk Fat Globule-EGF Factor 8 improves Hepatic Steatosis and Inflammation.
    Hepatology. 2020 Apr 15. doi: 10.1002/hep.31277.
    PubMed     Abstract available


  289. MONTALVO-GORDON I, Chi-Cervera LA, Garcia-Tsao G
    Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Apr 15. doi: 10.1002/hep.31270.
    PubMed     Abstract available


  290. DAVE S, Park S, Murad MH, Barnard A, et al
    Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis.
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31267.
    PubMed     Abstract available


  291. SERPER M, Weinberg EM, Cohen JB, Reese PP, et al
    Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation.
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31264.
    PubMed     Abstract available


  292. PRIMIGNANI M, Tosetti G, Tripodi A
    Thromboelastography guided blood product transfusion in cirrhosis with coagulopathy: real saving or just less waste?
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31263.
    PubMed     Abstract available


  293. KUMAR A, Sharma P, Arora A
    A new prognostic algorithm based on stage of cirrhosis and HVPG to improve risk-stratification after variceal bleeding.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31254.
    PubMed     Abstract available


  294. LAPUMNUAYPOL K, Danford CJ, Lau DTY, Pisa JF, et al
    Hepatology Highlights.
    Hepatology. 2020;71:1143-1145.
    PubMed    


  295. RATZIU V
    Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.
    Hepatology. 2020;71:1146-1149.
    PubMed    


  296. WANG S, Friedman SL
    Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation.
    Hepatology. 2020;71:1150-1153.
    PubMed    


  297. HILSCHER MB, Shah VH
    Small but Mighty: Platelets in NASH and Other Chronic Liver Diseases.
    Hepatology. 2020;71:1501-1504.
    PubMed    


  298. YKI-JARVINEN H
    Ceramides: A Cause of Insulin Resistance in Nonalcoholic Fatty Liver Disease in Both Murine Models and Humans.
    Hepatology. 2020;71:1499-1501.
    PubMed    


  299. HAJIFATHALIAN K, Torabi Sagvand B, McCullough A
    Reply.
    Hepatology. 2020;71:1526.
    PubMed    


  300. BRAILLON A
    Letter to the Editor: Modest Alcohol Consumption and Nonalcoholic Fatty Liver Disease: An Oxymoron?
    Hepatology. 2020;71:1525.
    PubMed    


  301. CARVAO J, Jasmins L
    Letter to the Editor: Glomerular Filtration Rate Assessment in Liver Disease (GRAIL): Are We There Yet?
    Hepatology. 2020;71:1522-1523.
    PubMed    


  302. KHALAF RT, Sokol RJ
    New Insights Into Intestinal Failure-Associated Liver Disease in Children.
    Hepatology. 2020;71:1486-1498.
    PubMed     Abstract available


  303. XIONG X, Kuang H, Liu T, Lin JD, et al
    A Single-Cell Perspective of the Mammalian Liver in Health and Disease.
    Hepatology. 2020;71:1467-1473.
    PubMed    


  304. IBRAHIM SH, Jonas MM, Taylor SA, Gutierrez Sanchez LH, et al
    Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant.
    Hepatology. 2020;71:1474-1485.
    PubMed     Abstract available


  305. XIONG J, Liu T, Mi L, Kuang H, et al
    hnRNPU/TrkB Defines a Chromatin Accessibility Checkpoint for Liver Injury and Nonalcoholic Steatohepatitis Pathogenesis.
    Hepatology. 2020;71:1228-1246.
    PubMed     Abstract available


  306. LIU J, Wu Z, Han D, Wei C, et al
    Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-kappaB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.
    Hepatology. 2020;71:1262-1278.
    PubMed     Abstract available


  307. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
    Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
    Hepatology. 2020;71:1331-1349.
    PubMed     Abstract available


  308. CHEN F, Esmaili S, Rogers GB, Bugianesi E, et al
    Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.
    Hepatology. 2020;71:1213-1227.
    PubMed     Abstract available


  309. ZHANG C, Lin R, Li Z, Yang S, et al
    Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
    Hepatology. 2020;71:1297-1315.
    PubMed     Abstract available


  310. SHIGETA K, Datta M, Hato T, Kitahara S, et al
    Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
    Hepatology. 2020;71:1247-1261.
    PubMed     Abstract available


    March 2020
  311. LIU Y, Yang W, VoPham T, Ma Y, et al
    Plant-based and animal-based low-carbohydrate diets and risk of hepatocellular carcinoma among US men and women.
    Hepatology. 2020 Mar 29. doi: 10.1002/hep.31251.
    PubMed     Abstract available


  312. QIN J, Wang H, Qin X, Zhang P, et al
    Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient.
    Hepatology. 2020 Mar 27. doi: 10.1002/hep.31257.
    PubMed     Abstract available


  313. WANG J, Ma J, Nie H, Zhang XJ, et al
    Hepatic Regulator of G protein Signaling 5 Ameliorates NAFLD by Suppressing TAK1-JNK/p38 Signaling.
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31242.
    PubMed     Abstract available


  314. GELLERT-KRISTENSEN H, Richardson TG, Davey Smith G, Nordestgaard BG, et al
    Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31238.
    PubMed     Abstract available


  315. VATS R, Liu S, Zhu J, Mukhi D, et al
    Impaired bile secretion promotes hepatobiliary injury in Sickle Cell Disease.
    Hepatology. 2020 Mar 19. doi: 10.1002/hep.31239.
    PubMed     Abstract available


  316. LI CL, Ho MC, Lin YY, Tzeng ST, et al
    Cell-free virus-host chimera DNA from Hepatitis B virus integration sites as a circulating biomarker of hepatocellular cancer.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31230.
    PubMed     Abstract available


  317. SZE KM, Ho DW, Chiu YT, Tsui YM, et al
    HBV-TERT Promoter Integration Harnesses Host ELF4 Resulting in TERT Gene Transcription in Hepatocellular Carcinoma.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31231.
    PubMed     Abstract available


  318. SCHWACHA-EIPPER B, Minciuna I, Banz V, Dufour JF, et al
    Immunotherapy as a downstaging therapy for liver transplantation.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31234.
    PubMed     Abstract available


  319. ISAACS-TEN A, Echeandia M, Moreno-Gonzalez M, Brion A, et al
    Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability.
    Hepatology. 2020 Mar 13. doi: 10.1002/hep.31228.
    PubMed     Abstract available


  320. PEA A, Jamieson NB, Braconi C
    Biology and clinical application of regulatory RNAs in hepatocellular carcinoma.
    Hepatology. 2020 Mar 11. doi: 10.1002/hep.31225.
    PubMed     Abstract available


  321. NAGAI S, Kitajima T, Yeddula S, Salgia R, et al
    Effect of mandatory 6-month waiting period on waitlist and transplant outcomes in patients with hepatocellular carcinoma.
    Hepatology. 2020 Mar 10. doi: 10.1002/hep.31223.
    PubMed     Abstract available


  322. PAN WM, Wang H, Zhang XF, Xu P, et al
    miR-210 participates in hepatic ischemia reperfusion injury by forming a negative feedback loop with SMAD4.
    Hepatology. 2020 Mar 10. doi: 10.1002/hep.31221.
    PubMed     Abstract available


  323. LIU X, Liu J, Xiao W, Zeng Q, et al
    SIRT1 regulates N(6) -methyladenosine RNA modification in hepatocarcinogenesis by inducing RANBP2-dependent FTO SUMOylation.
    Hepatology. 2020 Mar 10. doi: 10.1002/hep.31222.
    PubMed     Abstract available


  324. LIEBER SR, Heller BJ, Howard CW, Sandler RS, et al
    Complications Associated with Anesthesia Services in Endoscopic Procedures Among Patients with Cirrhosis.
    Hepatology. 2020 Mar 10. doi: 10.1002/hep.31224.
    PubMed     Abstract available


  325. FRANCIS H, Wu N, Alpini G, Meng F, et al
    Hepatocyte Autophagy: Maintaining a Toxic-Free Environment.
    Hepatology. 2020 Mar 9. doi: 10.1002/hep.31219.
    PubMed     Abstract available


  326. ZENG J, Wu D, Hu H, Young JAT, et al
    Activation of the liver X receptor pathway inhibits HBV replication in primary human hepatocytes.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31217.
    PubMed     Abstract available


  327. TERKELSEN MK, Bendixen SM, Hansen D, Scott EAH, et al
    Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31215.
    PubMed     Abstract available


  328. AZAD AI, Krishnan A, Troop L, Li Y, et al
    Targeted Apoptosis Of Ductular Reactive Cells Reduces Hepatic Fibrosis In A Mouse Model of Cholestasis.
    Hepatology. 2020 Mar 3. doi: 10.1002/hep.31211.
    PubMed     Abstract available


  329. KARDASHIAN A, Florman SS, Haydel B, Ruiz RM, et al
    Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Hepatology. 2020 Mar 2. doi: 10.1002/hep.31210.
    PubMed     Abstract available


  330. PATEL K, Harrison SA, Elkashab M, Trotter JF, et al
    Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial.
    Hepatology. 2020 Mar 1. doi: 10.1002/hep.31205.
    PubMed     Abstract available


  331. JALAN-SAKRIKAR N, Schwartz RE, Amir M, Wedd J, et al
    Hepatology Highlights.
    Hepatology. 2020;71:771-773.
    PubMed    


  332. STENDER S, Loomba R
    PNPLA3 Genotype and Risk of Liver and All-Cause Mortality.
    Hepatology. 2020;71:777-779.
    PubMed    


  333. TANER T, Heimbach JK
    Something Wicked this Way Comes.
    Hepatology. 2020;71:1119-1121.
    PubMed    


  334. WONG GL, Wong VW
    Reply.
    Hepatology. 2020;71:1134.
    PubMed    


  335. LO GH
    Letter to the Editor: Could Variceal Screening Stratified by Liver/Spleen Stiffness Replace the Role of Endoscopy?
    Hepatology. 2020;71:1133.
    PubMed    


  336. RIZVI S, Gores GJ
    The Two Faces of Relaxin in Cancer: Antitumor or Protumor?
    Hepatology. 2020;71:1117-1119.
    PubMed    


  337. SUGIYAMA T
    Letter to the Editor: Bone Health and Denosumab Treatment in Autoimmune Liver Diseases: A Possible Involvement of Physical Activity.
    Hepatology. 2020;71:1131-1132.
    PubMed    


  338. ARASE Y, Kagawa T
    Reply.
    Hepatology. 2020;71:1132-1133.
    PubMed    


  339. YANG D, Yan J, Weng J
    Reply.
    Hepatology. 2020;71:1129.
    PubMed    


  340. LU ZN, Han ZG
    Reply.
    Hepatology. 2020;71:1130-1131.
    PubMed    


  341. WANG JB, Bai ZF, Xiao XH
    Letter to the Editor: Is Aristolochic Acid the Major Cause of Liver Cancer in China and Asia?
    Hepatology. 2020;71:1130.
    PubMed    


  342. SPANN A, Yasodhara A, Kang J, Watt K, et al
    Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review.
    Hepatology. 2020;71:1093-1105.
    PubMed     Abstract available


  343. UNALP-ARIDA A, Ruhl CE
    Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Hepatology. 2020;71:820-834.
    PubMed     Abstract available


  344. LU ZN, Luo Q, Zhao LN, Shi Y, et al
    The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
    Hepatology. 2020;71:929-942.
    PubMed     Abstract available


  345. AJMERA VH, Liu A, Singh S, Yachoa G, et al
    Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:849-860.
    PubMed     Abstract available


  346. DE CHIARA F, Thomsen KL, Habtesion A, Jones H, et al
    Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:874-892.
    PubMed     Abstract available


  347. CHANG Y, Ryu S, Kim Y, Cho YK, et al
    Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis.
    Hepatology. 2020;71:861-873.
    PubMed     Abstract available


  348. ABERG F, Puukka P, Salomaa V, Mannisto S, et al
    Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts.
    Hepatology. 2020;71:835-848.
    PubMed     Abstract available


    February 2020
  349. ITOH S, Yoshizumi T, Yugawa K, Imai D, et al
    Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association with Vascular Formation.
    Hepatology. 2020 Feb 29. doi: 10.1002/hep.31206.
    PubMed     Abstract available


  350. SHEN Y, Malik SA, Amir M, Kumar P, et al
    Decreased Hepatocyte Autophagy Leads to Synergistic IL-1beta and TNF Mouse Liver Injury and Inflammation.
    Hepatology. 2020 Feb 28. doi: 10.1002/hep.31209.
    PubMed     Abstract available


  351. SAILLARD C, Schmauch B, Laifa O, Moarii M, et al
    Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides.
    Hepatology. 2020 Feb 28. doi: 10.1002/hep.31207.
    PubMed     Abstract available


  352. TU C, Xiong H, Hu Y, Wang W, et al
    CRLS1 ameliorates nonalcoholic steatohepatitis through ATF3 transcriptional inactivation.
    Hepatology. 2020 Feb 25. doi: 10.1002/hep.31202.
    PubMed     Abstract available


  353. ZHU Y, Kwong LN
    Insights into the origin of intrahepatic cholangiocarcinoma from mouse models.
    Hepatology. 2020 Feb 24. doi: 10.1002/hep.31200.
    PubMed     Abstract available


  354. ZERMATTEN MG, Fraga M, Moradpour D, Bertaggia Calderara D, et al
    Haemostatic alterations in cirrhotic patients: from primary haemostasis to fibrinolysis.
    Hepatology. 2020 Feb 23. doi: 10.1002/hep.31201.
    PubMed     Abstract available


  355. LEI Y, Hoogerland JA, Bloks VW, Bos T, et al
    Hepatic ChREBP activation limits NAFLD development in a mouse model for Glycogen Storage Disease type Ia.
    Hepatology. 2020 Feb 21. doi: 10.1002/hep.31198.
    PubMed     Abstract available


  356. DING J, Zhao J, Huan L, Liu Y, et al
    Inflammation-induced LINC00665 increases the malignancy through activating PKR/NF-kappaB pathway in hepatocellular carcinoma.
    Hepatology. 2020 Feb 21. doi: 10.1002/hep.31195.
    PubMed     Abstract available


  357. PEERAPHATDIT TB, Nkomo VT, Naksuk N, Simonetto DA, et al
    Long-Term Outcomes After Transcatheter and Surgical Aortic Valve Replacement in Patients With Cirrhosis: A Guide for the Hepatologist.
    Hepatology. 2020 Feb 20. doi: 10.1002/hep.31193.
    PubMed     Abstract available


  358. SHARMA A, Verma AK, Kofron M, Kudira R, et al
    Lipopolysaccharide Reverses Hepatic Stellate Cell Activation via Modulation of cMyb, SMADs and C/EBP Transcription Factors.
    Hepatology. 2020 Feb 16. doi: 10.1002/hep.31188.
    PubMed     Abstract available


  359. VITALE A, Trevisani F, Farinati F, Cillo U, et al
    Treatment of hepatocellular carcinoma in the Precision Medicine era: from treatment stage migration to therapeutic hierarchy.
    Hepatology. 2020 Feb 16. doi: 10.1002/hep.31187.
    PubMed     Abstract available


  360. CHATURANTABUT S, Shwartz A, Garnaas MK, LaBella K, et al
    Estrogen acts via estrogen receptor 2b to regulate hepatobiliary fate during vertebrate development.
    Hepatology. 2020 Feb 14. doi: 10.1002/hep.31184.
    PubMed     Abstract available


  361. GUARALDI G, Maurice JB, Marzolini C, Monteith K, et al
    New drugs for non-alcoholic steatohepatitis and HIV infection: great expectations with a great absent?
    Hepatology. 2020 Feb 13. doi: 10.1002/hep.31177.
    PubMed     Abstract available


  362. NAULT JC, Villanueva A
    Biomarkers for hepatobiliary cancers.
    Hepatology. 2020 Feb 11. doi: 10.1002/hep.31175.
    PubMed     Abstract available


  363. DEBES JD, Boonstra A, de Knegt RJ
    NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse.
    Hepatology. 2020 Feb 10. doi: 10.1002/hep.31170.
    PubMed     Abstract available


  364. BHAN I, Ting DT
    Re: "Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease".
    Hepatology. 2020 Feb 8. doi: 10.1002/hep.31169.
    PubMed     Abstract available


  365. JEFFREY GP, Gordon LG, Hill MM, Ramm GA, et al
    Liquid biopsies for Hepatocellular cancer and their potential in clinical practice.
    Hepatology. 2020 Feb 7. doi: 10.1002/hep.31168.
    PubMed     Abstract available


  366. KUMAR S, Verma AK, Rani R, Sharma A, et al
    Hepatic deficiency of augmenter of liver regeneration predisposes to nonalcoholic steatohepatitis and fibrosis.
    Hepatology. 2020 Feb 7. doi: 10.1002/hep.31167.
    PubMed     Abstract available


  367. NATARAJAN Y, Kramer JR, Yu X, Li L, et al
    Risk of Cirrhosis and Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease and Normal Liver Enzymes.
    Hepatology. 2020 Feb 5. doi: 10.1002/hep.31157.
    PubMed     Abstract available


  368. RICH NE, John BV, Parikh ND, Rowe I, et al
    Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis.
    Hepatology. 2020 Feb 4. doi: 10.1002/hep.31159.
    PubMed     Abstract available


  369. AHN JC, Teng PC, Chen PJ, Posadas E, et al
    Detection of circulating tumor cells and their implications as a novel biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma.
    Hepatology. 2020 Feb 4. doi: 10.1002/hep.31165.
    PubMed     Abstract available


  370. DEROO R, Trepo E, Holvoet T, De Pauw M, et al
    Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis.
    Hepatology. 2020 Feb 4. doi: 10.1002/hep.31164.
    PubMed     Abstract available


  371. JOPHLIN LL, Cao S, Shah VH
    The transcriptome of hepatic fibrosis revealed by single cell RNA sequencing.
    Hepatology. 2020 Feb 3. doi: 10.1002/hep.31155.
    PubMed     Abstract available


  372. NIEHAUS CE, Strunz B, Cornillet M, Falk CS, et al
    MAIT cells are enriched and highly functional in ascites of patients with decompensated liver cirrhosis.
    Hepatology. 2020 Feb 3. doi: 10.1002/hep.31153.
    PubMed     Abstract available


  373. KAPLAN A, Rosenblatt R, Russo NW, Brown RS Jr, et al
    Hepatology Highlights.
    Hepatology. 2020;71:405-407.
    PubMed    


  374. GUILLOT A, Tacke F
    The Unexpected Role of Neutrophils for Resolving Liver Inflammation by Transmitting MicroRNA-223 to Macrophages.
    Hepatology. 2020;71:749-751.
    PubMed    


  375. PANDEY S
    Letter to the Editor: Re: Noninvasive Tests in Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Critical Insights from STELLAR Trials.
    Hepatology. 2020;71:763-764.
    PubMed    


  376. HASSAN S, Sebastian S, Maharjan S, Lesha A, et al
    Liver-on-a-Chip Models of Fatty Liver Disease.
    Hepatology. 2020;71:733-740.
    PubMed    


  377. SANDAHL TD, Laursen TL, Munk DE, Vilstrup H, et al
    The Prevalence of Wilson's Disease: An Update.
    Hepatology. 2020;71:722-732.
    PubMed     Abstract available


  378. ARASE Y, Tsuruya K, Hirose S, Ogiwara N, et al
    Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases.
    Hepatology. 2020;71:757-759.
    PubMed    


  379. PENRICE D, Simonetto DA
    Nodular Regenerative Hyperplasia Associated With Primary Liver Malignancies.
    Hepatology. 2020;71:760-761.
    PubMed    


  380. BAIGES A, Turon F, Simon-Talero M, Tasayco S, et al
    Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study.
    Hepatology. 2020;71:658-669.
    PubMed     Abstract available


  381. SCHUMACHER JD, Kong B, Wu J, Rizzolo D, et al
    Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.
    Hepatology. 2020;71:670-685.
    PubMed     Abstract available


  382. ALLEN AM, Shah VH, Therneau TM, Venkatesh SK, et al
    The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery.
    Hepatology. 2020;71:510-521.
    PubMed     Abstract available


  383. ARORA V, Maiwall R, Rajan V, Jindal A, et al
    Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.
    Hepatology. 2020;71:600-610.
    PubMed     Abstract available


    January 2020
  384. FENG A, Masadeh M, Murali AR
    Recurrent Isolated Hyperbilirubinemia from Drug-Induced Impaired Hepatic Bilirubin Uptake.
    Hepatology. 2020 Jan 31. doi: 10.1002/hep.31154.
    PubMed     Abstract available


  385. LIN FP, Ferrando AA, Dennis RA, Dunn MA, et al
    Exercise-Induced Hyperammonemia Does Not Precipitate Overt Hepatic Encephalopathy.
    Hepatology. 2020 Jan 30. doi: 10.1002/hep.31148.
    PubMed     Abstract available


  386. YI Z, Deng M, Scott MJ, Fu G, et al
    IRG1/Itaconate Activates Nrf2 in Hepatocytes to Protect Against Liver Ischemia-Reperfusion Injury.
    Hepatology. 2020 Jan 30. doi: 10.1002/hep.31147.
    PubMed     Abstract available


  387. WALLACE D, Cowling T, PcPhail MJ, Brown SE, et al
    Assessing the time-dependent impact of performance status on outcomes after liver transplantation.
    Hepatology. 2020 Jan 22. doi: 10.1002/hep.31124.
    PubMed     Abstract available


  388. LOOMBA R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, et al
    Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis.
    Hepatology. 2020 Jan 21. doi: 10.1002/hep.31121.
    PubMed     Abstract available


  389. FERNANDEZ-VARO G, Perramon M, Carvajal S, Oro D, et al
    Bespoken nanoceria: A new effective treatment in experimental hepatocellular carcinoma.
    Hepatology. 2020 Jan 21. doi: 10.1002/hep.31139.
    PubMed     Abstract available


  390. LA MURA V, Garcia-Guix M, Berzigotti A, Abraldes JG, et al
    A new prognostic algorithm based on stage of cirrhosis and HVPG to improve risk-stratification after variceal bleeding.
    Hepatology. 2020 Jan 20. doi: 10.1002/hep.31125.
    PubMed     Abstract available


  391. MA L, Li H, Hu J, Zheng J, et al
    Indole Alleviates Diet-induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell PFKFB3.
    Hepatology. 2020 Jan 17. doi: 10.1002/hep.31115.
    PubMed     Abstract available


  392. JIANG JX, Fish SR, Tomilov A, Li Y, et al
    Non-phagocytic Activation of NOX2 is Implicated in Progressive Non-alcoholic Steatohepatitis During Aging.
    Hepatology. 2020 Jan 17. doi: 10.1002/hep.31118.
    PubMed     Abstract available


  393. ANGELIDAKIS G, Krishnan S, Cabrera NL, Jiang Y, et al
    Virologic Impact of Radiotherapy in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma.
    Hepatology. 2020 Jan 16. doi: 10.1002/hep.31114.
    PubMed     Abstract available


  394. FABRELLAS N, Carol M, Palacio E, Aban M, et al
    Nursing care of patients with cirrhosis.
    Hepatology. 2020 Jan 16. doi: 10.1002/hep.31117.
    PubMed     Abstract available


  395. KOLB JM, Conzen K, Wachs M, Crossno J Jr, et al
    Liver Transplantation for Decompensated Cirrhosis Secondary to Telomerase Reverse Transcriptase (TERT) Mutation.
    Hepatology. 2020 Jan 14. doi: 10.1002/hep.31111.
    PubMed     Abstract available


  396. RATZIU V, Sanyal A, Harrison SA, Wong VW, et al
    Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
    Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108.
    PubMed     Abstract available


  397. ZHANG Z, Trippler M, Real CI, Werner M, et al
    Hepatitis B virus particles activate toll-like receptor 2 signaling initial upon infection of primary human hepatocytes.
    Hepatology. 2020 Jan 11. doi: 10.1002/hep.31112.
    PubMed     Abstract available


  398. TANTAI X, Liu N, Wang J
    Letter to Editor: The Association Between Diabetes and Hepatocellular carcinoma in Patients With Cirrhosis Caused by Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020 Jan 6. doi: 10.1002/hep.31099.
    PubMed     Abstract available


  399. FENG Z, Rong P, Wang W
    Hepatocellular Carcinoma Risk in Patients With NASH Cirrhosis and Diabetes: Insufficient for Individual Management.
    Hepatology. 2020 Jan 6. doi: 10.1002/hep.31100.
    PubMed     Abstract available


  400. LIAO Z, Chen L, Zhang X, Zhang H, et al
    PTPRepsilon Acts as a Metastatic Promoter in Hepatocellular Carcinoma by Facilitating Recruitment of SMAD3 to TGF-beta Receptor 1.
    Hepatology. 2020 Jan 6. doi: 10.1002/hep.31104.
    PubMed     Abstract available


  401. ZHU M, Li L, Lu T, Yoo H, et al
    Uncovering biological factors that regulate hepatocellular carcinoma growth using patient derived xenograft assays.
    Hepatology. 2020 Jan 3. doi: 10.1002/hep.31096.
    PubMed     Abstract available


  402. SHAH PA, Lau DTY, Russo NW, Brown RS Jr, et al
    Hepatology Highlights.
    Hepatology. 2020;71:1-3.
    PubMed    



  403. Seeking Editor for Hepatology.
    Hepatology. 2020;71.
    PubMed    


  404. NEUSCHWANDER-TETRI BA
    Too Much Sugar-The Not-So-Sweet Reality of Its Impact on Our Health.
    Hepatology. 2020;71:377-379.
    PubMed    


  405. THALHEIMER U
    Letter to the Editor: The Obsolescence of Sclerotherapy.
    Hepatology. 2020;71:393.
    PubMed    


  406. CHEUNG AC, Walker DI, Juran BD, Miller GW, et al
    Studying the Exposome to Understand the Environmental Determinants of Complex Liver Diseases.
    Hepatology. 2020;71:352-362.
    PubMed    


  407. SHANG L, Mashek DG
    The Underpinnings of PNPLA3-Mediated Fatty Liver Emerge.
    Hepatology. 2020;71:375-377.
    PubMed    


  408. JANSSON-KNODELL CL, Gawrieh S, McIntyre AD, Liang T, et al
    Apolipoprotein B and PNPLA3 Double Heterozygosity in a Father-Son Pair With Advanced Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:383-385.
    PubMed    


  409. BALOG S, Li Y, Ogawa T, Miki T, et al
    Development of Capsular Fibrosis Beneath the Liver Surface in Humans and Mice.
    Hepatology. 2020;71:291-305.
    PubMed     Abstract available


  410. KWAN SY, Sheel A, Song CQ, Zhang XO, et al
    Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes.
    Hepatology. 2020;71:275-290.
    PubMed     Abstract available


  411. LAITINEN TT, Vahtera J, Pahkala K, Magnussen CG, et al
    Childhood Socioeconomic Disadvantage and Risk of Fatty Liver in Adulthood: The Cardiovascular Risk in Young Finns Study.
    Hepatology. 2020;71:67-75.
    PubMed     Abstract available


  412. GELLERT-KRISTENSEN H, Nordestgaard BG, Tybjaerg-Hansen A, Stender S, et al
    High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
    Hepatology. 2020;71:56-66.
    PubMed     Abstract available


    December 2019
  413. JOB S, Rapoud D, Dos Santos A, Gonzalez P, et al
    Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma.
    Hepatology. 2019 Dec 25. doi: 10.1002/hep.31092.
    PubMed     Abstract available


  414. DONG ZR, Sun D, Yang YF, Zhou W, et al
    TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage.
    Hepatology. 2019 Dec 22. doi: 10.1002/hep.31076.
    PubMed     Abstract available


  415. CHANDRAMOULI S, Lee WM, Lo J, Toomay S, et al
    Prophylactic Transjugular Intrahepatic Portosystemic Shunt Placement for Cirrhosis Management in Pregnancy.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31081.
    PubMed     Abstract available


  416. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    PubMed     Abstract available


  417. JI GOH M, Kim S, Woo SY, Sinn DH, et al
    Statins and reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: Author's Reply.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31079.
    PubMed     Abstract available


  418. KARVAR S, Ansa-Addo EA, Suda J, Singh S, et al
    Moesin, an ERM family member, regulates hepatic fibrosis.
    Hepatology. 2019 Dec 20. doi: 10.1002/hep.31078.
    PubMed     Abstract available


  419. HUANG R, Wang J, Wu W, Yan X, et al
    Letter to the Editor: Statins and reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B.
    Hepatology. 2019 Dec 19. doi: 10.1002/hep.31080.
    PubMed     Abstract available


  420. DEVARBHAVI H
    Response to "Liver Transplantation for Acute Liver Failure Due to Dengue Fever" by Galante A et al. Hepatology. 2019;70:1863-65.
    Hepatology. 2019 Dec 17. doi: 10.1002/hep.31074.
    PubMed     Abstract available


  421. YANG NB, Li GX, Chu JG, Wang YJ, et al
    Letter to the Editors: Consider More Factors When Studying Risk of Cirrhosis and Hepatocellular Cancer in NAFLD Patients.
    Hepatology. 2019 Dec 17. doi: 10.1002/hep.31075.
    PubMed     Abstract available


  422. HU ZQ, Zhou SL, Li J, Zhou ZJ, et al
    Circular RNA Sequencing Identifies CircASAP1 as a Key Regulator in Hepatocellular Carcinoma Metastasis.
    Hepatology. 2019 Dec 15. doi: 10.1002/hep.31068.
    PubMed     Abstract available


  423. D'AMICO G, Abraldes JG, Rebora P, Valsecchi MG, et al
    Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis.
    Hepatology. 2019 Dec 14. doi: 10.1002/hep.31070.
    PubMed     Abstract available


  424. HU Z, Liangqing D, Li S, Li Z, et al
    Splicing Regulator p54(nrb) /NONO Enhances Carcinogenesis Through Oncogenic Isoform Switch of BIN1 in Hepatocellular Carcinoma.
    Hepatology. 2019 Dec 9. doi: 10.1002/hep.31062.
    PubMed     Abstract available


  425. LI Z, Weller SG, Drizyte-Miller K, Chen J, et al
    Maturation of Lipophagic Organelles in Hepatocytes is Dependent Upon a Rab10-Dynamin-2 Complex.
    Hepatology. 2019 Dec 6. doi: 10.1002/hep.31059.
    PubMed     Abstract available



  426. 2019 Hepatology Referees (Volumes 69 and 70).
    Hepatology. 2019;70:2245-2250.
    PubMed    


  427. PISA JF, Brown RS Jr, Yang LM, Lau DTY, et al
    Hepatology Highlights.
    Hepatology. 2019;70:1881-1884.
    PubMed    


    November 2019
  428. LIU XL, Pan Q, Cao HX, Xin FZ, et al
    Lipotoxic Hepatocyte-Derived Exosomal miR-192-5p Activates Macrophages via Rictor/Akt/FoxO1 Signaling in NAFLD.
    Hepatology. 2019 Nov 28. doi: 10.1002/hep.31050.
    PubMed     Abstract available


  429. XIAO X, Dev S, Canali S, Bayer A, et al
    Endothelial Bmp2 knockout exacerbates hemochromatosis in Hfe knockout mice but not Bmp6 knockout mice.
    Hepatology. 2019 Nov 28. doi: 10.1002/hep.31048.
    PubMed     Abstract available


  430. GYORI GP, Pereyra D, Rumpf B, Hackl H, et al
    Von Willebrand factor facilitates MELD-independent risk stratification on the waiting list for liver transplantation.
    Hepatology. 2019 Nov 27. doi: 10.1002/hep.31047.
    PubMed     Abstract available


  431. ROGAL S, Youk A, Zhang H, Gellad WF, et al
    Impact of Alcohol Use Disorder Treatment on Clinical Outcomes among Patients with Cirrhosis.
    Hepatology. 2019 Nov 23. doi: 10.1002/hep.31042.
    PubMed     Abstract available


  432. YU H, Li M, He R, Fang P, et al
    MVP promotes hepatocellular carcinoma via targeting IRF2 and decreasing p53 activity.
    Hepatology. 2019 Nov 23. doi: 10.1002/hep.31045.
    PubMed     Abstract available


  433. OVEREEM AW, Li Q, Qiu YL, Carton-Garcia F, et al
    A molecular mechanism underlying genotype-specific intrahepatic cholestasis resulting from MYO5B mutations.
    Hepatology. 2019 Nov 21. doi: 10.1002/hep.31002.
    PubMed     Abstract available


  434. OCHIAI Y, Yamaguchi J, Kokuryo T, Yokoyama Y, et al
    Trefoil factor family 1 inhibits the development of hepatocellular carcinoma by regulating beta-catenin activation.
    Hepatology. 2019 Nov 16. doi: 10.1002/hep.31039.
    PubMed     Abstract available


  435. KOSHY AN, Farouque O, Calafiore P, Gow PJ, et al
    Diagnosis of Cirrhotic Cardiomyopathy: The Role of an Impaired Cardiac Reserve.
    Hepatology. 2019 Nov 11. doi: 10.1002/hep.31034.
    PubMed     Abstract available


  436. HWANG S, He Y, Xiang X, Seo W, et al
    Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets.
    Hepatology. 2019 Nov 9. doi: 10.1002/hep.31031.
    PubMed     Abstract available


  437. LEE BP, Vittinghoff E, Pletcher MJ, Dodge JL, et al
    Medicaid Policy and Liver Transplant for Alcohol-Related Liver Disease.
    Hepatology. 2019 Nov 8. doi: 10.1002/hep.31027.
    PubMed     Abstract available


  438. HAN G, Berhane S, Toyoda H, Bettinger D, et al
    Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.
    Hepatology. 2019 Nov 7. doi: 10.1002/hep.31022.
    PubMed     Abstract available


  439. WANG X, Gao B
    gammadeltaT cells and CD1d, novel immune players in alcoholic and nonalcoholic steatohepatitis?
    Hepatology. 2019 Nov 7. doi: 10.1002/hep.31025.
    PubMed     Abstract available


  440. KUTKUT I, Rachwan RJ, Timsina LR, Ghabril MS, et al
    Pre-Liver Transplant Cardiac Catheterization is Associated with Low Rate of Myocardial Infarction and Cardiac Mortality.
    Hepatology. 2019 Nov 7. doi: 10.1002/hep.31023.
    PubMed     Abstract available


  441. LUK ST, Ng KY, Zhou L, Tong M, et al
    Deficiency in embryonic stem cell marker REX1 activates MKK6-dependent p38 MAPK signaling to drive hepatocarcinogenesis.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31020.
    PubMed     Abstract available


  442. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    PubMed     Abstract available


  443. FANG AP, Long JA, Zhang YJ, Liu ZY, et al
    Serum bioavailable, rather than total, 25-hydroxyvitamin D levels are associated with hepatocellular carcinoma survival.
    Hepatology. 2019 Nov 2. doi: 10.1002/hep.31013.
    PubMed     Abstract available


  444. KANWAL F, Kramer J, Li L, Dai J, et al
    Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Non-alcoholic Fatty Liver Disease.
    Hepatology. 2019 Nov 1. doi: 10.1002/hep.31014.
    PubMed     Abstract available


  445. AMIR M, Vora RS, Tafesh ZH, Jesudian A, et al
    Hepatology Highlights.
    Hepatology. 2019;70:1497-1499.
    PubMed    


    October 2019
  446. ASRANI SK
    Accurate assessment of renal function in cirrhosis.
    Hepatology. 2019 Oct 25. doi: 10.1002/hep.31006.
    PubMed     Abstract available


  447. SYED-ABDUL MM, Parks EJ, Gaballah AH, Bingham K, et al
    First-in-class fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities.
    Hepatology. 2019 Oct 20. doi: 10.1002/hep.31000.
    PubMed     Abstract available


  448. STICKEL F, Lutz P, Buch S, Nischalke HD, et al
    Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers.
    Hepatology. 2019 Oct 19. doi: 10.1002/hep.30996.
    PubMed     Abstract available


  449. SONG K, Kwon H, Han C, Chen W, et al
    YAP in Kupffer cells enhances the production of pro-inflammatory cytokines and promotes the development of non-alcoholic steatohepatitis.
    Hepatology. 2019 Oct 14. doi: 10.1002/hep.30990.
    PubMed     Abstract available


  450. TANEJA V
    Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
    Hepatology. 2019 Oct 14. doi: 10.1002/hep.30992.
    PubMed     Abstract available


  451. LEUNG CON, Tong M, Chung KPS, Zhou L, et al
    Overriding adaptive resistance to sorafenib via combination therapy with SHP2 blockade in hepatocellular carcinoma.
    Hepatology. 2019 Oct 14. doi: 10.1002/hep.30989.
    PubMed     Abstract available


  452. HYDE AM, Carbonneau M, Abraldes JG, Tandon P, et al
    Advanced Practice Providers: Raising Our Defenses Against the Rising Tide of Cirrhosis.
    Hepatology. 2019 Oct 12. doi: 10.1002/hep.30987.
    PubMed     Abstract available


  453. LIU F, Goh GB, Tiniakos D, Wee A, et al
    qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986.
    PubMed     Abstract available


  454. FELLI E, Saviano A, Tripon S, Baumert TF, et al
    Letter to the Editor: Abdominal Surgery in Idiopathic Noncirrhotic Portal Hypertension: Is Preemptive TIPS Reducing Postoperative Complications?
    Hepatology. 2019 Oct 9. doi: 10.1002/hep.30985.
    PubMed     Abstract available


  455. POLI E, Kounis I, Guettier C, Verstuyft C, et al
    Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
    Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
    PubMed     Abstract available


  456. SHAHEEN R, Alsahli S, Ewida N, Alzahrani F, et al
    Biallelic mutations in TTC26 (IFT56) cause severe biliary ciliopathy in humans.
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30982.
    PubMed     Abstract available


  457. HUANG R, Wang J, Zhang Z, Yan X, et al
    Letter to the Editor: Impact of non-alcoholic steatohepatitis on liver-related outcomes in chronic hepatitis B.
    Hepatology. 2019 Oct 6. doi: 10.1002/hep.30981.
    PubMed     Abstract available


  458. SUN Q, Zhang Z, Lu Y, Liu Q, et al
    Loss of Xanthine Oxidoreductase Potentiates Propagation of Hepatocellular Carcinoma Stem Cells.
    Hepatology. 2019 Oct 3. doi: 10.1002/hep.30978.
    PubMed     Abstract available


    September 2019
  459. LIU Y, Chen K, Li F, Gu Z, et al
    Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice.
    Hepatology. 2019 Sep 30. doi: 10.1002/hep.30975.
    PubMed     Abstract available


  460. GOH MJ, Sinn DH, Kim S, Woo SY, et al
    Statin Use and the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.
    Hepatology. 2019 Sep 25. doi: 10.1002/hep.30973.
    PubMed     Abstract available


  461. KARSDAL MA, Detlefsen S, Daniels SJ, Nielsen MJ, et al
    Is the total amount as important as localization and type of collagen in liver fibrosis due to steatohepatitis?
    Hepatology. 2019 Sep 25. doi: 10.1002/hep.30969.
    PubMed     Abstract available


  462. PERKONS NR, Kiefer RM, Noji MC, Pourfathi M, et al
    Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy.
    Hepatology. 2019 Sep 25. doi: 10.1002/hep.30970.
    PubMed     Abstract available


  463. NAKANO Y, Kamiya A, Sumiyoshi H, Tsuruya K, et al
    A novel deactivation factor of fibrogenic hepatic stellate cells induces regression of liver fibrosis in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30965.
    PubMed     Abstract available


  464. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    PubMed     Abstract available


  465. QIU W, Wang B, Gao Y, Tian Y, et al
    Targeting HDAC6 Reprograms TH 17 Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma.
    Hepatology. 2019 Sep 20. doi: 10.1002/hep.30960.
    PubMed     Abstract available


  466. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
    Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
    Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
    PubMed     Abstract available


  467. KUMAR A, Sharma P, Arora A
    Portal Pressure in Non-Cirrhotic Portal Hypertension: To Measure or Not to Measure.
    Hepatology. 2019 Sep 18. doi: 10.1002/hep.30957.
    PubMed     Abstract available


  468. DA BL, Koh C, Heller T
    REPLY: Portal Pressure in Non-Cirrhotic Portal Hypertension: To Measure or Not to Measure.
    Hepatology. 2019 Sep 18. doi: 10.1002/hep.30955.
    PubMed     Abstract available


  469. MATSUZAKA T, Kuba M, Koyasu S, Yamamoto Y, et al
    Hepatocyte Elovl6 determines ceramide acyl-chain length and hepatic insulin sensitivity in mice.
    Hepatology. 2019 Sep 17. doi: 10.1002/hep.30953.
    PubMed     Abstract available


  470. TORRES-HERNANDEZ A, Wang W, Nikiforov Y, Tejada K, et al
    gammadelta T cells Promote Steatohepatitis by Orchestrating Innate and Adaptive Immune Programming.
    Hepatology. 2019 Sep 17. doi: 10.1002/hep.30952.
    PubMed     Abstract available


  471. FANG J, Ji YX, Zhang P, Cheng L, et al
    Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3.
    Hepatology. 2019 Sep 17. doi: 10.1002/hep.30950.
    PubMed     Abstract available


  472. CHEN J, Du F, Dang Y, Li X, et al
    FGF19-mediated upregulation of SOX18 promotes hepatocellular carcinoma metastasis by transactivating FGFR4 and FLT4.
    Hepatology. 2019 Sep 16. doi: 10.1002/hep.30951.
    PubMed     Abstract available


  473. ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
    MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
    Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
    PubMed     Abstract available


  474. ZHONG W, Wei X, Hao L, Lin TD, et al
    Paneth cell dysfunction mediates alcoholic steatohepatitis through promoting bacterial translocation in mice: role of zinc deficiency.
    Hepatology. 2019 Sep 14. doi: 10.1002/hep.30945.
    PubMed     Abstract available


  475. LOOMBA R, Adams LA
    Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH.
    Hepatology. 2019 Sep 13. doi: 10.1002/hep.30946.
    PubMed     Abstract available


  476. KIM HB, Elisofon SA
    Hepatology Elsewhere.
    Hepatology. 2019 Sep 13. doi: 10.1002/hep.30935.
    PubMed     Abstract available


  477. GOUYA L, Ventura P, Balwani M, Bissell DM, et al
    EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks.
    Hepatology. 2019 Sep 12. doi: 10.1002/hep.30936.
    PubMed     Abstract available


  478. HUANG Z, Zhou JK, Wang K, Chen H, et al
    PDLIM1 inhibits tumor metastasis through activating Hippo signaling in hepatocellular carcinoma.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30930.
    PubMed     Abstract available


  479. DONG B, Zhou Y, Wang W, Scott J, et al
    Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30937.
    PubMed     Abstract available


  480. BI X, Deising A, Frenette C
    Acute Liver Failure from Exertional Heatstroke Can Result in Excellent Long-term Survival with Liver Transplantation.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30938.
    PubMed     Abstract available


  481. MOORING M, Fowl BH, Lum SZC, Liu Y, et al
    Hepatocyte Stress Increases Expression of YAP and TAZ in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30928.
    PubMed     Abstract available


  482. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
    Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
    PubMed     Abstract available


  483. YANG Z, Feng J, Xiao L, Chen X, et al
    Tumor-Derived PGLYRP2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma.
    Hepatology. 2019 Sep 3. doi: 10.1002/hep.30924.
    PubMed     Abstract available


    August 2019
  484. WONG TL, Ng KY, Vin Tan K, Chan LH, et al
    CRAF methylation by PRMT6 regulates aerobic glycolysis driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation.
    Hepatology. 2019 Aug 30. doi: 10.1002/hep.30923.
    PubMed     Abstract available


  485. MATYAS C, Erdelyi K, Trojnar E, Zhao S, et al
    Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy.
    Hepatology. 2019 Aug 30. doi: 10.1002/hep.30916.
    PubMed     Abstract available


  486. BLASI A, Patel VC, Adelmeijer J, Azarian S, et al
    Mixed fibrinolytic phenotypes in decompensated cirrhosis and ACLF with hypofibrinolysis in those with complications and poor survival.
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30915.
    PubMed     Abstract available


  487. KWON HM, Moon YJ, Jung KW, Park YS, et al
    Appraisal of cardiac ejection fraction with liver disease severity: Implication in post-liver transplantation mortality.
    Hepatology. 2019 Aug 28. doi: 10.1002/hep.30913.
    PubMed     Abstract available


  488. BEUERS U, Hohenester S
    Fatigue in Primary Biliary Cholangitis: no Place for Rituximab.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30906.
    PubMed     Abstract available


  489. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
    Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
    PubMed     Abstract available


  490. PATRA T, Meyer K, Ray RB, Ray R, et al
    Hepatitis C virus mediated inhibition of miR-181c activates ATM signaling and promotes hepatocyte growth.
    Hepatology. 2019 Aug 10. doi: 10.1002/hep.30893.
    PubMed     Abstract available


  491. GUO WZ, Fang HB, Cao SL, Chen SY, et al
    Steap3 deficiency in hepatocytes protects the liver against ischemia/reperfusion injury by suppressing TAK1.
    Hepatology. 2019 Aug 8. doi: 10.1002/hep.30882.
    PubMed     Abstract available


  492. ZHOU Y, Dong B, Kim KH, Choi S, et al
    Vitamin D receptor activation in liver macrophages protects against hepatic endoplasmic reticulum stress in mice.
    Hepatology. 2019 Aug 5. doi: 10.1002/hep.30887.
    PubMed     Abstract available


  493. HIRSOVA P, Malhi H, Russo N, Shah PA, et al
    Hepatology Highlights.
    Hepatology. 2019;70:455-458.
    PubMed    


    July 2019
  494. MANDORFER M, Kozbial K, Schwabl P, Chromy D, et al
    Changes in HVPG predict hepatic decompensation in patients who achieved SVR to IFN-free therapy.
    Hepatology. 2019 Jul 31. doi: 10.1002/hep.30885.
    PubMed     Abstract available


  495. CHOI S, Dong B, Lin CJ, Heo MJ, et al
    Methyl-sensing nuclear receptor Liver Receptor Homolog-1 regulates mitochondrial function in mouse hepatocytes.
    Hepatology. 2019 Jul 29. doi: 10.1002/hep.30884.
    PubMed     Abstract available


  496. KIM HD, Park S, Jeong S, Lee YJ, et al
    4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8(+) T cells in Hepatocellular Carcinoma.
    Hepatology. 2019 Jul 28. doi: 10.1002/hep.30881.
    PubMed     Abstract available


  497. ZIOGAS IA, van der Windt DJ, Wilson GC, Furlan A, et al
    Surgical Management of Ciliated Hepatic Foregut Cyst.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30877.
    PubMed     Abstract available


  498. MEHTA N, Dodge JL, Grab JD, Yao FY, et al
    National Experience on Down-staging of Hepatocellular Carcinoma before Liver Transplant: Influence of Tumor Burden, AFP, and Wait Time.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30879.
    PubMed     Abstract available


  499. LUO F, Liao R
    Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: Benefit or Not.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30872.
    PubMed     Abstract available


  500. ZHANG XP, Gao YZ, Chen ZH, Cheng SQ, et al
    Reply to "Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: Benefit or Not".
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30873.
    PubMed     Abstract available


  501. IZZY M, VanWagner LB, Lin G, Altieri M, et al
    Redefining Cirrhotic Cardiomyopathy For The Modern Era.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30875.
    PubMed     Abstract available


  502. KYRITSI K, Chen L, O'Brien A, Francis H, et al
    Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880.
    PubMed     Abstract available


  503. CHOUDHARY NS, Saigal S, Soin AS
    Liver transplantation for Acute Liver Failure due to Dengue fever: first successful reported case worldwide.
    Hepatology. 2019 Jul 22. doi: 10.1002/hep.30869.
    PubMed     Abstract available


  504. LO GH
    Letter of Editor: Colder weather and fewer sunlight hours truly increase alcohol consumption and alcoholic cirrhosis ?
    Hepatology. 2019 Jul 19. doi: 10.1002/hep.30865.
    PubMed     Abstract available


  505. DA BL, Surana P, Kapuria D, Vittal A, et al
    Portal Pressure in Non-Cirrhotic Portal Hypertension: To Measure or Not to Measure.
    Hepatology. 2019 Jul 18. doi: 10.1002/hep.30862.
    PubMed     Abstract available


  506. ALLER MA, Arias J, Blanco-Rivero J
    The porto-hepatic spectrum of cirrhotic encephalopathy.
    Hepatology. 2019 Jul 17. doi: 10.1002/hep.30860.
    PubMed     Abstract available


  507. MAIWALL R, Rao Pasupuleti SS, Bihari C, Rastogi A, et al
    Incidence, Risk Factors, and Outcomes of Transition of Acute Kidney Injury to Chronic Kidney Disease in Cirrhosis: A Prospective Cohort Study.
    Hepatology. 2019 Jul 16. doi: 10.1002/hep.30859.
    PubMed     Abstract available


  508. YANG JD, Ahmed F, Mara KC, Addissie BD, et al
    Diabetes is Associated with Increased Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease.
    Hepatology. 2019 Jul 15. doi: 10.1002/hep.30858.
    PubMed     Abstract available


  509. CHOI HSJ, Brouwer WP, Zanjir WMR, de Man RA, et al
    Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B.
    Hepatology. 2019 Jul 15. doi: 10.1002/hep.30857.
    PubMed     Abstract available


  510. MARRERO JA
    Obesity and Liver Disease: The New Era of Liver Transplantation.
    Hepatology. 2019 Jul 13. doi: 10.1002/hep.30854.
    PubMed     Abstract available


  511. BUBICI C, Lepore A, Papa S
    ASKing no more: the emerging role of DUSP12 in the regulation of hepatic lipid metabolism.
    Hepatology. 2019 Jul 12. doi: 10.1002/hep.30851.
    PubMed     Abstract available


  512. JIA X, Lu S, Zeng Z, Liu Q, et al
    Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma.
    Hepatology. 2019 Jul 12. doi: 10.1002/hep.30852.
    PubMed     Abstract available


  513. SIMONETTO DA, Kamath PS, Shah VH
    Assessing surgical risk in idiopathic portal hypertension: some answers, an extrapolation, and more questions.
    Hepatology. 2019 Jul 12. doi: 10.1002/hep.30847.
    PubMed     Abstract available


  514. WANG AY, Smith EZ, Sauer BG, Henry ZH, et al
    A pilot experience of endoscopic submucosal dissection of Barrett's dysplasia despite esophageal varices and decompensated cirrhosis.
    Hepatology. 2019 Jul 11. doi: 10.1002/hep.30850.
    PubMed     Abstract available


  515. MAJUMDAR A, Campos S, Gurusamy K, Pinzani M, et al
    Defining the minimum acceptable diagnostic accuracy of non-invasive fibrosis testing in cirrhosis: a decision analytic modelling study.
    Hepatology. 2019 Jul 11. doi: 10.1002/hep.30846.
    PubMed     Abstract available


  516. WU SH, Hsu JS, Chen HL, Chien MM, et al
    Plectin Mutations in Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2019 Jul 3. doi: 10.1002/hep.30841.
    PubMed     Abstract available


  517. MOUSA OY, Malhi H, Russo N, Jesudian A, et al
    Hepatology Highlights.
    Hepatology. 2019;70:1-4.
    PubMed    


    June 2019
  518. CHOUDHARY NS, Saraf N, Saigal S, Soin AS, et al
    Incidence and Mortality of Acute on Chronic Liver Failure using Two Definitions in Patients with Compensated Cirrhosis.
    Hepatology. 2019 Jun 27. doi: 10.1002/hep.30837.
    PubMed     Abstract available


  519. FIRL DJ, Sasaki K, Agopian VG, Gorgen A, et al
    Charting the Path Forward for Risk Prediction in Liver Transplant for HCC: International Validation of HALTHCC amongst 4,089 patients.
    Hepatology. 2019 Jun 27. doi: 10.1002/hep.30838.
    PubMed     Abstract available


  520. PAPATHEODORIDI AM, Chrysavgis L, Koutsilieris M, Chatzigeorgiou A, et al
    The role of senescence in the development of non-alcoholic fatty liver disease and progression to non-alcoholic steatohepatitis.
    Hepatology. 2019 Jun 23. doi: 10.1002/hep.30834.
    PubMed     Abstract available


  521. WANG Y, Wen H, Fu J, Cai L, et al
    Hepatocyte TRAF6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lys6- Linked Polyubiquitination of ASK1.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30822.
    PubMed     Abstract available


  522. KANWAL F, Kramer JR, Asch SM, Cao Y, et al
    Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30823.
    PubMed     Abstract available


  523. VILARINHO S, Mistry PK
    Exome Sequencing in Clinical Hepatology.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30826.
    PubMed     Abstract available


  524. LI J, Wang J, Yu S, Yuan G, et al
    Hepatocellular Carcinoma Surveillance In High-Risk Patients With Cirrhosis:Contrast-enhanced Ultrasound May Be A Choice.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30819.
    PubMed     Abstract available


  525. LIU R, Kang JD, Sartor RB, Sikaroodi M, et al
    Neuroinflammation in Murine Cirrhosis is Dependent on the Gut Microbiome and is Attenuated by Fecal Transplant.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30827.
    PubMed     Abstract available


  526. CAREY EJ, Lai JC, Sonnenday C, Tapper EB, et al
    A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30828.
    PubMed     Abstract available


  527. HUANG M, Kim HG, Zhong X, Dong C, et al
    Sesn3 protects against diet-induced nonalcoholic steatohepatitis in mice via suppression of the TGFbeta signal transduction.
    Hepatology. 2019 Jun 19. doi: 10.1002/hep.30820.
    PubMed     Abstract available


  528. DIMRI M, Humphries A, Laknaur A, Elattar S, et al
    Nqo1 ablation inhibits activation of the PI3K/Akt and MAPK/ERK pathways and blocks metabolic adaptation in hepatocellular carcinoma.
    Hepatology. 2019 Jun 19. doi: 10.1002/hep.30818.
    PubMed     Abstract available


  529. KLOMPENHOUWER AJ, Thomeer MGJ, Dinjens WNM, de Man RA, et al
    Phenotype or genotype: new decision-making dilemmas in hepatocellular adenoma.
    Hepatology. 2019 Jun 17. doi: 10.1002/hep.30812.
    PubMed     Abstract available


  530. RENNE SL, Woo HY, Allegra S, Rudini N, et al
    VETC (vessels encapsulating tumor clusters) is a powerful predictor of aggressive hepatocellular carcinoma.
    Hepatology. 2019 Jun 17. doi: 10.1002/hep.30814.
    PubMed     Abstract available


  531. FUJIWARA N, Singal AG, Hoshida Y
    Dose and duration of aspirin use to reduce incidental hepatocellular carcinoma.
    Hepatology. 2019 Jun 17. doi: 10.1002/hep.30813.
    PubMed     Abstract available


  532. NAULT JC, Martin Y, Caruso S, Hirsch TZ, et al
    Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma.
    Hepatology. 2019 Jun 17. doi: 10.1002/hep.30811.
    PubMed     Abstract available


  533. WINER BY, Gaska JM, Lipkowitz G, Bram Y, et al
    Analysis of host responses to hepatitis B and delta viral infections in a micro-scalable hepatic co-culture system.
    Hepatology. 2019 Jun 17. doi: 10.1002/hep.30815.
    PubMed     Abstract available


  534. ZHENG Q, Zhao J, Yu H, Zong H, et al
    Tumor-specific Transcripts are Frequently Expressed in Hepatocellular Carcinoma with Clinical Implication and Potential Function.
    Hepatology. 2019 Jun 7. doi: 10.1002/hep.30805.
    PubMed     Abstract available


  535. GALANTE A, Adeyi O, Lau L, Humar A, et al
    Liver transplantation for Acute Liver Failure due to Dengue fever: first successful reported case worldwide.
    Hepatology. 2019 Jun 4. doi: 10.1002/hep.30803.
    PubMed     Abstract available


  536. WU H, Yang TY, Li Y, Ye WL, et al
    TRAF6 promotes hepatocarcinogenesis by interacting with HDAC3 to enhance c-Myc gene expression and protein stability.
    Hepatology. 2019 Jun 3. doi: 10.1002/hep.30801.
    PubMed     Abstract available


  537. SURI JS, Ezaz G, Lau DTY, Kulai TB, et al
    Hepatology Highlights.
    Hepatology. 2019;69:2311-2314.
    PubMed    


    May 2019
  538. KUMAR M, Ahmad J, Maiwall R, Choudhury A, et al
    Thromboelastography-Guided Blood Component Use in Patients With Cirrhosis With Nonvariceal Bleeding: A Randomized Controlled Trial.
    Hepatology. 2019 May 31. doi: 10.1002/hep.30794.
    PubMed     Abstract available


  539. QIN G, Tu X, Li H, Cao P, et al
    lncRNA PSTAR Promotes p53 Signaling by Inhibiting hnRNP K deSUMOylation and Suppresses Hepatocellular Carcinoma.
    Hepatology. 2019 May 30. doi: 10.1002/hep.30793.
    PubMed     Abstract available


  540. WEI Y, Chen X, Liang C, Ling Y, et al
    A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma.
    Hepatology. 2019 May 30. doi: 10.1002/hep.30795.
    PubMed     Abstract available


  541. WANG CY, Xiao X, Bayer A, Xu Y, et al
    Ablation of hepatocyte Smad1, Smad5 and Smad8 causes severe tissue iron loading and liver fibrosis in mice.
    Hepatology. 2019 May 24. doi: 10.1002/hep.30780.
    PubMed     Abstract available


  542. TERZIROLI BERETTA-PICCOLI B, Thompson R, Foskett P, Cerny A, et al
    A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adulthood.
    Hepatology. 2019 May 24. doi: 10.1002/hep.30783.
    PubMed     Abstract available


  543. SERPER M, Kaplan DE, Shults J, Reese PP, et al
    Quality measures, all-cause mortality, and healthcare utilization in a national cohort of Veterans with cirrhosis.
    Hepatology. 2019 May 20. doi: 10.1002/hep.30779.
    PubMed     Abstract available


  544. HOOGERLAND JA, Lei Y, Wolters JC, de Boer JF, et al
    Glucose-6-phosphate regulates hepatic bile acid synthesis in mice.
    Hepatology. 2019 May 18. doi: 10.1002/hep.30778.
    PubMed     Abstract available


  545. WANG P, Wang WJ, Choi-Nurvitadhi J, Lescaille Y, et al
    Rat OATP1A1 Interacts Directly With OATP1A4 Facilitating Its Maturation and Trafficking to the Hepatocyte Plasma Membrane.
    Hepatology. 2019 May 18. doi: 10.1002/hep.30772.
    PubMed     Abstract available


  546. SIEW SM, Cunningham SC, Zhu E, Tay SS, et al
    Prevention of cholestatic liver disease and reduced tumorigenicity in a murine model of PFIC type 3 using hybrid AAV-piggyBac gene therapy.
    Hepatology. 2019 May 17. doi: 10.1002/hep.30773.
    PubMed     Abstract available


  547. PERRET C, Decaens T
    mTOR inhibitors, new drugs for CTNNB1-mutated hepatocellular carcinomas?
    Hepatology. 2019 May 16. doi: 10.1002/hep.30768.
    PubMed     Abstract available


  548. JIANG N, Li X, Xing YF, Qiao YD, et al
    Local regional therapy before liver transplantation for hepatocellular carcinoma.
    Hepatology. 2019 May 15. doi: 10.1002/hep.30769.
    PubMed     Abstract available


  549. GLUCHOWSKI NL, Gabriel KR, Chitraju C, Bronson RT, et al
    Hepatocyte Deletion of Triglyceride-Synthesis Enzyme DGAT2 Reduces Steatosis without Increasing Inflammation or Fibrosis.
    Hepatology. 2019 May 13. doi: 10.1002/hep.30765.
    PubMed     Abstract available


  550. CHOUDHARY NS, Saigal S, Saraf N, Soin AS, et al
    Prognostic role of ammonia in cirrhotic patients.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30758.
    PubMed     Abstract available


  551. YAN ZZ, Huang YP, Wang X, Wang HP, et al
    Integrated Omics Reveals Tollip as an Aggravator and Therapeutic Target for Hepatic Ischemia-Reperfusion Injury in Mice.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30705.
    PubMed     Abstract available


  552. OGESE MO, Jenkins RE, Adair K, Tailor A, et al
    Exosomal transport of hepatocyte-derived drug-modified proteins to the immune system.
    Hepatology. 2019 May 9. doi: 10.1002/hep.30701.
    PubMed     Abstract available


  553. NA S, Wang H, Bank T, Perera A, et al
    FAK and beta-Catenin Cooperate to Induce Hepatocellular Carcinoma.
    Hepatology. 2019 May 9. doi: 10.1002/hep.30707.
    PubMed     Abstract available


  554. MA F, Zhu Y, Liu X, Zhou Q, et al
    Dyrk3 loss activates the purine metabolism and promotes hepatocellular carcinoma progression.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30703.
    PubMed     Abstract available


  555. TAPPER EB, Hao S, Lin M, Mafi JN, et al
    The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30695.
    PubMed     Abstract available


  556. XU Z, Xu M, Liu P, Zhang S, et al
    The mTORC2-Akt cascade is crucial for c-Myc to promote hepatocarcinogenesis in mice and men.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30697.
    PubMed     Abstract available


  557. XIAO Y, Liu R, Li X, Gurley EC, et al
    Long non-coding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30698.
    PubMed     Abstract available


  558. TRIVEDI HD, Lau DTY, Kulai TB, Malhi H, et al
    Hepatology Highlights.
    Hepatology. 2019;69:1849-1851.
    PubMed    


    April 2019
  559. NARDELLI S, Lattanzi B, Merli M, Farcomeni A, et al
    Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis.
    Hepatology. 2019 Apr 30. doi: 10.1002/hep.30692.
    PubMed     Abstract available


  560. BAJAJ JS, Salzman NH, Acharya C, Sterling RK, et al
    Fecal Microbial Transplant Capsules are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.
    Hepatology. 2019 Apr 30. doi: 10.1002/hep.30690.
    PubMed     Abstract available


  561. ALISON MR, Lin WR
    Periportal Sox9-positive hepatocytes: progenitors with a biliary leaning.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30687.
    PubMed     Abstract available


  562. BHANJI RA, Montano-Loza AJ, Watt KD
    SARCOPENIA IN CIRRHOSIS: Looking beyond the skeletal muscle loss to see the systemic disease.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30686.
    PubMed     Abstract available


  563. CHEUNG A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, et al
    Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30672.
    PubMed     Abstract available


  564. BADAWY AA
    The Kynurenine Pathway in Hepatic Cirrhosis.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30680.
    PubMed     Abstract available


  565. STARLINGER P, Pereyra D, Hackl M, Assinger A, et al
    miRNA Signatures in Cirrhotic Patients.
    Hepatology. 2019 Apr 29. doi: 10.1002/hep.30682.
    PubMed     Abstract available


  566. LI YM, Liu ZY, Wang JC, Yu JM, et al
    RIP3 deficiency recruits myeloid-derived suppressor cells to hepatocellular carcinoma through the CXCL1-CXCR2 axis.
    Hepatology. 2019 Apr 25. doi: 10.1002/hep.30676.
    PubMed     Abstract available


  567. DEROSSI C, Bambino K, Morrison J, Sakarin I, et al
    Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans.
    Hepatology. 2019 Apr 23. doi: 10.1002/hep.30677.
    PubMed     Abstract available


  568. XIE Y, Matsumoto H, Kennedy S, Newberry EP, et al
    Impaired chylomicron assembly modifies hepatic metabolism through bile acid dependent and transmissible microbial adaptations.
    Hepatology. 2019 Apr 20. doi: 10.1002/hep.30669.
    PubMed     Abstract available


  569. WANG Y, Tu K, Liu D, Guo L, et al
    P300 Acetyltransferase is a Cytoplasm-to-Nucleus Shuttle for SMAD2/3 and TAZ Nuclear Transport in TGFbeta-stimulated Hepatic Stellate Cells.
    Hepatology. 2019 Apr 20. doi: 10.1002/hep.30668.
    PubMed     Abstract available


  570. STOTTS MJ, Adjapong O, Kaplan DE
    A Psoriasiform Drug Eruption Secondary to Nivolumab for Hepatocellular Carcinoma: a Case Report.
    Hepatology. 2019 Apr 20. doi: 10.1002/hep.30659.
    PubMed     Abstract available


  571. LI Q, Pan X, Zhu D, Deng Z, et al
    Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma via the miR-338-3p/PKM2 axis under hypoxic stress.
    Hepatology. 2019 Apr 20. doi: 10.1002/hep.30671.
    PubMed     Abstract available


  572. HAGE C, Hoves S, Strauss L, Bissinger S, et al
    Sorafenib Induces Pyroptosis in Macrophages and Triggers NK Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.
    Hepatology. 2019 Apr 19. doi: 10.1002/hep.30666.
    PubMed     Abstract available


  573. LEVITSKY J, Asrani SK, Abecassis M, Ruiz R, et al
    External Validation of a Pre-Transplant Biomarker Model (REVERSE) Predictive of Renal Recovery after Liver Transplantation.
    Hepatology. 2019 Apr 19. doi: 10.1002/hep.30667.
    PubMed     Abstract available


  574. SANYAL AJ, Harrison SA, Ratziu V, Abdelmalek MF, et al
    The Natural History of Advanced Fibrosis due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials.
    Hepatology. 2019 Apr 16. doi: 10.1002/hep.30664.
    PubMed     Abstract available


  575. YANG HD, Kim HS, Kim SY, Na MJ, et al
    HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-mediated Anti-tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.
    Hepatology. 2019 Apr 16. doi: 10.1002/hep.30657.
    PubMed     Abstract available


  576. DO A, Kuszewski EJ, Mehal WZ
    Incorporating Weight Loss Medications into Hepatology Practice for Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Apr 16. doi: 10.1002/hep.30658.
    PubMed     Abstract available


  577. LIU R, Li X, Zhu W, Wang Y, et al
    Cholangiocyte-derived exosomal LncRNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis.
    Hepatology. 2019 Apr 15. doi: 10.1002/hep.30662.
    PubMed     Abstract available


  578. HE Y, Hwang S, Cai Y, Kim SJ, et al
    MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30645.
    PubMed     Abstract available


  579. DESROCHES-CASTAN A, Tillet E, Ricard N, Ouarne M, et al
    BMP9 is a paracrine factor controlling liver sinusoidal endothelial cell fenestration and protecting from hepatic fibrosis.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30655.
    PubMed     Abstract available


  580. LI N, Wei L, Liu X, Bai H, et al
    A frizzled-like cysteine rich domain in glypican-3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30646.
    PubMed     Abstract available


  581. CHEN YJ, Tsai CF, Wang YP, Lu CL, et al
    To the editor: Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics.
    Hepatology. 2019 Apr 8. doi: 10.1002/hep.30641.
    PubMed     Abstract available


  582. DHANASEKARAN R, Felsher DW
    A Tale of Two Complications of Obesity: Nonalcoholic steatohepatitis (NASH) and Hepatocellular carcinoma (HCC).
    Hepatology. 2019 Apr 8. doi: 10.1002/hep.30649.
    PubMed     Abstract available


  583. VUPPALANCHI R, Chalasani N
    HEP-18-0797.R2 - Liver Stiffness Measurements in Patients with Non-cirrhotic Portal Hypertension - The Devil is In the Details.
    Hepatology. 2019 Apr 5. doi: 10.1002/hep.30640.
    PubMed     Abstract available


  584. MOON AM, Hayashi PH, Barritt AS 4th
    Proton pump inhibitors in cirrhosis: a marker of morbid conditions or cause of mortality.
    Hepatology. 2019 Apr 5. doi: 10.1002/hep.30642.
    PubMed     Abstract available


  585. NARDELLI S, Gioia S, Ridola L, Farcomeni A, et al
    PPIs in cirrhosis: more evidences for a careful prescription!
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30639.
    PubMed     Abstract available


  586. NAIR KM, Vora RS, Mousa OY, Malhi H, et al
    Hepatology Highlights.
    Hepatology. 2019;69:1365-1368.
    PubMed    


  587. ZHOU SL, Yin D, Hu ZQ, Luo CB, et al
    A Positive Feedback Loop between Cancer Stem-Like Cells and Tumor- Associated Neutrophils Controls Hepatocellular Carcinoma Progression.
    Hepatology. 2019 Apr 1. doi: 10.1002/hep.30630.
    PubMed     Abstract available


    March 2019
  588. BROWN ZJ, Greten TF, Heinrich B
    Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy.
    Hepatology. 2019 Mar 30. doi: 10.1002/hep.30633.
    PubMed     Abstract available


  589. KAO WY, Tan EC, Su CW
    Reply to comment: Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma.
    Hepatology. 2019 Mar 30. doi: 10.1002/hep.30632.
    PubMed     Abstract available


  590. ELKRIEF L, Ferrusquia-Acosta J, Payance A, Moga L, et al
    Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study.
    Hepatology. 2019 Mar 29. doi: 10.1002/hep.30628.
    PubMed     Abstract available


  591. RUSSELL BE, Whaley KG, Bove KE, Labilloy A, et al
    Expanding and Underscoring the Hepato-Encephalopathic Phenotype of QIL1/MIC13.
    Hepatology. 2019 Mar 26. doi: 10.1002/hep.30627.
    PubMed     Abstract available


  592. YANG J, Trepo E, Nahon P, Cao Q, et al
    A HSD17B13 variant protects from hepatocellular carcinoma development in alcoholic liver disease.
    Hepatology. 2019 Mar 25. doi: 10.1002/hep.30623.
    PubMed     Abstract available


  593. WANG YL, Liu JY, Yang JE, Yu XM, et al
    Lnc-UCID promotes G1/S transition and hepatoma growth by preventing DHX9-mediated CDK6 downregulation.
    Hepatology. 2019 Mar 13. doi: 10.1002/hep.30613.
    PubMed     Abstract available


  594. WANG C, Zheng X, Jiang P, Tang R, et al
    Genome Wide Association Studies of Specific Antinuclear Autoantibody Sub-phenotypes in Primary Biliary Cholangitis.
    Hepatology. 2019 Mar 10. doi: 10.1002/hep.30604.
    PubMed     Abstract available


  595. MA M, Xu H, Liu G, Wu J, et al
    MITA1, a novel energy stress-inducible lncRNA, promotes hepatocellular carcinoma metastasis.
    Hepatology. 2019 Mar 6. doi: 10.1002/hep.30602.
    PubMed     Abstract available


  596. HUANG Z, Wu LM, Zhang JL, Sabri A, et al
    DUSP12 Regulates Hepatic Lipid Metabolism through Inhibition of Lipogenesis and ASK1 Pathways.
    Hepatology. 2019 Mar 1. doi: 10.1002/hep.30597.
    PubMed     Abstract available


  597. MOUSA O, Malhi H, Schwartz RE, Kulai TB, et al
    Hepatology Highlights.
    Hepatology. 2019;69:927-930.
    PubMed    


    February 2019
  598. HUELIN P, Sola E, Elia C, Sole C, et al
    Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis. A prospective study.
    Hepatology. 2019 Feb 27. doi: 10.1002/hep.30592.
    PubMed     Abstract available


  599. HARA K, Takeda A, Tsurugai Y, Saigusa Y, et al
    Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: a Propensity Score Analysis.
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30591.
    PubMed     Abstract available


  600. HARRISON SA, Rossi SJ, Paredes AH, Trotter JF, et al
    NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30590.
    PubMed     Abstract available


  601. WANG Y, Kory N, Cohen JC, Hobbs HH, et al
    PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice.
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30583.
    PubMed     Abstract available


  602. TODESCA P, Marzi L, Critelli RM, Cuffari B, et al
    Angiopoietin-2/Tie2 inhibition by regorafenib associates with striking response in a patient with aggressive hepatocellular carcinoma.
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30588.
    PubMed     Abstract available


  603. RIMBAS RC, Rimbas M, Vinereanu D
    Echocardiographic Predictors of a Worse Outcome in Patients With Liver Cirrhosis: What Should We Assess?
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30584.
    PubMed     Abstract available


  604. WANG R, Zhu P
    Tuberculosis and anti-tuberculosis treatments cannot be ignored when evaluating cirrhotic patients co-infected with HIV or not.
    Hepatology. 2019 Feb 25. doi: 10.1002/hep.30582.
    PubMed     Abstract available


  605. KAPURIA D, Ben-Yakov G, Ortolano R, Ho-Cho M, et al
    The Spectrum of Hepatic Involvement in Patients with Telomere Disease.
    Hepatology. 2019 Feb 21. doi: 10.1002/hep.30578.
    PubMed     Abstract available


  606. MEHAL WZ, Loomba R
    The Intestinal Microbiome, Plasma Metabolome and Liver Transcriptome- A Conspiracy Driving Hepatic Steatosis.
    Hepatology. 2019 Feb 19. doi: 10.1002/hep.30577.
    PubMed     Abstract available


  607. SINHA J, Mehta N, Dodge JL, Poltavskiy E, et al
    Are There Upper Limits in Tumor Burden for Down-staging of HCC to Liver Transplant? Analysis of the All-comers Protocol.
    Hepatology. 2019 Feb 19. doi: 10.1002/hep.30570.
    PubMed     Abstract available


  608. WEN W, Schwabe RF
    Soluble fibers improve metabolic syndrome but may cause liver disease and hepatocellular carcinoma.
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30565.
    PubMed     Abstract available


  609. NGUYEN MH
    Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30560.
    PubMed     Abstract available


  610. LAI SW, Lin CL
    Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30566.
    PubMed     Abstract available


  611. CHIU V, Hogen R, Sher L, Wade N, et al
    Telomerase Variants in Patients with Cirrhosis Awaiting Liver Transplantation.
    Hepatology. 2019 Feb 14. doi: 10.1002/hep.30557.
    PubMed     Abstract available


  612. TONG J, Han CJ, Zhang JZ, He WZ, et al
    Hepatic IRF6 alleviates liver steatosis and metabolic disorder by transcriptionally suppressing PPARgamma.
    Hepatology. 2019 Feb 12. doi: 10.1002/hep.30559.
    PubMed     Abstract available


  613. QIAO Y, Wang J, Karagoz E, Liang B, et al
    Axin1 deletion induced hepatocarcinogenesis requires intact beta-Catenin but not Notch cascade in mice.
    Hepatology. 2019 Feb 8. doi: 10.1002/hep.30556.
    PubMed     Abstract available


  614. DEY P
    Carbon Tetrachloride (CCl4 )-Induced Classical Liver Cirrhosis Model: Revisiting The Mode Of Action.
    Hepatology. 2019 Feb 8. doi: 10.1002/hep.30555.
    PubMed     Abstract available


  615. ALBILLOS A, Munoz L, Alvarez-Mon M
    Reply to: Carbon Tetrachloride (CCl4)-Induced Classical Liver Cirrhosis Model: Revisiting The Mode Of Action.
    Hepatology. 2019 Feb 8. doi: 10.1002/hep.30554.
    PubMed     Abstract available


  616. TSANG FH, Law CT, Tang CT, Cheng CL, et al
    Aberrant super-enhancer landscape in human hepatocellular carcinoma.
    Hepatology. 2019 Feb 5. doi: 10.1002/hep.30544.
    PubMed     Abstract available


  617. MWANGI SM, Li G, Ye L, Liu Y, et al
    Glial Cell Line Derived Neurotrophic Factor Enhances Autophagic Flux in Mouse and Rat Hepatocytes and Protects Against Palmitate Lipotoxicity.
    Hepatology. 2019 Feb 4. doi: 10.1002/hep.30541.
    PubMed     Abstract available


  618. RUSSO N, Brown RS Jr, Shah SL, Krisko TI, et al
    Hepatology Highlights.
    Hepatology. 2019;69:469-472.
    PubMed    


    January 2019
  619. SHALIMAR, Sheikh MF, Mookerjee RP, Agarwal B, et al
    Prognostic Role of Ammonia in Cirrhotic Patients.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30534.
    PubMed     Abstract available


  620. TAPPER EB
    Predicting Overt Hepatic Encephalopathy for the Population with Cirrhosis.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30533.
    PubMed     Abstract available


  621. BAI L, Chen MM, Chen ZD, Zhang P, et al
    FBXW5 mediates the ubiquitination of ASK1 and exacerbates nonalcoholic steatohepatitis.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30537.
    PubMed     Abstract available


  622. KIM D, Brocker CN, Takahashi S, Yagai T, et al
    Keratin 23 is a PPARA-dependent, MYC-amplified oncogene that promotes hepatocyte proliferation.
    Hepatology. 2019 Jan 29. doi: 10.1002/hep.30530.
    PubMed     Abstract available


  623. ZEUZEM S, Bourgeois S, Greenbloom S, Buti M, et al
    JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1.
    Hepatology. 2019 Jan 28. doi: 10.1002/hep.30527.
    PubMed     Abstract available


  624. PORTA C, Broglia C, Negri F
    Medical treatment of advanced hepatocellular carcinoma patients: the issue is not the right drug, but the right patient.
    Hepatology. 2019 Jan 25. doi: 10.1002/hep.30521.
    PubMed     Abstract available


  625. WONG GL, Liang LY, Kwok R, Hui AJ, et al
    Low risk of variceal bleeding in cirrhotic patients after variceal screening stratified by liver/spleen stiffness.
    Hepatology. 2019 Jan 25. doi: 10.1002/hep.30522.
    PubMed     Abstract available


  626. YE X, Li C, Zu X, Lin M, et al
    A Large-Scale Multicenter Study Validates AKR1B10 as a New Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
    Hepatology. 2019 Jan 23. doi: 10.1002/hep.30519.
    PubMed     Abstract available


  627. PRATT DS
    Hepatology Elsewhere.
    Hepatology. 2019 Jan 23. doi: 10.1002/hep.30517.
    PubMed     Abstract available


  628. HASAN KM, Friedman TC, Shao X, Parveen M, et al
    E-cigarettes and Western Diet: Important Metabolic Risk Factors for Hepatic Diseases.
    Hepatology. 2019 Jan 21. doi: 10.1002/hep.30512.
    PubMed     Abstract available


  629. CAI J, Zhang XJ, Li H
    The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Jan 17. doi: 10.1002/hep.30506.
    PubMed     Abstract available


  630. ZHENG Y, Qu H, Xiong X, Wang Y, et al
    Deficiency of the mitochondrial glycerol 3-phosphate dehydrogenase contributes to hepatic steatosis.
    Hepatology. 2019 Jan 17. doi: 10.1002/hep.30507.
    PubMed     Abstract available


  631. CHEN H, Gao F, He M, Ding XF, et al
    Long-read RNA Sequencing identifies Novel Splice Variants in Hepatocellular Carcinoma and Tumor-specific Isoforms.
    Hepatology. 2019 Jan 13. doi: 10.1002/hep.30500.
    PubMed     Abstract available


  632. MAHMUD N, Kaplan DE, Taddei TH, Goldberg DS, et al
    Incidence and Mortality of Acute on Chronic Liver Failure using Two Definitions in Patients with Compensated Cirrhosis.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30494.
    PubMed     Abstract available


  633. GOEPPERT B, Toth R, Singer S, Albrecht T, et al
    Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30493.
    PubMed     Abstract available


  634. HEERKENS M, Dedden S, Scheepers H, Van Paassen P, et al
    Effect of plasmapheresis on cholestatic pruritus and autotaxin activity during pregnancy.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30496.
    PubMed     Abstract available


  635. RUSSO N, Jesudian A, Shen NT, Brown RS Jr, et al
    Hepatology Highlights.
    Hepatology. 2019;69:1-4.
    PubMed    


    December 2018
  636. KANWAL F, Tapper EB, Ho C, Asrani SK, et al
    Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Dec 26. doi: 10.1002/hep.30489.
    PubMed     Abstract available


  637. SHIFFMAN ML, Sussman NL, Ravendhran N, Ditmyer M, et al
    Financial compensation for hepatologists in different practice settings.
    Hepatology. 2018 Dec 26. doi: 10.1002/hep.30488.
    PubMed     Abstract available


  638. MOORE A, Wu L, Chuang JC, Sun X, et al
    Arid1a loss drives non-alcoholic steatohepatitis in mice via epigenetic dysregulation of hepatic lipogenesis and fatty acid oxidation.
    Hepatology. 2018 Dec 25. doi: 10.1002/hep.30487.
    PubMed     Abstract available


  639. HUYNH H, Lee LY, Goh KY, Ong R, et al
    Infigratinib mediates vascular normalization, impairs metastasis and improves chemotherapy in hepatocellular carcinoma.
    Hepatology. 2018 Dec 21. doi: 10.1002/hep.30481.
    PubMed     Abstract available


  640. COTTER TG, Charlton M
    The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality from Cirrhosis.
    Hepatology. 2018 Dec 20. doi: 10.1002/hep.30408.
    PubMed     Abstract available


  641. SALMON-CERON D, Nahon P, Layese R, Bourcier V, et al
    HIV/HCV co-infected cirrhotic patients are no longer at higher risk for HCC or end-stage liver disease as compared to HCV mono-infected patients.
    Hepatology. 2018 Dec 19. doi: 10.1002/hep.30400.
    PubMed     Abstract available


  642. CHEHADE S, Adams PC
    Severe hemochromatosis arthropathy in the absence of iron overload.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30469.
    PubMed     Abstract available


  643. LEE D, Xu IM, Chiu DK, Leibold J, et al
    Induction of Oxidative Stress via Inhibition of Thioredoxin Reductase 1 is an Effective Therapeutic Approach for Hepatocellular Carcinoma.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30467.
    PubMed     Abstract available


  644. RIVEIRO-BARCIELA M, Gironella M, Senin A, Salcedo MT, et al
    Decompensated liver disease due to primary hepatic amyloidosis: Is liver transplantation still mandatory?
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30464.
    PubMed     Abstract available


  645. ZUO X, Chen Z, Cai J, Gao W, et al
    5-hydroxytryptamine receptor 1D aggravates hepatocellular carcinoma progression via FoxO6 in AKT-dependent and independent manners.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30430.
    PubMed     Abstract available


  646. FUNKE K, Rockey DC
    Cholestatic drug induced liver injury caused by mifepristone.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30465.
    PubMed     Abstract available


  647. YANG JD, Patel T
    Early Detection of Hepatocellular Carcinoma - Expanding the Utility of Circulating Tumor Markers.
    Hepatology. 2018 Dec 17. doi: 10.1002/hep.30468.
    PubMed     Abstract available


  648. UNZU C, Planet E, Brandenberg N, Fusil F, et al
    Pharmacological induction of a progenitor state for the efficient expansion of primary human hepatocytes.
    Hepatology. 2018 Dec 14. doi: 10.1002/hep.30425.
    PubMed     Abstract available


  649. MEHTA N, Dodge JL, Roberts JP, Hirose R, et al
    Alpha-fetoprotein Decrease from >1000 to <500 ng/ml in Patients with Hepatocellular Carcinoma Leads to Improved Post-Transplant Outcomes.
    Hepatology. 2018 Dec 13. doi: 10.1002/hep.30413.
    PubMed     Abstract available


  650. RAND EB
    Cirrhotic Cardiomyopathy in children with BA: A new objective parameter to predict morbidity and mortality on the waitlist - and beyond!
    Hepatology. 2018 Dec 12. doi: 10.1002/hep.30419.
    PubMed     Abstract available


  651. CLARIA J, Moreau R, Fenaille F, Amoros A, et al
    Orchestration of Tryptophan-Kynurenine pathway, acute decompensation and acute-on-chronic liver failure in cirrhosis.
    Hepatology. 2018 Dec 6. doi: 10.1002/hep.30363.
    PubMed     Abstract available


  652. HUANG L, Cai J, Guo H, Gu J, et al
    ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30404.
    PubMed     Abstract available


  653. MO DC, Jia RR, Zhong JH
    Hepatic Resection Compared to Chemoembolization in Intermediate to Advanced-Stage HCC: a comment for moving forward.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30409.
    PubMed     Abstract available


  654. BALE R, Schullian P, Eberle G, Putzer D, et al
    Stereotactic radiofrequency ablation of hepatocellular carcinoma - A histopathological study in explanted livers.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30406.
    PubMed     Abstract available


  655. HUCK I, Gunewardena S, Espanol-Suner R, Willenbring H, et al
    Hepatocyte Nuclear Factor 4 alpha (HNF4alpha) Activation is Essential for Termination of Liver Regeneration.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30405.
    PubMed     Abstract available


  656. KHAMBU B, Li T, Yan S, Yu C, et al
    Hepatic Autophagy Deficiency Compromises FXR Functionality and Causes Cholestatic Injury.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30407.
    PubMed     Abstract available


  657. SIMONETTO DA, Piccolo Serafim L, Gallo de Moraes A, Gajic O, et al
    Management of Sepsis in Patients with Cirrhosis: current evidence and practical approach.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30412.
    PubMed     Abstract available


  658. LAW CT, Wei L, Tsang FH, Chan CY, et al
    HELLS regulates chromatin remodeling and epigenetic silencing of multiple tumor suppressor genes in human hepatocellular carcinoma.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30414.
    PubMed     Abstract available


  659. ALVES-BEZERRA M, Li Y, Acuna M, Ivanova AA, et al
    Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids into Triglyceride Biosynthesis.
    Hepatology. 2018 Dec 5. doi: 10.1002/hep.30411.
    PubMed     Abstract available



  660. 2018 HEPATOLOGY Referees (Volumes 67 and 68).
    Hepatology. 2018;68:2446-2452.
    PubMed    


  661. SHEN NT, Brown RS Jr, Imai N, Krisko TI, et al
    Hepatology Highlights.
    Hepatology. 2018;68:2049-2052.
    PubMed    


  662. VILAR-GOMEZ E, Vuppalanchi R, Gawrieh S, Ghabril M, et al
    Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30368.
    PubMed     Abstract available


  663. GIOIA S, Nardelli S, Riggio O
    Liver stiffness in non-cirrhotic portal hypertension - The Devil is in the diagnosis.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30367.
    PubMed     Abstract available


  664. FANG JH, Xu L, Shang LR, Pan CZ, et al
    Vessels that encapsulate tumor clusters (VETC) pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30366.
    PubMed     Abstract available


  665. MA Y, Yang W, Simon TG, Smith-Warner SA, et al
    Dietary patterns and risk of hepatocellular carcinoma among US men and women.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30362.
    PubMed     Abstract available


  666. ARORA V, Sarin SK
    Reply.
    Hepatology. 2018;68:2444.
    PubMed    


  667. VERMA S, Agarwal S, Singh S, Pandey N, et al
    Letter To Editor: Terlipressin is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute On Chronic Liver Failure.
    Hepatology. 2018;68:2442-2443.
    PubMed    


  668. IMAI N, Cohen DE
    Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD.
    Hepatology. 2018;68:2062-2065.
    PubMed    


  669. BRENNER DA
    Of Mice and Men and Nonalcoholic Steatohepatitis.
    Hepatology. 2018;68:2059-2061.
    PubMed    


  670. KHADERI S, Sussman N, Kanwal F
    Project ECHO: The Specialist Will See You Now.
    Hepatology. 2018;68:2066-2068.
    PubMed    


  671. MIN JH, Kim JM, Kim YK, Kang TW, et al
    Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System.
    Hepatology. 2018;68:2254-2266.
    PubMed     Abstract available


  672. LOPICCOLO J, Brener MI, Oshima K, Lipson EJ, et al
    Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade.
    Hepatology. 2018;68:2431-2433.
    PubMed    


  673. CALVOPINA DA, Chatfield MD, Weis A, Coleman MA, et al
    MicroRNA Sequencing Identifies a Serum MicroRNA Panel, Which Combined With Aspartate Aminotransferase to Platelet Ratio Index Can Detect and Monitor Liver Disease in Pediatric Cystic Fibrosis.
    Hepatology. 2018;68:2301-2316.
    PubMed     Abstract available


  674. ALLEN AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, et al
    Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database.
    Hepatology. 2018;68:2230-2238.
    PubMed     Abstract available


  675. GE X, Arriazu E, Magdaleno F, Antoine DJ, et al
    High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.
    Hepatology. 2018;68:2380-2404.
    PubMed     Abstract available


  676. SU GL, Glass L, Tapper EB, Van T, et al
    Virtual Consultations Through the Veterans Administration SCAN-ECHO Project Improves Survival for Veterans With Liver Disease.
    Hepatology. 2018;68:2317-2324.
    PubMed     Abstract available


  677. XU X, Krumm C, So JS, Bare CJ, et al
    Preemptive Activation of the Integrated Stress Response Protects Mice From Diet-Induced Obesity and Insulin Resistance by Fibroblast Growth Factor 21 Induction.
    Hepatology. 2018;68:2167-2181.
    PubMed     Abstract available


  678. GONG S, Yan Z, Liu Z, Niu M, et al
    Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30361.
    PubMed     Abstract available


    November 2018
  679. NEONG SF, Billington EO, Congly SE
    Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: Review of pathogenesis and management.
    Hepatology. 2018 Nov 23. doi: 10.1002/hep.30359.
    PubMed     Abstract available


  680. MA Y, Belyaeva OV, Brown PM, Fujita K, et al
    HSD17B13 is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non-Alcoholic Fatty Liver Disease.
    Hepatology. 2018 Nov 11. doi: 10.1002/hep.30350.
    PubMed     Abstract available


  681. MUNOZ L, Borrero MJ, Ubeda M, Conde E, et al
    Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis.
    Hepatology. 2018 Nov 10. doi: 10.1002/hep.30349.
    PubMed     Abstract available


  682. SUN H, Huang Q, Huang M, Wen H, et al
    Human CD96 correlates to NK cell exhaustion and predicts the prognosis of human hepatocellular carcinoma.
    Hepatology. 2018 Nov 8. doi: 10.1002/hep.30347.
    PubMed     Abstract available


  683. SANTAMARIA E, Rodriguez-Ortigosa CM, Uriarte I, Latasa MU, et al
    The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis.
    Hepatology. 2018 Nov 8. doi: 10.1002/hep.30348.
    PubMed     Abstract available


  684. SHAHEEN AA, Swain MG
    Using proper methods to identify cirrhosis patients in administrative databases is crucial to correctly predict outcomes.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30343.
    PubMed     Abstract available


  685. LABGAA I, Demartines N, Melloul E
    Surgical Resection vs. Transarterial Chemoembolization for Intermediate Stage Hepatocellular Carcinoma (BCLC-B): An Unsolved Question.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30338.
    PubMed     Abstract available


  686. TAPPER EB, Baki J, Parikh ND, Lok AS, et al
    Frailty, Psychoactive Medications, and Cognitive Dysfunction are Associated with Poor Patient-Reported Outcomes in Cirrhosis.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30336.
    PubMed     Abstract available


  687. WANG YH, Chuang YH, Wu CF, Jan MC, et al
    Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30339.
    PubMed     Abstract available


  688. FLYNN MJ, Sayed AA, Sharma R, Siddique A, et al
    Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30337.
    PubMed     Abstract available



  689. Hepatology Highlights.
    Hepatology. 2018;68:1665-1667.
    PubMed    


  690. O'LEARY JG, Rajender Reddy K, Wong F, Garcia-Tsao G, et al
    Reply.
    Hepatology. 2018;68:2046-2048.
    PubMed    


  691. CARDOSO FS
    Acute-on-Chronic Liver Failure defined by NACSELD: The Impact on Prognosis and Futility of Care.
    Hepatology. 2018;68:2046.
    PubMed    


  692. MUZYKANTOV VR, Brenner JS
    Vascular Immunotargeting: Take the Highway to the First Exit.
    Hepatology. 2018;68:1672-1674.
    PubMed    


  693. TARGHER G, Byrne CD
    Ad Libitum Mediterranean or Low-Fat Diets as Treatments for Nonalcoholic Fatty Liver Disease?
    Hepatology. 2018;68:1668-1671.
    PubMed    


  694. KORATALA A, Alquadan KF
    Diminishing Kidney Reserve and the "Pseudo"normal Creatinine.
    Hepatology. 2018;68:2045.
    PubMed    


  695. NOH JH, Gorospe M
    AKTions by Cytoplasmic lncRNA CASC9 Promote Hepatocellular Carcinoma Survival.
    Hepatology. 2018;68:1675-1677.
    PubMed    


  696. TUFONI M, Serena Ricci C, Zaccherini G
    A Case of Immune-Mediated Liver Injury Induced by Olaparib.
    Hepatology. 2018;68:2039-2041.
    PubMed    


  697. KLINGENBERG M, Gross M, Goyal A, Polycarpou-Schwarz M, et al
    The Long Noncoding RNA Cancer Susceptibility 9 and RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein L Form a Complex and Coregulate Genes Linked to AKT Signaling.
    Hepatology. 2018;68:1817-1832.
    PubMed     Abstract available


  698. WU R, Murali R, Kabe Y, French SW, et al
    Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition.
    Hepatology. 2018;68:1726-1740.
    PubMed     Abstract available


  699. YU CJ, Wang QS, Wu MM, Song BL, et al
    TRUSS Exacerbates NAFLD Development by Promoting IkappaBalpha Degradation in Mice.
    Hepatology. 2018;68:1769-1785.
    PubMed     Abstract available


  700. KIM G, Lee SE, Lee YB, Jun JE, et al
    Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study.
    Hepatology. 2018;68:1755-1768.
    PubMed     Abstract available


    October 2018
  701. VITALE A, Farinati F, Borzio M, Trevisani F, et al
    The critical issue of restaging patients with hepatocellular carcinoma.
    Hepatology. 2018 Oct 30. doi: 10.1002/hep.30322.
    PubMed     Abstract available


  702. FARRELL G, Schattenberg JM, Leclercq I, Yeh MM, et al
    Mouse models of nonalcoholic steatohepatitis Towards optimization of their relevance to human NASH.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30333.
    PubMed     Abstract available


  703. ASLAM A, Ishtiaq R, Lau DTY
    Commentary for Hepatology Elsewhere Timely administration of birth dose HBV vaccine may break the chain of perinatal transmission.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30332.
    PubMed     Abstract available


  704. CASTRO NARRO GE, Gamboa Dominguez A, Consuelo Sanchez A, Salazar Martinez A, et al
    Combined Hepatocellular-Cholangiocarcinoma in a Patient with Cirrhosis due to Cholesteryl Ester Storage Disease.
    Hepatology. 2018 Oct 29. doi: 10.1002/hep.30331.
    PubMed     Abstract available


  705. KIM HL, An J, Park JA, Park SH, et al
    Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High Risk Patients with Cirrhosis.
    Hepatology. 2018 Oct 26. doi: 10.1002/hep.30330.
    PubMed     Abstract available


  706. FU Y, Urban DJ, Nani RR, Zhang YF, et al
    Glypican-3 Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.
    Hepatology. 2018 Oct 24. doi: 10.1002/hep.30326.
    PubMed     Abstract available


  707. HUO TI, Liu PH, Hsu CY
    Staging and restaging for hepatocellular carcinoma: Solution of confusion?
    Hepatology. 2018 Oct 24. doi: 10.1002/hep.30324.
    PubMed     Abstract available


  708. YAN J, Yao B, Kuang H, Yang X, et al
    Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD.
    Hepatology. 2018 Oct 19. doi: 10.1002/hep.30320.
    PubMed     Abstract available


  709. CHEN Y, Hao X, Sun R, Wei H, et al
    NK cell-derived IFN-gamma promotes hepatocellular carcinoma through EpCAM-EMT axis in hepatitis B virus transgenic mice.
    Hepatology. 2018 Oct 17. doi: 10.1002/hep.30317.
    PubMed     Abstract available


  710. BANALES JM, Inarrairaegui M, Arbelaiz A, Milkiewicz P, et al
    Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis.
    Hepatology. 2018 Oct 16. doi: 10.1002/hep.30319.
    PubMed     Abstract available


  711. VENTURA-COTS M, Watts AE, Cruz-Lemini M, Shah ND, et al
    Colder weather and fewer sunlight hours increase alcohol consumption and alcoholic cirrhosis worldwide.
    Hepatology. 2018 Oct 16. doi: 10.1002/hep.30315.
    PubMed     Abstract available


  712. ABRALDES JG, Trebicka J, Chalasani N, D'Amico G, et al
    Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension.
    Hepatology. 2018 Oct 15. doi: 10.1002/hep.30314.
    PubMed     Abstract available


  713. KO E, Seo HW, Jung ES, Ju S, et al
    PI3Kdelta is a new therapeutic target in hepatocellular carcinoma.
    Hepatology. 2018 Oct 9. doi: 10.1002/hep.30307.
    PubMed     Abstract available


  714. PERUGORRIA MJ, Olaizola P, Banales JM
    Cholangiocyte-to-Hepatocyte Differentiation: a Context Dependent Process and an Opportunity for Regenerative Medicine.
    Hepatology. 2018 Oct 8. doi: 10.1002/hep.30305.
    PubMed     Abstract available


  715. NARDELLI S, Gioia S, Ridola L, Farcomeni A, et al
    Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30304.
    PubMed     Abstract available


  716. LAI SW
    Proton pump inhibitors use and risk of hepatocellular carcinoma.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30302.
    PubMed     Abstract available


  717. BLANER WS
    Hepatic Stellate Cells (HSCs) and Retinoids: Towards A Much More Defined Relationship.
    Hepatology. 2018 Oct 4. doi: 10.1002/hep.30293.
    PubMed     Abstract available


  718. ZHANG T, Duan J, Zhang L, Li Z, et al
    LXRalpha Promotes Hepatosteatosis in Part via Activation of MicroRNA-378 Transcription and Inhibition of Ppargc1beta Expression.
    Hepatology. 2018 Oct 3. doi: 10.1002/hep.30301.
    PubMed     Abstract available



  719. Hepatology Highlights.
    Hepatology. 2018;68:1213-1216.
    PubMed    


  720. CHEN JF, Lin BL
    Reply.
    Hepatology. 2018;68:1661.
    PubMed    


  721. YANG Y, Feng Y, Zhao X, Wang L, et al
    A New Concept: Pre-HCC Disease.
    Hepatology. 2018;68:1662.
    PubMed    


  722. PANDEY S
    Association of Nonalcoholic Fatty Liver Disease With Relative Skeletal Muscle Mass: A Public Health Perspective.
    Hepatology. 2018;68:1657.
    PubMed    


  723. BAJAJ JS, Moreau R, Kamath PS, Vargas HE, et al
    Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?
    Hepatology. 2018;68:1621-1632.
    PubMed     Abstract available


  724. TRICO D, Caprio S, Rosaria Umano G, Pierpont B, et al
    Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings From a Multiethnic Cohort.
    Hepatology. 2018;68:1376-1390.
    PubMed     Abstract available


  725. GRAHAM RP, Lackner C, Terracciano L, Gonzalez-Cantu Y, et al
    Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.
    Hepatology. 2018;68:1441-1447.
    PubMed     Abstract available


  726. SALEM R, Gabr A, Riaz A, Mora R, et al
    Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.
    Hepatology. 2018;68:1429-1440.
    PubMed     Abstract available


    September 2018
  727. SIRICA AE, Gores GJ, Groopman JD, Selaru FM, et al
    Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30289.
    PubMed     Abstract available


  728. WILKINSON PD, Delgado ER, Alencastro F, Leek MP, et al
    The polyploid state restricts hepatocyte proliferation and liver regeneration.
    Hepatology. 2018 Sep 23. doi: 10.1002/hep.30286.
    PubMed     Abstract available


  729. COSTENTIN CE, Bababekov YJ, Zhu AX, Yeh H, et al
    Is it time to reconsider the Milan Criteria for selecting patients with hepatocellular carcinoma for deceased-donor liver transplantation?
    Hepatology. 2018 Sep 19. doi: 10.1002/hep.30278.
    PubMed     Abstract available


  730. SATSANGI S
    Noradrenaline for hepatorenal syndrome in patients with acute-on chronic liver failure- Hope still remains!
    Hepatology. 2018 Sep 19. doi: 10.1002/hep.30283.
    PubMed     Abstract available


  731. VOLK M, Mellinger J, Bansal MB, Gellad ZF, et al
    A Roadmap for Value-Based Payment Models among Patients with Cirrhosis.
    Hepatology. 2018 Sep 18. doi: 10.1002/hep.30277.
    PubMed     Abstract available


  732. MUMTAZ K, Issak A, Porter K, Kelly S, et al
    Validation of Risk Score in Predicting Early Readmissions in Decompensated Cirrhotic patients: A Model Based on the Administrative Database.
    Hepatology. 2018 Sep 15. doi: 10.1002/hep.30274.
    PubMed     Abstract available


  733. SONG ATW, Abdala E, de Martino RB, Malbouisson LMS, et al
    Liver transplantation for fulminant hepatitis due to yellow fever.
    Hepatology. 2018 Sep 15. doi: 10.1002/hep.30273.
    PubMed     Abstract available


  734. RUSSELL JO, Lu WY, Okabe H, Abrams M, et al
    Hepatocyte-specific beta-catenin deletion during severe liver injury provokes cholangiocytes to differentiate into hepatocytes.
    Hepatology. 2018 Sep 14. doi: 10.1002/hep.30270.
    PubMed     Abstract available


  735. RAEVENS S, Colle I
    Why pulse oximetry is inaccurate in liver cirrhosis - ancient knowledge.
    Hepatology. 2018 Sep 8. doi: 10.1002/hep.30260.
    PubMed     Abstract available


  736. CAMPANI C, Guido M, Colagrande S, Bartoli F, et al
    A large rheumatoid nodule mimicking hepatic malignancy.
    Hepatology. 2018 Sep 8. doi: 10.1002/hep.30261.
    PubMed     Abstract available


  737. YOUNOSSI ZM, Tampi R, Priyadarshini M, Nader F, et al
    Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30254.
    PubMed     Abstract available


  738. INZAUGARAT ME, Johnson CD, Holtmann TM, McGeough MD, et al
    NLRP3 inflammasome activation in hepatic stellate cells induces murine liver fibrosis.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30252.
    PubMed     Abstract available


  739. YOUNOSSI Z, Tacke F, Arrese M, Sharma BC, et al
    Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30251.
    PubMed     Abstract available


  740. KAMATH B, Mack CL
    From hepatocyte to cholangiocyte: the remarkable potential of transdifferentiation to treat cholestatic diseases.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30250.
    PubMed     Abstract available


  741. KAO WY, Su CW, Tan EC, Lee PC, et al
    Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B or C.
    Hepatology. 2018 Sep 2. doi: 10.1002/hep.30247.
    PubMed     Abstract available


  742. BROWN RS JR, Schwartz RE
    Hepatology Highlights.
    Hepatology. 2018;68:795-797.
    PubMed    


  743. LO GH
    The Use of Steroid for Transcatheter Arterial Chemoembolization: To Relieve Symptoms or to Mask Adverse Events?
    Hepatology. 2018;68:1207.
    PubMed    


  744. FUJIWARA K, Yasui S, Yokosuka O, Oda S, et al
    A Role of Renal Replacement Therapy for Acute Liver Failure.
    Hepatology. 2018;68:1204.
    PubMed    


  745. CUMMINGS D, Ferstenberg R
    Recommendations for the Evaluation for Autoimmune Liver Disease in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2018;68:1203.
    PubMed    


  746. LEWIS K, Takebe T
    Tumoroid a la carte: Path for personalization.
    Hepatology. 2018;68:1189-1191.
    PubMed    


  747. DENISOV EV, Perelmuter VM
    A fixed partial epithelial-mesenchymal transition (EMT) triggers carcinogenesis, whereas asymmetrical division of hybrid EMT cells drives cancer progression.
    Hepatology. 2018;68:807-810.
    PubMed    


  748. MATAK A, Lahiri P, Ford E, Pabst D, et al
    Stochastic phenotype switching leads to intratumor heterogeneity in human liver cancer.
    Hepatology. 2018;68:933-948.
    PubMed     Abstract available


  749. RANDALL MH, Stoermann M, Rockey DC
    A "Faux" Case of Acute Liver Failure in a 28-Year-Old Pregnant Woman.
    Hepatology. 2018;68:1200-1202.
    PubMed    


  750. YANG E, Peng L, Lee WM
    Multiple admissions for acetaminophen overdose: Acetaminophen frequent fliers, a new entity?
    Hepatology. 2018;68:1197-1199.
    PubMed    


  751. CHAPIN CA, Burn T, Meijome T, Loomes KM, et al
    Indeterminate pediatric acute liver failure is uniquely characterized by a CD103(+) CD8(+) T-cell infiltrate.
    Hepatology. 2018;68:1087-1100.
    PubMed     Abstract available


  752. LAN T, Li C, Yang G, Sun Y, et al
    Sphingosine kinase 1 promotes liver fibrosis by preventing miR-19b-3p-mediated inhibition of CCR2.
    Hepatology. 2018;68:1070-1086.
    PubMed     Abstract available


    August 2018
  753. KISIEL JB, Dukek BA, Kanipakam RVSR, Ghoz HM, et al
    Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation.
    Hepatology. 2018 Aug 31. doi: 10.1002/hep.30244.
    PubMed     Abstract available


  754. MOTINO O, Frances DE, Casanova N, Fuertes-Agudo M, et al
    Protective role of hepatocyte cyclooxygenase-2 expression against liver ischemia-reperfusion injury in mice.
    Hepatology. 2018 Aug 29. doi: 10.1002/hep.30241.
    PubMed     Abstract available


  755. CHOI J, Kim GA, Han S, Lee W, et al
    Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early Stage Hepatocellular Carcinoma.
    Hepatology. 2018 Aug 28. doi: 10.1002/hep.30233.
    PubMed     Abstract available


  756. MANTOVANI S, Oliviero B, Lombardi A, Varchetta S, et al
    Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma.
    Hepatology. 2018 Aug 28. doi: 10.1002/hep.30235.
    PubMed     Abstract available


  757. MARETTI-MIRA AC, Wang X, Wang L, DeLeve LD, et al
    Incomplete differentiation of engrafted bone marrow endothelial progenitor cells initiates hepatic fibrosis in the rat.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30227.
    PubMed     Abstract available


  758. ALLEGRETTI AS, Parada XV, Ortiz GA, Long J, et al
    Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30230.
    PubMed     Abstract available


  759. LIGAT G, Schuster C, Baumert TF
    HBV core variants, liver fibrosis and hepatocellular carcinoma.
    Hepatology. 2018 Aug 23. doi: 10.1002/hep.30231.
    PubMed     Abstract available


  760. HLADY RA, Sathyanarayan A, Thompson JJ, Zhou D, et al
    Integrating the Epigenome to Identify Novel Drivers of Hepatocellular Carcinoma.
    Hepatology. 2018 Aug 22. doi: 10.1002/hep.30211.
    PubMed     Abstract available


  761. KO S, Monga SP
    Hepatic zonation now on hormones!
    Hepatology. 2018 Aug 18. doi: 10.1002/hep.30221.
    PubMed     Abstract available


  762. INADA Y, Mizukoshi E, Seike T, Tamai T, et al
    Characteristics of immune response to tumor-associated antigens and immune cell profile in hepatocellular carcinoma patients.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30212.
    PubMed     Abstract available


  763. WANG X, Ribeiro M, Iracheta-Vellve A, Lowe P, et al
    Macrophage-specific HIF-1alpha contributes to impaired autophagic flux in non-alcoholic steatohepatitis.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30215.
    PubMed     Abstract available


  764. GHALLAB A, Hofmann U, Sezgin S, Vartak N, et al
    Bile micro-infarcts in cholestasis are initiated by rupture of the apical hepatocyte membrane and cause shunting of bile to sinusoidal blood.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30213.
    PubMed     Abstract available


  765. PANDEY S
    Letter to the Editor: The Genetic Architecture of Diet-induced Hepatic Fibrosis in Mice: A Public Health Perspective.
    Hepatology. 2018 Aug 4. doi: 10.1002/hep.30207.
    PubMed     Abstract available


  766. YANG L, Wang W, Wang X, Zhao J, et al
    CREG in Hepatocytes Ameliorates Liver Ischemia/Reperfusion Injury in a TAK1-Dependent Manner in Mice.
    Hepatology. 2018 Aug 4. doi: 10.1002/hep.30203.
    PubMed     Abstract available


  767. GORGIS NM, Kennedy C, Lam F, Thompson K, et al
    Clinical Consequences of Cardiomyopathy in Children with Biliary Atresia Requiring Liver Transplantation.
    Hepatology. 2018 Aug 3. doi: 10.1002/hep.30204.
    PubMed     Abstract available


  768. YKI-JARVINEN H
    Diabetes, liver cancer and cirrhosis: What next?
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30136.
    PubMed     Abstract available


  769. ALCARAZ-QUILES J, Casulleras M, Oettl K, Titos E, et al
    Oxidized albumin triggers a cytokine storm in leukocytes through p38 MAP kinase: role in systemic inflammation in decompensated cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30135.
    PubMed     Abstract available


  770. L'HERMITTE A, Pham S, Cadoux M, Couchy G, et al
    Lect2 controls inflammatory monocytes to constrain the growth and progression of hepatocellular carcinoma.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30140.
    PubMed     Abstract available


  771. LI CL, Li CY, Lin YY, Ho MC, et al
    Androgen Receptor Enhances Hepatic TERT Transcription after Hepatitis B Virus Integration or Point Mutation in Promoter Region.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30201.
    PubMed     Abstract available


  772. GANE EJ, Stedman CA, Schwabe C, Vijgen L, et al
    Short Duration AL-335, Odalasvir, With/Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30126.
    PubMed     Abstract available


  773. LIU LZ, Zhang Z, Zheng BH, Shi Y, et al
    CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30134.
    PubMed     Abstract available


  774. FORDE KA, Fallon MB, Krowka MJ, Sprys M, et al
    Pulse Oximetry is Insensitive for Detection of Hepatopulmonary Syndrome in Patients evaluated for Liver Transplantation.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30139.
    PubMed     Abstract available


  775. YOUNOSSI ZM
    Patient-reported Outcomes and the Economic Effects of Non-Alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis - The Value Proposition.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30125.
    PubMed     Abstract available


  776. COTTON RT, Tran Cao HS, Rana AA, Sada YH, et al
    Impact of the Treating Hospital on Care Outcomes for Hepatocellular Carcinoma.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30128.
    PubMed     Abstract available


  777. DROLZ A, Horvatits T, Rutter K, Landahl F, et al
    Lactate improves prediction of short-term mortality in critically ill cirrhosis patients: a multinational study.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30151.
    PubMed     Abstract available


  778. SINGAL AG, Tiro JA, Murphy CC, Marrero JA, et al
    Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients with Cirrhosis: A Randomized Clinical Trial.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30129.
    PubMed     Abstract available


  779. HLADY RA, Robertson KD
    A three-pronged epigenetic approach to the treatment of hepatocellular carcinoma.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30133.
    PubMed     Abstract available


  780. LIU J, Jiang J, Mo J, Liu D, et al
    Global DNA 5-hydroxymethylcytosine and 5-formylcytosine contents are decreased in the early stage of hepatocellular carcinoma.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30146.
    PubMed     Abstract available


  781. SHEN Y, Czaja MJ
    A Novel Mechanism of Starvation-Stimulated Hepatic Autophagy: Calcium-Induced O-GlcNAc-Dependent Signaling.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30118.
    PubMed     Abstract available


  782. SQUIRES JE, Rudnick DA, Hardison RM, Horslen S, et al
    Liver Transplant Listing in Pediatric Acute Liver Failure (PALF): Practices and Participant Characteristics.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30116.
    PubMed     Abstract available


  783. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30145.
    PubMed     Abstract available


  784. TAFESH ZH, Brown RS Jr, Russo N, Rosenblatt R, et al
    Hepatology Highlights.
    Hepatology. 2018;68:393-396.
    PubMed    


  785. DE MATTOS AZ, de Mattos AA
    Evaluating Prognosis of Patients With Acute-On-Chronic Liver Failure: Is the Simplest Score Good Enough?
    Hepatology. 2018;68:790.
    PubMed    


  786. O'LEARY JG, Rajender Reddy K, Wong F, Garcia-Tsao G, et al
    Reply.
    Hepatology. 2018;68:791.
    PubMed    


  787. PENG TC
    Role of Sarcopenia in Nonalcoholic Fatty Liver Disease: Definition Is Crucially Important.
    Hepatology. 2018;68:788-789.
    PubMed    


  788. GRETEN TF
    The ABC of adaptive immunity in liver cancer.
    Hepatology. 2018;68:777-779.
    PubMed    


  789. HUANG R, Gao ZH, Tang A, Sebastiani G, et al
    Transient elastography is an unreliable marker of liver fibrosis in patients with portal vein thrombosis.
    Hepatology. 2018;68:783-785.
    PubMed    


  790. MOEST W, van der Deure W, Koster T, Spee-Dropkova M, et al
    Glycogen storage disease type Ia: Adult presentation with microcytic anemia and liver adenomas.
    Hepatology. 2018;68:780-782.
    PubMed    


  791. DUAN JL, Ruan B, Yan XC, Liang L, et al
    Endothelial Notch activation reshapes the angiocrine of sinusoidal endothelia to aggravate liver fibrosis and blunt regeneration in mice.
    Hepatology. 2018;68:677-690.
    PubMed     Abstract available


  792. CAUSSY C, Reeder SB, Sirlin CB, Loomba R, et al
    Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
    Hepatology. 2018;68:763-772.
    PubMed     Abstract available


  793. WANGENSTEEN KJ, Wang YJ, Dou Z, Wang AW, et al
    Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform.
    Hepatology. 2018;68:663-676.
    PubMed     Abstract available


  794. LUDVIGSSON JF, Marschall HU, Hagstrom H, Hoijer J, et al
    Pregnancy outcome in women undergoing liver biopsy during pregnancy: A nationwide population-based cohort study.
    Hepatology. 2018;68:625-633.
    PubMed     Abstract available


    July 2018
  795. HERNANDEZ-GEA V, Baiges A, Turon F, Garcia-Pagan JC, et al
    Idiopathic Portal Hypertension.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30132.
    PubMed     Abstract available


  796. GARCIA-TSAO G, Fuchs M, Shiffman M, Borg BB, et al
    Emricasan (IDN-6556) Lowers Portal Pressure in Patients with Compensated Cirrhosis and Severe Portal Hypertension.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30199.
    PubMed     Abstract available


  797. LOOMES KM, Spino C, Goodrich NP, Hangartner TN, et al
    Bone Density in Children with Chronic Liver Disease Correlates with Growth and Cholestasis.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30196.
    PubMed     Abstract available


  798. CORTES E, Lachowski D, Rice A, Chronopoulos A, et al
    RAR-beta is downregulated in HCC & cirrhosis and its expression inhibits myosin-driven activation and durotaxis in hepatic stellate cells.
    Hepatology. 2018 Jul 28. doi: 10.1002/hep.30193.
    PubMed     Abstract available


  799. MAZZARELLI C, Cannon MD, Hudson M, Heaton N, et al
    Hepatocellular Carcinoma as a complication of vascular disease of the liver after Fontan procedure.
    Hepatology. 2018 Jul 28. doi: 10.1002/hep.30194.
    PubMed     Abstract available


  800. LI W, Li Y, Siraj S, Jin H, et al
    FUNDC1-mediated mitophagy suppresses hepatocarcinogenesis by inhibition of inflammasome activation.
    Hepatology. 2018 Jul 27. doi: 10.1002/hep.30191.
    PubMed     Abstract available


  801. RODERFELD M, Padem S, Lichtenberger J, Quack T, et al
    Schistosoma mansoni egg secreted antigens activate HCC-associated transcription factors c-Jun and STAT3 in hamster and human hepatocytes.
    Hepatology. 2018 Jul 27. doi: 10.1002/hep.30192.
    PubMed     Abstract available


  802. VITALE A, Farinati F, Noaro G, Burra P, et al
    Restaging patients with hepatocellular carcinoma before additional treatment decisions: a multicenter cohort study.
    Hepatology. 2018 Jul 26. doi: 10.1002/hep.30185.
    PubMed     Abstract available


  803. DIAZ-GONZALEZ A, Monclus E, Darnell A, Sole M, et al
    Liver metastases from gastric adenocarcinoma mimicking multinodular hepatocellular carcinoma.
    Hepatology. 2018 Jul 25. doi: 10.1002/hep.30120.
    PubMed     Abstract available


  804. ARAB JP, Arrese M
    "Old remedies to heal the liver: novel effects of digoxin in hepatic sterile inflammation".
    Hepatology. 2018 Jul 23. doi: 10.1002/hep.30188.
    PubMed     Abstract available


  805. HONG W, Zhang CZ, Lu SX, Zhang MF, et al
    A CCDC50 splice variant is modulated by SRSF3 and promotes hepatocellular carcinoma via the Ras signaling pathway.
    Hepatology. 2018 Jul 20. doi: 10.1002/hep.30147.
    PubMed     Abstract available


  806. ZHOU X, Wen Y, Tian Y, He M, et al
    Hsp90alpha-dependent Bclaf1 promotes hepatocellular carcinoma proliferation by regulating c-MYC mRNA stability.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30172.
    PubMed     Abstract available


  807. VUPPALANCHI R, Mathur K, Pyko M, Samala N, et al
    Liver Stiffness Measurements in Patients with Non-cirrhotic Portal Hypertension - The Devil is In the Details.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30167.
    PubMed     Abstract available


  808. ROMAN E, Gely C, Flavia M, Poca M, et al
    Patients with compensated cirrhosis are also at risk of falling.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30180.
    PubMed     Abstract available


  809. NAVIN P, Hilscher M, Welle C, Mounajjed T, et al
    The Utility of MR Elastography to Differentiate Nodular Regenerative Hyperplasia from Cirrhosis.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30175.
    PubMed     Abstract available


  810. SAYINER M, Golabi P, Stepanova M, Younossi I, et al
    Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174.
    PubMed     Abstract available


  811. LIAO SH, Su TH, Jeng YM, Liang PC, et al
    Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30162.
    PubMed     Abstract available


  812. CINGOLANI F, Czaja MJ
    Oxidized Albumin - a Trojan Horse for p38 MAPK-Mediated Inflammation in Decompensated Cirrhosis.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30164.
    PubMed     Abstract available


  813. ZHANG J, Han C, Ungerleider N, Chen W, et al
    A novel TGF-beta and H19 signaling axis in tumor-initiating hepatocytes that regulates hepatic carcinogenesis.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30153.
    PubMed     Abstract available


  814. BARCENA-VARELA M, Caruso S, Llerena S, Alvarez-Sola G, et al
    Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30168.
    PubMed     Abstract available


  815. KIM D, Li AA, Perumpail BJ, Gadiparthi C, et al
    Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30161.
    PubMed     Abstract available


  816. HAIDER C, Hnat J, Wagner R, Huber H, et al
    Transforming Growth Factor-beta and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30166.
    PubMed     Abstract available


  817. RUSSO N, Brown RS Jr, Shen NT, Pisa JF, et al
    Hepatology highlights.
    Hepatology. 2018;68:1-3.
    PubMed    


  818. POLYZOS SA, Kountouras J, Anastasiadis S, Doulberis M, et al
    Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?
    Hepatology. 2018;68:389.
    PubMed    


  819. VERMA N, Singh A, Singh V
    Reply.
    Hepatology. 2018;68:388.
    PubMed    


  820. CARR RM
    Proton pump inhibitors, Enterococcus, and the liver, oh my!
    Hepatology. 2018;68:376-379.
    PubMed    


  821. ARMENGOL C, Cairo S
    Identification of theranostic biomarkers to improve the stratification of patients with pediatric liver cancer: Opportunities and challenges.
    Hepatology. 2018;68:10-12.
    PubMed    


  822. HERNAEZ R, Kanwal F, El-Serag HB
    Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis.
    Hepatology. 2018;68:7-9.
    PubMed    


  823. BILL R, Montani M, Blum B, Dufour JF, et al
    Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver.
    Hepatology. 2018;68:384-386.
    PubMed    


  824. ORLIEN SMS, Sandven I, Berhe NB, Ismael NY, et al
    Khat chewing increases the risk for developing chronic liver disease: A hospital-based case-control study.
    Hepatology. 2018;68:248-257.
    PubMed     Abstract available


  825. CAI Y, Li H, Liu M, Pei Y, et al
    Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity.
    Hepatology. 2018;68:48-61.
    PubMed     Abstract available


    June 2018
  826. HUI ST, Kurt Z, Tuominen I, Norheim F, et al
    The Genetic Architecture of Diet-induced Hepatic Fibrosis in Mice.
    Hepatology. 2018 Jun 16. doi: 10.1002/hep.30113.
    PubMed     Abstract available


  827. HAYASHI S, Khan A, Simons BC, Homan C, et al
    A novel association between core mutations in hepatitis B virus genotype F1b and hepatocellular carcinoma in Alaskan Native People.
    Hepatology. 2018 Jun 12. doi: 10.1002/hep.30111.
    PubMed     Abstract available


  828. BHUSHAN B, Stoops JW, Mars WM, Orr A, et al
    TCPOBOP-induced hepatomegaly & hepatocyte proliferation is attenuated by combined disruption of MET & EGFR signaling.
    Hepatology. 2018 Jun 11. doi: 10.1002/hep.30109.
    PubMed     Abstract available


  829. CHINO F, Pollis KE, Choi S, Salama JK, et al
    Stereotactic Body Radiation Therapy-induced Abscopal Effect on Hepatocellular Carcinoma after Treatment for Lung Cancer: A Case Report.
    Hepatology. 2018 Jun 11. doi: 10.1002/hep.30100.
    PubMed    


  830. PELLICANO R, Durazzo M
    Upper GI bleeding in cirrhotic patients: Which method to search for Helicobacter pylori infection?
    Hepatology. 2018 Jun 11. doi: 10.1002/hep.30108.
    PubMed    


  831. RUSSO N, Brown RS Jr, Cohen-Mekelburg S, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2018;67:2065-2067.
    PubMed    


  832. HUO TI, Hsu CY, Liu PH
    Magic mirror on the wall: Which is the best biomarker for hepatocellular carcinoma?
    Hepatology. 2018;67:2482-2483.
    PubMed    


  833. DEAR JW
    New biomarkers for drug-induced liver injury.
    Hepatology. 2018;67:2480-2481.
    PubMed    


  834. ZHANG C, Song F
    Knockout of ULK1/2 protects against acetaminophen-induced acute liver injury independent of autophagy?
    Hepatology. 2018;67:2476-2477.
    PubMed    


  835. LAI S, Iwakiri Y
    Is miR-21 a potent target for liver fibrosis?
    Hepatology. 2018;67:2082-2084.
    PubMed    


  836. BELLENTANI S, Bedogni G, Tiribelli C
    Two drinks per day does not take your fatty liver away.
    Hepatology. 2018;67:2072-2073.
    PubMed    


  837. ZHAO Q, Tang X, Wu J
    The association between nonalcoholic fatty liver disease and metabolic comorbidities.
    Hepatology. 2018;67:2474.
    PubMed    


  838. ZHANG XJ, She ZG, Li H
    Time to step-up the fight against NAFLD.
    Hepatology. 2018;67:2068-2071.
    PubMed    


  839. SUN Y, Li TY, Song L, Zhang C, et al
    Liver-specific deficiency of unc-51 like kinase 1 and 2 protects mice from acetaminophen-induced liver injury.
    Hepatology. 2018;67:2397-2413.
    PubMed     Abstract available


  840. SUN W, Zhang Y, Wong KC, Liu K, et al
    Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3.
    Hepatology. 2018;67:2302-2319.
    PubMed     Abstract available


  841. CHEN M, Wei L, Law CT, Tsang FH, et al
    RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
    Hepatology. 2018;67:2254-2270.
    PubMed     Abstract available


  842. ABERG F, Helenius-Hietala J, Puukka P, Farkkila M, et al
    Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population.
    Hepatology. 2018;67:2141-2149.
    PubMed     Abstract available


    May 2018
  843. GOEDEKE L, Bates J, Vatner DF, Perry RJ, et al
    Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30097.
    PubMed     Abstract available


  844. BLASI A, Calvo A, Prado V, Reverter E, et al
    Coagulation failure in patients with Acute-on-Chronic Liver Failure (ACLF) and decompensated cirrhosis: beyond INR.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30103.
    PubMed     Abstract available


  845. YAN J, Lei J, Chen L, Deng H, et al
    FAT10 overexpression disturbs WISP1 protein and mRNA expression to promote hepatocellular carcinoma progression.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30105.
    PubMed     Abstract available


  846. SCHULZE RJ, McNiven MA
    Fasting Inhibits the Recruitment of Kinesin-1 to Lipid Droplets and Stalls Hepatic Triglyceride Secretion.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30104.
    PubMed    


  847. KHANNA A, Jopson L, Howel D, Bryant A, et al
    Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30099.
    PubMed     Abstract available


  848. LIU M, Zhang L, Li H, Hinoue T, et al
    Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor SGI-110 in Hepatocellular Carcinoma.
    Hepatology. 2018 May 18. doi: 10.1002/hep.30091.
    PubMed     Abstract available


  849. BAJAJ JS, Savidge T, Kassam ZA, Hylemon PB, et al
    Fecal Microbial Transplant for Antibiotic-Associated Disruption in Cirrhosis.
    Hepatology. 2018 May 18. doi: 10.1002/hep.30092.
    PubMed    


  850. MULLISH BH, McDonald JAK, Thursz MR, Marchesi JR, et al
    Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis is Restored by Fecal Transplant.
    Hepatology. 2018 May 18. doi: 10.1002/hep.30090.
    PubMed    


  851. WRIGHT TL, Reddy KR
    Thomas D. Boyer, MD: A visionary hepatologist, investigator, mentor and colleague.
    Hepatology. 2018 May 12. doi: 10.1002/hep.30089.
    PubMed    


  852. SUN P, Lu YX, Cheng D, Zhang K, et al
    Monocyte chemoattractant protein-induced protein 1 targets hypoxia-inducible factor 1alpha to protect against hepatic ischemia/reperfusion injury.
    Hepatology. 2018 May 9. doi: 10.1002/hep.30086.
    PubMed     Abstract available


  853. WINKLER N, Strubing F, Gross W, Mier W, et al
    Phenomenon of endothelial antibody capture: Principles and potential for locoregional targeting of hepatic tumors.
    Hepatology. 2018 May 7. doi: 10.1002/hep.30072.
    PubMed     Abstract available


  854. PANG Y, Kartsonaki C, Turnbull I, Guo Y, et al
    Diabetes, plasma glucose and incidence of fatty liver, cirrhosis and liver cancer: A prospective study of 0.5 million people.
    Hepatology. 2018 May 7. doi: 10.1002/hep.30083.
    PubMed     Abstract available


  855. MANSKE K, Kallin N, Konig V, Schneider A, et al
    Outcome of anti-viral immunity in the liver is shaped by the level of antigen expressed in infected hepatocytes.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30080.
    PubMed     Abstract available


  856. WANG C, Cheng Y, Zhang X, Li N, et al
    Vacuolar Protein Sorting 33B Is a Tumor Suppressor in Hepatocarcinogenesis.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30077.
    PubMed     Abstract available


  857. GAO S, Silasi-Mansat R, Behar M, Lupu F, et al
    Excessive plasmin compromises hepatic sinusoidal vascular integrity after acetaminophen overdose.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30070.
    PubMed     Abstract available


  858. RAEVENS S, Fallon MB
    Potential clinical targets in hepatopulmonary syndrome: lessons from experimental models.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30079.
    PubMed     Abstract available


  859. SUN P, Zeng Q, Cheng D, Zhang K, et al
    Caspase Recruitment Domain Protein 6 protects against hepatic steatosis and insulin resistance by suppressing Ask1.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30075.
    PubMed     Abstract available


  860. PROPERZI C, O'Sullivan TA, Sherriff JL, Ching HL, et al
    Ad libitum Mediterranean and Low Fat Diets both Significantly Reduce Hepatic Steatosis: a Randomized Controlled Trial.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30076.
    PubMed     Abstract available


  861. COHEN-MEKELBURG S, Schwartz RE, Rosenblatt R, Brown RS Jr, et al
    Hepatology Highlights.
    Hepatology. 2018;67:1647-1650.
    PubMed    


  862. FAN H, Zhu JH
    A novel frailty index improves risk prediction of waitlist mortality over the model for end-stage liver disease score alone.
    Hepatology. 2018;67:2059.
    PubMed    


  863. ZATLOUKAL K
    Bringing the cell nucleus in the focus of NAFLD.
    Hepatology. 2018;67:1654-1656.
    PubMed    


  864. WANG L
    Mesenchymal stromal cells in treatment of acute-on-chronic liver failure.
    Hepatology. 2018;67:2056-2057.
    PubMed    


  865. MUSSO G, Gambino R
    Targeting mitochondrial pyruvate carrier in nonalcoholic steatohepatitis: Growing evidence and future challenges.
    Hepatology. 2018;67:2055.
    PubMed    


  866. SAHA B, Momen-Heravi F, Furi I, Kodys K, et al
    Extracellular vesicles from mice with alcoholic liver disease carry a distinct protein cargo and induce macrophage activation through heat shock protein 90.
    Hepatology. 2018;67:1986-2000.
    PubMed     Abstract available


  867. WIN S, Than TA, Zhang J, Oo C, et al
    New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases.
    Hepatology. 2018;67:2013-2024.
    PubMed     Abstract available


  868. STRAVITZ RT, Ellerbe C, Durkalski V, Schilsky M, et al
    Bleeding complications in acute liver failure.
    Hepatology. 2018;67:1931-1942.
    PubMed     Abstract available


  869. QI X, Mendez-Sanchez N, Mancuso A, Romeiro FG, et al
    Who should receive endoscopic variceal ligation after recovering from acute variceal bleeding?
    Hepatology. 2018;67:2057-2058.
    PubMed    


  870. WAN S, Meyer AS, Weiler SME, Rupp C, et al
    Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness.
    Hepatology. 2018;67:1842-1856.
    PubMed     Abstract available


  871. CHEN R, Zhu S, Fan XG, Wang H, et al
    High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis.
    Hepatology. 2018;67:1823-1841.
    PubMed     Abstract available


  872. SIDDIQUI MS, Harrison SA, Abdelmalek MF, Anstee QM, et al
    Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.
    Hepatology. 2018;67:2001-2012.
    PubMed     Abstract available


  873. ALLEN AM, Therneau TM, Larson JJ, Coward A, et al
    Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study.
    Hepatology. 2018;67:1726-1736.
    PubMed     Abstract available


  874. BRADY GF, Kwan R, Ulintz PJ, Nguyen P, et al
    Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease.
    Hepatology. 2018;67:1710-1725.
    PubMed     Abstract available


    April 2018
  875. LIANG Q, Liu Z, Zhu C, Wang B, et al
    Intrahepatic T cell receptor beta immune repertoire is essential for liver regeneration.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.30067.
    PubMed     Abstract available


  876. ALAO H, Cam M, Keembiyehetty C, Zhang F, et al
    Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During DAA Therapy.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.29921.
    PubMed     Abstract available


  877. YIN Y, Xu X, Tang J, Zhang W, et al
    CD97 Promotes Tumor Aggressiveness through the Traditional G Protein-Coupled Receptor-mediated signaling in Hepatocellular Carcinoma.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.30068.
    PubMed     Abstract available


  878. CULLARO G, Park M, Lai JC
    "Normal" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients with Cirrhosis.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30058.
    PubMed     Abstract available


  879. TAYLOR AE, Carey AN, Kudira R, Lages CS, et al
    Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30061.
    PubMed     Abstract available


  880. LUO P, Qin C, Zhu L, Fang C, et al
    Ubiquitin-specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance and Inflammation via Sirt6.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30062.
    PubMed     Abstract available


  881. YANG JD, Gores GJ
    Does Cirrhosis Associated with Well Controlled Viral Hepatitis Confer a Risk for Extrahepatic Cancer?
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30063.
    PubMed    


  882. VERRIER ER, Yim SA, Heydmann L, El Saghire H, et al
    Hepatitis B virus evasion from cGAS sensing in human hepatocytes.
    Hepatology. 2018 Apr 20. doi: 10.1002/hep.30054.
    PubMed     Abstract available


  883. IZZY M, Oh J, Watt KD
    Cirrhotic cardiomyopathy after transplantation: Neither the transient nor innocent bystander.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30040.
    PubMed     Abstract available


  884. KWONG AJ, Kim WR, Flemming JA
    De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30045.
    PubMed     Abstract available


  885. KO E, Kim JS, Ju S, Seo HW, et al
    Oxidatively modified PDIA3 promotes DKC1-mediated malignancy and survival of hepatocellular carcinoma cells.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30039.
    PubMed     Abstract available


  886. LEMMER A, Van-Wagner LB, Ganger D
    Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients with Congestive Hepatopathy.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30048.
    PubMed     Abstract available


  887. PONZIANI FR, Bhoori S, Castelli C, Putignani L, et al
    Hepatocellular Carcinoma is Associated with Gut Microbiota Profile and Inflammation in Non-Alcoholic Fatty Liver Disease.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30036.
    PubMed     Abstract available


  888. BAJAJ JS, Kakiyama G, Savidge T, Takei H, et al
    Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis is Restored by Fecal Transplant.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30037.
    PubMed     Abstract available


  889. MARRONE G, De Chiara F, Bottcher K, Levi A, et al
    The AMPK-v-ATPase-pH axis: A key regulator of the pro-fibrogenic phenotype of human hepatic stellate cells.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30029.
    PubMed     Abstract available


  890. ALLAIRE M, Nahon P, Layese R, Bourcier V, et al
    Extra hepatic cancers are the leading cause of death in cirrhotic patients achieving HBV control or HCV eradication.
    Hepatology. 2018 Apr 16. doi: 10.1002/hep.30034.
    PubMed     Abstract available


  891. WANG C, Tong Y, Wen Y, Cai J, et al
    Hepatocellular Carcinoma-associated Protein TD26 Interacts and Enhances SREBP1 Activity to Promote Tumor Cell Proliferation and Growth.
    Hepatology. 2018 Apr 16. doi: 10.1002/hep.30030.
    PubMed     Abstract available


  892. VAN GOLEN RF, Reiniers MJ, van Gorp J, Tushuizen ME, et al
    Utilizing mechanistic biomarkers in treating paracetamol hepatotoxicity.
    Hepatology. 2018 Apr 16. doi: 10.1002/hep.30028.
    PubMed    


  893. WOO HG, Kim YJ
    Multi-platform genomic roadmap of hepatocellular carcinoma: A matter of molecular heterogeneity.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29925.
    PubMed    


  894. WENDUM D, Layese R, Ganne-Carrie N, Bourcier V, et al
    Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29927.
    PubMed     Abstract available


  895. ZHANG F, Hu Z, Li G, Huo S, et al
    Hepatic CREBZF Couples Insulin to Lipogenesis by Inhibiting Insig activity and Contributes to Hepatic Steatosis in Diet-Induced Insulin-Resistant Mice.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29926.
    PubMed     Abstract available


  896. FANG JH, Zhang ZJ, Shang LR, Luo YW, et al
    Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29920.
    PubMed     Abstract available


  897. LI H, Feng D, Cai Y, Liu Y, et al
    Hepatocytes and neutrophils cooperatively suppress bacterial infection by differentially regulating lipocalin-2 and NETs.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29919.
    PubMed     Abstract available


  898. XIE L, Yin J, Xia R, Zhuang G, et al
    Cost-effectiveness of antiviral treatment after resection in HBV-related hepatocellular carcinoma patients with compensated cirrhosis.
    Hepatology. 2018 Apr 7. doi: 10.1002/hep.29922.
    PubMed     Abstract available


  899. CLOYD JM, Pawlik TM
    Diagnostic and Therapeutic Implications of Novel Peptides in Hepatocellular Carcinoma.
    Hepatology. 2018 Apr 7. doi: 10.1002/hep.29923.
    PubMed    


  900. MARRERO JA, Kulik LM, Sirlin C, Zhu AX, et al
    Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Apr 6. doi: 10.1002/hep.29913.
    PubMed    


  901. VARGA ZV, Erdelyi K, Paloczi J, Cinar R, et al
    Disruption of renal arginine metabolism promotes kidney injury in hepatorenal syndrome.
    Hepatology. 2018 Apr 6. doi: 10.1002/hep.29915.
    PubMed     Abstract available


  902. VAN DER WINDT DJ, Sud V, Zhang H, Varley PR, et al
    Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in non-alcoholic steatohepatitis.
    Hepatology. 2018 Apr 6. doi: 10.1002/hep.29914.
    PubMed     Abstract available


  903. NIEC R, Schwartz RE, Rosenblatt R, Gupta V, et al
    Hepatology Highlights.
    Hepatology. 2018;67:1195-1197.
    PubMed    


  904. RABIEE A, Hamilton JPA
    Pregnancy in Wilson disease.
    Hepatology. 2018;67:1201-1203.
    PubMed    


  905. STARLINGER P, Pereyra D, Haegele S, Braeuer P, et al
    Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection.
    Hepatology. 2018;67:1516-1530.
    PubMed     Abstract available


  906. WOO BAIDAL JA, Cheng ER, Rifas-Shiman SL, Oken E, et al
    Association of vitamin E intake at early childhood with alanine aminotransferase levels at mid-childhood.
    Hepatology. 2018;67:1339-1347.
    PubMed     Abstract available


  907. PFEIFFENBERGER J, Beinhardt S, Gotthardt DN, Haag N, et al
    Pregnancy in Wilson's disease: Management and outcome.
    Hepatology. 2018;67:1261-1269.
    PubMed     Abstract available


    March 2018
  908. FIRL DJ, Kimura S, McVey J, Hashimoto K, et al
    Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with HALTHCC improves ablate and wait strategy.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29907.
    PubMed     Abstract available


  909. BHANJI RA, Watt KD
    Reply to letter to the editor: "Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis".
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29908.
    PubMed    


  910. FAILLACI F, Marzi L, Critelli R, Milosa F, et al
    Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29911.
    PubMed     Abstract available


  911. HOFMANN AF, Marschall HU
    Plasma Bile Acid Concentrations in Humans: Suggestions for Presentation in Tabular Form.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29909.
    PubMed    


  912. KUREBAYASHI Y, Ojima H, Tsujikawa H, Kubota N, et al
    Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29904.
    PubMed     Abstract available


  913. PAYANCE A, Silva-Junior G, Bissonnette J, Tanguy M, et al
    Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29903.
    PubMed     Abstract available


  914. WU J, Zhao Y, Park YK, Lee JY, et al
    Loss of PDK4 switches the hepatic NF-kappaB/TNF pathway from pro-survival to pro-apoptosis.
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29902.
    PubMed     Abstract available


  915. YOUNOSSI ZM
    Reply letter to the editor: Combination Therapy for Non-alcoholic Steatohepatitis (NASH).
    Hepatology. 2018 Mar 30. doi: 10.1002/hep.29896.
    PubMed    


  916. MELLINGER JL, Shedden K, Winder GS, Tapper E, et al
    The High Burden of Alcoholic Cirrhosis in Privately Insured Persons in the United States.
    Hepatology. 2018 Mar 26. doi: 10.1002/hep.29887.
    PubMed     Abstract available


  917. SLIJEPCEVIC D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, et al
    NTCP inhibition has hepatoprotective effects in cholestasis in mice.
    Hepatology. 2018 Mar 24. doi: 10.1002/hep.29888.
    PubMed     Abstract available


  918. NAULT JC, Couchy G, Caruso S, Meunier L, et al
    ASS1 and peri-portal gene expression in sonic hedgehog hepatocellular adenomas.
    Hepatology. 2018 Mar 24. doi: 10.1002/hep.29884.
    PubMed     Abstract available


  919. GUO JT, Block TM
    Do hepatitis B surface antigens have any role in viral carcinogenesis?
    Hepatology. 2018 Mar 24. doi: 10.1002/hep.29886.
    PubMed    


  920. CAUSSY C, Hsu C, Lo MT, Liu A, et al
    Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.
    Hepatology. 2018 Mar 23. doi: 10.1002/hep.29892.
    PubMed     Abstract available


  921. CHEN Z, Gao W, Pu L, Zhang L, et al
    PRDM8 Exhibits Anti-Tumor Activities Toward Hepatocellular Carcinoma by Targeting NAP1L1.
    Hepatology. 2018 Mar 23. doi: 10.1002/hep.29890.
    PubMed     Abstract available


  922. HYUN MH, Lee YS, Kim JH, Lee CU, et al
    Hepatic Resection Compared to Chemoembolization in Intermediate to Advanced Stage Hepatocellular Carcinoma: A Meta-analysis of High-Quality Studies.
    Hepatology. 2018 Mar 15. doi: 10.1002/hep.29883.
    PubMed     Abstract available


  923. VANWAGNER LB, Kanwal F
    Hepatology in a Changing Health Care Landscape: A Call for Health Services Research.
    Hepatology. 2018 Mar 14. doi: 10.1002/hep.29880.
    PubMed     Abstract available


  924. FUNG J, Cheung KS, Wong DK, Mak LY, et al
    Long Term Outcomes and Predictive Scores for Hepatocellular Carcinoma and HBsAg Seroclearance after HBeAg Seroclearance.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29874.
    PubMed     Abstract available


  925. ZHANG D, Tong X, Nelson BB, Jin E, et al
    The hepatic BMAL1/AKT/Lipogenesis axis protects against alcoholic liver disease via promoting PPARalpha pathway.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29878.
    PubMed     Abstract available


  926. MOYLAN CA, Abdelmalek MF
    Nonalcoholic Fatty Liver Disease with Cirrhosis Increases Familial Risk for Advanced Fibrosis.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29879.
    PubMed    


  927. WU Y, Shan B, Dai J, Xia Z, et al
    Dual Role for Inositol-requiring Enzyme 1alpha in Promoting the Development of Hepatocellular Carcinoma during Diet-induced Obesity.
    Hepatology. 2018 Mar 5. doi: 10.1002/hep.29871.
    PubMed     Abstract available


  928. PHILIPS CA, Augustine P, Mathew S, Valiathan GC, et al
    Letter to the editor: Growth factor therapy for decompensated cirrhosis - Much ado about nothing?
    Hepatology. 2018 Mar 3. doi: 10.1002/hep.29866.
    PubMed    


  929. ZHANG XP, Wang K, Guo WX, Chen ZH, et al
    Is sorafenib an optimal treatment for hepatocellular carcinoma with macrovascular invasion or metastatic disease?
    Hepatology. 2018 Mar 3. doi: 10.1002/hep.29862.
    PubMed    


  930. ROSENBLATT R, Brown RS Jr., Mukewar S, Schneider Y, et al
    Hepatology Highlights.
    Hepatology. 2018;67:817-819.
    PubMed    


  931. ABERG F
    Liver fibrosis scores in the general population: Better risk indices are needed!
    Hepatology. 2018;67:1186.
    PubMed    


  932. SOOKOIAN S, Pirola CJ
    The nonalcoholic steatohepatitis metabotype: Imbalance of circulating amino acids and transamination reactions reflect impaired mitochondrial function.
    Hepatology. 2018;67:1177-1178.
    PubMed    


  933. BRAILLON A
    Adding care to cure for patients with liver disease: A cultural shift.
    Hepatology. 2018;67:1172.
    PubMed    


  934. STRAVITZ RT, Gottfried M, Durkalski V, Fontana RJ, et al
    Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
    Hepatology. 2018;67:1003-1013.
    PubMed     Abstract available


    February 2018
  935. HENEGHAN MA, Cannon MD
    Hepatic diagnostics in pregnancy: Biopsy, biomarkers and beyond.
    Hepatology. 2018 Feb 27. doi: 10.1002/hep.29859.
    PubMed    


  936. WU JF, Lee CS, Lin WH, Jeng YM, et al
    Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy.
    Hepatology. 2018 Feb 27. doi: 10.1002/hep.29856.
    PubMed     Abstract available


  937. HUANG AC, Mehta N, Dodge JL, Yao FY, et al
    Direct-acting Antivirals Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence after Local-Regional Therapy or Liver Transplant Waitlist Dropout.
    Hepatology. 2018 Feb 24. doi: 10.1002/hep.29855.
    PubMed     Abstract available


  938. FOSTER GR, Agarwal K, Cramp ME, Moreea S, et al
    Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial.
    Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852.
    PubMed     Abstract available


  939. LEBEAUPIN C, Vallee D, Rousseau D, Patouraux S, et al
    Bax Inhibitor-1 protects from Non-Alcoholic Steatohepatitis by limiting IRE1alpha signaling.
    Hepatology. 2018 Feb 19. doi: 10.1002/hep.29847.
    PubMed     Abstract available


  940. CHEN H, Shen F, Sherban A, Nocon A, et al
    DEPTOR Suppresses Lipogenesis and Ameliorates Hepatic Steatosis and Acute-on-Chronic Liver Injury in Alcoholic Liver Disease.
    Hepatology. 2018 Feb 19. doi: 10.1002/hep.29849.
    PubMed     Abstract available


  941. ZAMORA-VALDES D, Watt KD, Kellogg TA, Poterucha JJ, et al
    Long-term outcomes of patients undergoing simultaneous Liver Transplantation and Sleeve Gastrectomy.
    Hepatology. 2018 Feb 19. doi: 10.1002/hep.29848.
    PubMed     Abstract available


  942. CAREY W
    Statin Use In Cirrhosis from Fatty Liver Disease.
    Hepatology. 2018 Feb 14. doi: 10.1002/hep.29842.
    PubMed    


  943. ZHU W, Peng Y, Wang L, Hong Y, et al
    Identification of alpha-fetoprotein-specific T cell receptors for hepatocellular carcinoma immunotherapy.
    Hepatology. 2018 Feb 14. doi: 10.1002/hep.29844.
    PubMed     Abstract available


  944. MAZZAFERRO V, Droz Dit Busset M, Bhoori S
    Alpha-Fetoprotein (AFP) in liver transplantation for HCC: The lower, the better.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29835.
    PubMed    


  945. KLEINER DE
    Hepatocellular Carcinoma: Liver Biopsy in the Balance.
    Hepatology. 2018 Feb 5. doi: 10.1002/hep.29831.
    PubMed     Abstract available


  946. JING R, Zhou X, Zhao J, Wei Y, et al
    Fluorescent peptide highlights micronodules in murine hepatocellular carcinoma models and human in vitro.
    Hepatology. 2018 Feb 5. doi: 10.1002/hep.29829.
    PubMed     Abstract available


  947. WANG M, Ju C
    Orchestrating liver repair - a newly discovered function of hepatic iNKT cells.
    Hepatology. 2018 Feb 5. doi: 10.1002/hep.29828.
    PubMed    


  948. OLAIZOLA P, Perugorria MJ, Banales JM
    Towards Personalized Medicine for Intrahepatic Cholangiocarcinoma: Pharmacogenomic Stratification of Patients.
    Hepatology. 2018 Feb 2. doi: 10.1002/hep.29830.
    PubMed    


    January 2018
  949. JUN G, Fang C, Zhang P, Wang PX, et al
    Tumor progression locus 2 in hepatocytes potentiates both liver and systemic metabolic disorders.
    Hepatology. 2018 Jan 30. doi: 10.1002/hep.29820.
    PubMed     Abstract available


  950. PU W, Li J, Zheng Y, Shen X, et al
    Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development.
    Hepatology. 2018 Jan 30. doi: 10.1002/hep.29819.
    PubMed     Abstract available


  951. RIDOLA L, Riggio O
    Prediction of Hepatic Encephalopathy: Why disregard well known risk factors?
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29808.
    PubMed    


  952. LIU X, Guo GL, Kong B, Hilburn DB, et al
    Farnesoid X Receptor Signaling Activates the Hepatic X-box Binding Protein 1 Pathway in vitro and in Mice.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29815.
    PubMed     Abstract available


  953. TAPPER EB, Ratz D, Lok AS, Su GL, et al
    Re: Prediction of Hepatic Encephalopathy: why disregard well known risk factors?
    Hepatology. 2018 Jan 24. doi: 10.1002/hep.29806.
    PubMed    


  954. KOSTALLARI E, Hirsova P, Prasnicka A, Verma VK, et al
    Hepatic stellate cell-derived PDGFRalpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2.
    Hepatology. 2018 Jan 23. doi: 10.1002/hep.29803.
    PubMed     Abstract available


  955. BRUNT E, Aishima S, Clavien PA, Fowler K, et al
    cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.
    Hepatology. 2018 Jan 23. doi: 10.1002/hep.29789.
    PubMed     Abstract available


  956. BERZIGOTTI A, Bosch J
    Reply to "Balancing exercise-induced weight loss with protein caloric requirement remains a challenge in overweight patients with cirrhosis".
    Hepatology. 2018 Jan 22. doi: 10.1002/hep.29799.
    PubMed    


  957. DHALIWAL A, Towey J, Haydon G, Elsharkawy AM, et al
    Balancing exercise-induced weight loss with protein caloric requirement remains a challenge in overweight patients with cirrhosis.
    Hepatology. 2018 Jan 22. doi: 10.1002/hep.29801.
    PubMed    


  958. WANG X, Du H, Shao S, Bo T, et al
    Cyclophilin D Deficiency Attenuates Mitochondrial Perturbation and Ameliorates Hepatic Steatosis.
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29788.
    PubMed     Abstract available


  959. LO GH
    Does antiplatelet therapy really reduce the risk of hepatocellular carcinoma in hepatitis B patients with antiviral drug?
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29794.
    PubMed    


  960. LU M, Wu J, Hao ZW, Shang YK, et al
    Basolateral CD147 Induces Hepatocyte Polarity Loss by E-cadherin Ubiquitination and Degradation in Hepatocellular Carcinoma Progress.
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29798.
    PubMed     Abstract available


  961. FERNANDEZ M
    Placental Growth Factor: New Treatment Target Bringing Hope in Hepatopulmonary Syndrome.
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29795.
    PubMed    


  962. WANG X, Zhang M, Ping F, Liu H, et al
    Identification and Therapeutic Intervention of Co-activated ALK, FGFR2 and EphA5 Kinases in Hepatocellular Carcinoma.
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29792.
    PubMed     Abstract available


  963. YEN CJ, Ai YL, Tsai HW, Chan SH, et al
    Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection.
    Hepatology. 2018 Jan 19. doi: 10.1002/hep.29790.
    PubMed     Abstract available


  964. KAGEYAMA S, Nakamura K, Fujii T, Ke B, et al
    Recombinant Relaxin Protects Liver Transplants from Ischemia Damage via Hepatocyte Glucocorticoid Receptor: From Bench-to-Bedside.
    Hepatology. 2018 Jan 19. doi: 10.1002/hep.29787.
    PubMed     Abstract available


  965. BAJAJ JS, Idilman R, Mabudian L, Hood M, et al
    Diet Affects Gut Microbiota and Modulates Hospitalization Risk Differentially In an International Cirrhosis Cohort.
    Hepatology. 2018 Jan 19. doi: 10.1002/hep.29791.
    PubMed     Abstract available


  966. ZHAO Z, Xu D, Wang Z, Wang L, et al
    Hepatic PPARalpha function is controlled by polyubiquitination and proteasome-mediated degradation via the coordinated actions of PAQR3 and HUWE1.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29786.
    PubMed     Abstract available


  967. GULAMHUSEIN AF, Lazaridis KN
    Primary Biliary Cholangitis, DNA and Beyond: The Relative Contribution of Genes.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29783.
    PubMed    


  968. WU SY, Lan SH, Wu SR, Chiu YC, et al
    Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system.
    Hepatology. 2018 Jan 12. doi: 10.1002/hep.29781.
    PubMed     Abstract available


  969. BOTTCHER K, Rombouts K, Saffioti F, Roccarina D, et al
    MAIT cells are chronically activated in patients with autoimmune liver disease and promote pro-fibrogenic hepatic stellate cell activation.
    Hepatology. 2018 Jan 12. doi: 10.1002/hep.29782.
    PubMed     Abstract available


  970. ZHENG H, Pomyen Y, Hernandez MO, Li C, et al
    Single cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma.
    Hepatology. 2018 Jan 9. doi: 10.1002/hep.29778.
    PubMed     Abstract available


  971. PATIDAR KR, Kang L, Bajaj JS, Carl D, et al
    Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis.
    Hepatology. 2018 Jan 8. doi: 10.1002/hep.29772.
    PubMed     Abstract available


  972. O'LEARY JG, Reddy KR, Garcia-Tsao G, Biggins SW, et al
    NACSELD Acute-on-Chronic Liver Failure (NACSELD-ACLF) Score Predicts 30-Day Survival in Hospitalized Patients with Cirrhosis.
    Hepatology. 2018 Jan 8. doi: 10.1002/hep.29773.
    PubMed     Abstract available


  973. PALARIA A, Angelo JR, Guertin T, Mager J, et al
    Patterning of the hepato-pancreatobiliary boundary by BMP reveals heterogeneity within the murine liver bud.
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29769.
    PubMed     Abstract available


  974. NOVIKOV A, Schwartz RE, Mukewar S, Brown RS Jr, et al
    Hepatology Highlights.
    Hepatology. 2018;67:1-3.
    PubMed    


  975. VUPPALANCHI R, Siddiqui MS, Van Natta ML, Hallinan E, et al
    Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.
    Hepatology. 2018;67:134-144.
    PubMed     Abstract available


  976. GAGGINI M, Carli F, Rosso C, Buzzigoli E, et al
    Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance.
    Hepatology. 2018;67:145-158.
    PubMed     Abstract available


  977. ESTES C, Razavi H, Loomba R, Younossi Z, et al
    Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
    Hepatology. 2018;67:123-133.
    PubMed     Abstract available


  978. ZHANG J, Li Z, Liu L, Wang Q, et al
    Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6/STAT3 signaling pathway.
    Hepatology. 2018;67:171-187.
    PubMed     Abstract available


  979. AYONRINDE OT, Adams LA, Mori TA, Beilin LJ, et al
    Sex differences between parental pregnancy characteristics and nonalcoholic fatty liver disease in adolescents.
    Hepatology. 2018;67:108-122.
    PubMed     Abstract available


  980. WREE A, Inzaugarat ME, Feldstein AE
    Transmembrane BAX Inhibitor motif-containing 1, a novel anti-inflammatory approach for nonalcoholic steatohepatitis treatment.
    Hepatology. 2018;67:438-441.
    PubMed    


  981. SINGH S, Loomba R
    Role of two-dimensional shear wave elastography in the assessment of chronic liver diseases.
    Hepatology. 2018;67:13-15.
    PubMed    


  982. SARKAR M, Baffy G
    Perinatal programming of adolescent nonalcoholic fatty liver disease: A case for gender inequality?
    Hepatology. 2018;67:7-9.
    PubMed    


  983. CHALASANI N, Younossi Z, Lavine JE, Charlton M, et al
    The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018;67:328-357.
    PubMed    


    December 2017
  984. ZIOL M, Pote N, Amaddeo G, Laurent A, et al
    Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.
    Hepatology. 2017 Dec 27. doi: 10.1002/hep.29762.
    PubMed     Abstract available


  985. VERMA N, Kaur A, Sharma R, Bhalla A, et al
    Outcomes after Multiple courses of Granulocyte-Colony Stimulating Factor and Growth Hormone in Decompensated Cirrhosis: Randomized Trial.
    Hepatology. 2017 Dec 26. doi: 10.1002/hep.29763.
    PubMed     Abstract available


  986. NEPAL C, O'Rourke CJ, Oliveira DV, Taranta A, et al
    Genomic Perturbations Reveal Distinct Regulatory Networks in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2017 Dec 26. doi: 10.1002/hep.29764.
    PubMed     Abstract available


  987. TAPPER EB, Kanwal F, Asrani SK, Ho C, et al
    Patient Reported Outcomes in Cirrhosis: A Scoping Review of the Literature.
    Hepatology. 2017 Dec 22. doi: 10.1002/hep.29756.
    PubMed     Abstract available


  988. YOSHIHARA T, Sakamori R, Furuta K, Shigekawa M, et al
    Hepatocellular Carcinoma Due to a Baffle Obstruction After the Mustard Operation: A Case Report.
    Hepatology. 2017 Dec 22. doi: 10.1002/hep.29758.
    PubMed     Abstract available


  989. WINTER A, Daures JP, Landais P
    Intention-to-treat survival benefit in liver transplantation: comments on Lai et al.
    Hepatology. 2017 Dec 22. doi: 10.1002/hep.29755.
    PubMed    


  990. BAJAJ JS, Hylemon PB
    Gut-Liver Axis Alterations in Alcoholic Liver Disease: Are Bile Acids the Answer?
    Hepatology. 2017 Dec 22. doi: 10.1002/hep.29760.
    PubMed    


  991. MORELLO E, Sutti S, Foglia B, Novo E, et al
    Hypoxia-inducible factor 2alpha drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29754.
    PubMed     Abstract available


  992. KIM DY, Han KH
    Staging for hepatocellular carcinoma in light of tumor heterogeneity: Time to change or update?
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29748.
    PubMed    


  993. SO J, Khaliq M, Evason K, Ninov N, et al
    Wnt/beta-catenin signaling controls intrahepatic biliary network formation in zebrafish by regulating Notch activity.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29752.
    PubMed     Abstract available


  994. TAPPER EB, Lok AS, Su GL
    Re: Risk stratification of suffering hepatic encephalopathy in liver cirrhosis patients: novel strategy with novel concerns.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29746.
    PubMed    


  995. ZHENG B, Zhu YJ, Jeong S, Wang HY, et al
    Risk stratification ofhepatic encephalopathy in liver cirrhosis patients: Novel strategy with novel concerns.
    Hepatology. 2017 Dec 21. doi: 10.1002/hep.29747.
    PubMed    


  996. CHO CS, Park HW, Ho A, Semple IA, et al
    Lipotoxicity induces hepatic protein inclusions through TBK1-mediated p62/SQSTM1 phosphorylation.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29742.
    PubMed     Abstract available


  997. ZOU X, Ramachandran P, Kendall TJ, Pellicoro A, et al
    11betaHSD1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29734.
    PubMed     Abstract available


  998. SHAN Z, Liu X, Chen Y, Wang M, et al
    Chitinase 3-like-1 Promotes Intrahepatic Activation of Coagulation Through Induction of Tissue Factor in Mice.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29733.
    PubMed     Abstract available


  999. KIM E, Kim D, Lee JS, Yoe J, et al
    Capicua suppresses hepatocellular carcinoma progression by controlling ETV4-MMP1 axis.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29738.
    PubMed     Abstract available


  1000. SU TH, Tseng TC, Kao JH
    HCC risk in patients with HBV-related cirrhosis receiving NA therapy: is HCC prevented or delayed?
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29740.
    PubMed    


  1001. SPELIOTES EK
    Thwart your destiny; effect of NAFLD genes on steatosis, liver injury and cirrhosis varies by body mass index.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29739.
    PubMed    


  1002. BRISEBOIS A, Ismond KP, Carbonneau M, Tandon P, et al
    Advance Care Planning (ACP) for specialists managing cirrhosis: a focus on patient-centered care.
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29731.
    PubMed     Abstract available


  1003. ALI AH, Tabibian JH, Naser-Ghodsi N, Lennon RJ, et al
    Surveillance for Hepatobiliary Cancers in Patients with Primary Sclerosing Cholangitis.
    Hepatology. 2017 Dec 15. doi: 10.1002/hep.29730.
    PubMed     Abstract available


  1004. QVARTSKHAVA N DR, Jin CJ Dr, Gorg B Dr, Haussinger D Prof Dr, et al
    Comment on Haakvort et al. 2017, Hepatology 65:281-293.
    Hepatology. 2017 Dec 12. doi: 10.1002/hep.29727.
    PubMed    


  1005. GARCIA-TSAO G
    Regression of HCV cirrhosis: Time will tell.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29720.
    PubMed    


  1006. YOUNOSSI ZM, Loomba R, Anstee QM, Rinella ME, et al
    Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29721.
    PubMed     Abstract available


  1007. TAPPER EB, Loomba R
    NAFLD, Metabolic Syndrome, and the Fight That Will Define Clinical Practice for a Generation of Hepatologists.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29722.
    PubMed    


  1008. YOUNOSSI ZM, Loomba R, Rinella ME, Bugianesi E, et al
    Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH).
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29724.
    PubMed     Abstract available


  1009. LEVY C
    Evolving role of Obeticholic acid in primary biliary cholangitis.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29726.
    PubMed    


  1010. PINATO DJ
    Breaking Kuhn's paradigm in advanced hepatocellular carcinoma.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29714.
    PubMed    


  1011. ZHANG H, Li X, Yang Y, Zhang Y, et al
    Significance and Mechanism of Androgen Receptor (AR) Overexpression and AR-mTOR Crosstalk in Hepatocellular Carcinoma.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29715.
    PubMed     Abstract available


  1012. MURILLO PEREZ F, Goet JC, Lammers WJ, Gulamhusein A, et al
    Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29717.
    PubMed     Abstract available


  1013. MASYUK TV, Masyuk AI, LaRusso NF
    Polycystic Liver Disease: The interplay of genes causative for hepatic and renal cystogenesis.
    Hepatology. 2017 Dec 6. doi: 10.1002/hep.29708.
    PubMed    


  1014. VAN DE GRAAF S, Slijepcevic D
    Reply to D Levy - HEPATOLOGY.
    Hepatology. 2017 Dec 6. doi: 10.1002/hep.29709.
    PubMed    


  1015. LEVY D
    The role of mEH, NTCP and OATP in hepatic sodium-dependent bile acid transport.
    Hepatology. 2017 Dec 6. doi: 10.1002/hep.29712.
    PubMed    


  1016. KAKABADZE Z, Kakabadze A, Chakhunashvili D, Karalashvili L, et al
    Decellularized human placenta supports hepatic tissue and allows rescue in acute liver failure.
    Hepatology. 2017 Dec 6. doi: 10.1002/hep.29713.
    PubMed     Abstract available


  1017. LI DK, Ren Y, Fierer DS, Rutledge S, et al
    The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29707.
    PubMed     Abstract available



  1018. 2017 Hepatology referees (volumes 65 and 66).
    Hepatology. 2017;66:2096-2101.
    PubMed    


  1019. TOW C, Brown RS Jr, Tafesh ZH, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2017;66:1709-1712.
    PubMed    


  1020. BHANJI RA, Narayanan P, Allen AM, Malhi H, et al
    Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis.
    Hepatology. 2017;66:2055-2065.
    PubMed     Abstract available


  1021. PETTA S, Valenti L, Tuttolomondo A, Dongiovanni P, et al
    Interferon lambda 4 rs368234815 TT>deltaG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.
    Hepatology. 2017;66:1885-1893.
    PubMed     Abstract available


  1022. HU Y, Shin DJ, Pan H, Lin Z, et al
    YAP suppresses gluconeogenic gene expression through PGC1alpha.
    Hepatology. 2017;66:2029-2041.
    PubMed     Abstract available


  1023. LI XF, Chen C, Xiang DM, Qu L, et al
    Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.
    Hepatology. 2017;66:1934-1951.
    PubMed     Abstract available


  1024. AUGUSTIN S, Pons M, Maurice JB, Bureau C, et al
    Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease.
    Hepatology. 2017;66:1980-1988.
    PubMed     Abstract available


  1025. SORIA A, Lapadula G, Fabbiani M, Gori A, et al
    Lower effectiveness of hepatitis C antiviral treatment in patients with hepatocellular carcinoma: Is active tumor the clue?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29700.
    PubMed    


  1026. JI F, Yeo YH, Wei MT, Wei B, et al
    Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: does direct-acting antiviral regimens matter?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29701.
    PubMed    


  1027. LIU X, Green RM
    Beyond Farnesoid X receptor to target new therapies for NAFLD.
    Hepatology. 2017;66:1724-1726.
    PubMed    


  1028. WANG C, Bernards R
    In vivo veritas: Finding novel genes involved in liver cancer through in vivo genetic screens.
    Hepatology. 2017;66:2078-2080.
    PubMed    


    November 2017
  1029. SINGH AK, Rooge SB, Varshney A, Vasudevan M, et al
    Global micro RNA expression profiling in the liver biopsies of Hepatitis B Virus infected patients suggests specific miRNA signatures for viral persistence and hepatocellular injury.
    Hepatology. 2017 Nov 30. doi: 10.1002/hep.29690.
    PubMed     Abstract available


  1030. CHANG FM, Wang YP, Lu CL
    Reply: Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29686.
    PubMed    


  1031. LIN CY
    Statins and risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: Methodological issues.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29687.
    PubMed    


  1032. LO GH, Reiberger T
    Peptic ulcer bleeding in cirrhotic patients: Is as bad as variceal bleeding?
    Hepatology. 2017 Nov 23. doi: 10.1002/hep.29680.
    PubMed     Abstract available


  1033. ZHANG J, Zhang Q, Lou Y, Fu Q, et al
    HIF-1alpha/IL-1beta signaling enhances hepatoma epithelial-mesenchymal transition via macrophages in a hypoxic-inflammatory microenvironment.
    Hepatology. 2017 Nov 23. doi: 10.1002/hep.29681.
    PubMed     Abstract available


  1034. PENG JM, Bera R, Chiou CY, Yu MC, et al
    Actin cytoskeleton remodeling drives epithelial-mesenchymal transition for hepatoma invasion and metastasis.
    Hepatology. 2017 Nov 23. doi: 10.1002/hep.29678.
    PubMed     Abstract available


  1035. BORZIO M, Dionigi E, Rossini A, Marignani M, et al
    External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. (HEP-17-0903).
    Hepatology. 2017 Nov 22. doi: 10.1002/hep.29662.
    PubMed     Abstract available


  1036. GIANNINI EG, Bucci L, Garuti F, Brunacci M, et al
    Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29668.
    PubMed     Abstract available


  1037. CAST A, Valanejad L, Wright M, Nguyen P, et al
    C/EBPalpha-dependent pre-neoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29677.
    PubMed     Abstract available


  1038. HARTMANN P, Hochrath K, Horvath A, Chen P, et al
    Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29676.
    PubMed     Abstract available


  1039. ORNOLFSSON KT, Olafsson S, Bergmann OM, Gershwin ME, et al
    Using the Icelandic Genealogical Database to define the familial risk of primary biliary cholangitis.
    Hepatology. 2017 Nov 21. doi: 10.1002/hep.29675.
    PubMed     Abstract available


  1040. ZHANG XP, Wang K, Chen ZH, Cheng SQ, et al
    Hepatocellular carcinoma with hepatic vein invasion should not be considered as a contraindication for liver resection.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29665.
    PubMed    


  1041. HOOKS KB, Audoux J, Fazli H, Lesjean S, et al
    New insights into diagnosis and therapeutic options for proliferative hepatoblastoma.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29672.
    PubMed     Abstract available


  1042. PEI Y, Chen XP, Zhang W
    Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: more details, more significance.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29666.
    PubMed    


  1043. SIMON TG, King LY, Chong DQ, Nguyen L, et al
    Diabetes, Metabolic Comorbidities and Risk of Hepatocellular Carcinoma: Results from Two Prospective Cohort Studies.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29660.
    PubMed     Abstract available


  1044. PARK H, O'Brien TR, Rehermann B
    The role of genetics in hepatic fibrosis amongst HCV patients.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29659.
    PubMed    


  1045. LIANG Y, Feng Y, Zong M, Wei X, et al
    beta-Catenin Deficiency in Hepatocytes Aggravates Hepatocarcinogenesis Driven by Oncogenic beta-Catenin and MET.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29661.
    PubMed     Abstract available


  1046. CHAUHAN A, Adams DH
    Exercise alters the hepatic immunophenotype to protect against inflammatory liver disease.
    Hepatology. 2017 Nov 16. doi: 10.1002/hep.29657.
    PubMed    


  1047. KAFFE E, Fiorotto R, Pellegrino F, Mariotti V, et al
    beta-catenin and IL-1beta dependent CXCL10 production drives progression of disease in a mouse model of Congenital Hepatic Fibrosis.
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29652.
    PubMed     Abstract available


  1048. LIU C, Yang Z, Wu J, Zhang L, et al
    lncRNA H19 interacts with polypyrimidine tract-binding protein 1 to reprogram hepatic lipid homeostasis.
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29654.
    PubMed     Abstract available


  1049. AFONSO MB, Rodrigues CMP
    microRevolution in understanding primary biliary cholangitis pathophysiology.
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29653.
    PubMed    


  1050. JARAMILLO-CALLE DA, Castano Quintero O, Marin JI, Cock-Rada AM, et al
    Is liver transplantation for intractable attacks of porphyria a viable treatment in a developing country?
    Hepatology. 2017 Nov 15. doi: 10.1002/hep.29650.
    PubMed    


  1051. HERMANN A, Wennmann DO, Gromnitza S, Edeling M, et al
    WWC proteins regulate hepatic cell differentiation and tumorigenesis via the Hippo signaling pathway.
    Hepatology. 2017 Nov 8. doi: 10.1002/hep.29647.
    PubMed     Abstract available


  1052. GARCIA-LEZANA T, Raurell I, Bravo M, Torres-Arauz M, et al
    Restoration of A Healthy Intestinal Microbiota Normalizes Portal Hypertension In A Rat Model of Nonalcoholic Steatohepatitis.
    Hepatology. 2017 Nov 7. doi: 10.1002/hep.29646.
    PubMed     Abstract available


  1053. VARSHNEY A, Panda JJ, Singh AK, Yadav N, et al
    Targeted delivery of miR-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29643.
    PubMed     Abstract available


  1054. CAUSSY C, Alquiraish MH, Nguyen P, Hernandez C, et al
    Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29639.
    PubMed     Abstract available


  1055. FAGGIOLI F, Palagano E, Di Tommaso L, Donadon M, et al
    B lymphocytes limit senescence-driven fibrosis resolution and favor hepatocarcinogenesis in mouse liver injury.
    Hepatology. 2017 Nov 3. doi: 10.1002/hep.29636.
    PubMed     Abstract available


  1056. GUPTA V, Schwartz RE, Shen N, Brown RS Jr, et al
    Hepatology Highlights.
    Hepatology. 2017;66:1367-1369.
    PubMed    


  1057. XIAO G, Zhu S, Xiao X, Yan L, et al
    Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.
    Hepatology. 2017;66:1486-1501.
    PubMed     Abstract available


  1058. AMATHIEU R, Al-Khafaji A, Sileanu FE, Foldes E, et al
    Significance of oliguria in critically ill patients with chronic liver disease.
    Hepatology. 2017;66:1592-1600.
    PubMed     Abstract available


  1059. FAN Y, Arechederra M, Richelme S, Daian F, et al
    A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.
    Hepatology. 2017;66:1644-1661.
    PubMed     Abstract available


  1060. NAM EJ, Hayashida K, Aquino RS, Couchman JR, et al
    Syndecan-1 limits the progression of liver injury and promotes liver repair in acetaminophen-induced liver injury in mice.
    Hepatology. 2017;66:1601-1615.
    PubMed     Abstract available


  1061. SCHWIMMER JB, Behling C, Angeles JE, Paiz M, et al
    Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease.
    Hepatology. 2017;66:1474-1485.
    PubMed     Abstract available


  1062. LU Y, Jiang Z, Dai H, Miao R, et al
    Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29633.
    PubMed     Abstract available


  1063. RAEMAN R, Anania FA
    Therapy for steatohepatitis: Do macrophages hold the clue?
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29630.
    PubMed    


  1064. CAVIGLIA JM, Yan J, Jang MK, Gwak GY, et al
    MicroRNA-21 and Dicer are Dispensable for Hepatic Stellate Cell Activation and the Development of Liver Fibrosis.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29627.
    PubMed     Abstract available


  1065. TAPPER EB, Parikh N, Sengupta N, Mellinger J, et al
    A Risk Score to Predict the Development of Hepatic Encephalopathy in a Population-Based Cohort of Patients with Cirrhosis.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29628.
    PubMed     Abstract available


  1066. YANG S, Rao J
    Comment on "an endoplasmic reticulum protein, Nogo-B, facilitates alcoholic liver disease through regulation of Kupffer cell polarization".
    Hepatology. 2017;66:1701-1702.
    PubMed    


  1067. XANTHAKOS SA, Trout AT, Dillman JR
    Magnetic resonance elastography assessment of fibrosis in children with NAFLD: Promising but not perfect.
    Hepatology. 2017;66:1373-1376.
    PubMed    


  1068. SCHWEITZER GG, Klein S
    Exercise and NAFLD: Is it worth the effort?
    Hepatology. 2017;66:1691-1694.
    PubMed    


  1069. DOU C, Zheng X, Liu Q, Tu K, et al
    Is the regulatory effect of PCAF and sirtuin 7 on phosphoglycerate kinase 1 acetylation a universal mechanism underlying hepatocellular carcinoma progression?
    Hepatology. 2017;66:1699-1700.
    PubMed    


  1070. KORF H, van der Merwe S
    Adipose-derived exosomal MicroRNAs orchestrate gene regulation in the liver: Is this the missing link in nonalcoholic fatty liver disease?
    Hepatology. 2017;66:1689-1691.
    PubMed    


  1071. CARBONE M, Bonato G, Invernizzi P
    Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29625.
    PubMed    


  1072. ELLIS JL, Bove KE, Schuetz EG, Leino D, et al
    Zebrafish abcb11b mutant reveals novel strategies to restore bile excretion impaired by bile salt export pump deficiency.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29632.
    PubMed     Abstract available


    October 2017
  1073. AOKI S, Cobbold M, Zhu AX, Duda DG, et al
    Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?
    Hepatology. 2017 Oct 27. doi: 10.1002/hep.29617.
    PubMed    


  1074. WANG S, Yan ZZ, Yang X, An S, et al
    Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver.
    Hepatology. 2017 Oct 27. doi: 10.1002/hep.29616.
    PubMed     Abstract available


  1075. JANSEN PLM
    Hydrodynamics of bile flow Lessons from computational modelling.
    Hepatology. 2017 Oct 27. doi: 10.1002/hep.29618.
    PubMed    


  1076. LIASKOU E, Hirschfield GM
    Genetic association studies and the risk factors for developing the 'immuno-bile-logic' disease PBC.
    Hepatology. 2017 Oct 24. doi: 10.1002/hep.29603.
    PubMed    


  1077. PATEL N, Sheehan-Dare G, Weir J, Verma S, et al
    Cutaneous metastasis as the first presentation of hepatocellular carcinoma.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29615.
    PubMed    


  1078. SHEN Q, Eun JW, Lee K, Kim HS, et al
    BANF1, PLOD3, SF3B4 as Early-stage Cancer Decision Markers and Drivers of Hepatocellular Carcinoma.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29606.
    PubMed     Abstract available


  1079. PRAKTIKNJO M, Book M, Luetkens J, Pohlmann A, et al
    Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29602.
    PubMed     Abstract available


  1080. SHEN F, Li Y, Yang Wang, Sozzi V, et al
    Hepatitis B Virus Sensitivity to Interferon-alpha in Hepatocytes is More Associated with Cellular Interferon Response than with Viral Genotype.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29609.
    PubMed     Abstract available


  1081. KO E, Seo HW, Jung G
    Telomere length and ROS levels are positively associated with a high risk of mortality and recurrence in hepatocellular carcinoma.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29604.
    PubMed     Abstract available


  1082. JANSEN C, Moller P, Meyer C, Kolbe CC, et al
    Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29612.
    PubMed     Abstract available


  1083. PHILIPS CA, Kumar L, Augustine P
    Partial Splenic Artery Embolization for Severe Hepatic Myelopathy in Cirrhosis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29597.
    PubMed     Abstract available


  1084. SHERMAN M
    Regorafenib for treatment of hepatocellular carcinoma.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29598.
    PubMed    


  1085. MIDDLETON MS, Van Natta ML, Heba ER, Alazraki A, et al
    Diagnostic Accuracy of Magnetic Resonance Imaging Hepatic Proton Density Fat Fraction in Pediatric Nonalcoholic Fatty Liver Disease.
    Hepatology. 2017 Oct 13. doi: 10.1002/hep.29596.
    PubMed     Abstract available


  1086. VON LOEFFELHOLZ C, Birkenfeld AL
    Is mIndy a mediator of energy metabolism reprogramming in hepatocellular carcinoma induced by IL-6/STAT3 signaling?
    Hepatology. 2017 Oct 12. doi: 10.1002/hep.29591.
    PubMed    


  1087. LU L, Yue S, Jiang L, Li C, et al
    Myeloid Notch1 Deficiency Activates RhoA/ROCK Pathway and Aggravates Hepatocellular Damage In Mouse Ischemic Livers.
    Hepatology. 2017 Oct 12. doi: 10.1002/hep.29593.
    PubMed     Abstract available


  1088. TOSKICH B, Patel T
    Radioembolization for hepatocellular carcinoma - the time has come.
    Hepatology. 2017 Oct 12. doi: 10.1002/hep.29590.
    PubMed    


  1089. CHEN Y, Zeng Z, Lu Y
    Is mIndy a mediator of energy metabolism reprogramming in hepatocellular carcinoma induced by IL-6/STAT3 signaling?
    Hepatology. 2017 Oct 12. doi: 10.1002/hep.29592.
    PubMed    


  1090. YANG JD, Mannalithara A, Piscitello AJ, Kisiel JB, et al
    Impact of Surveillance for Hepatocellular Carcinoma on Survival in Patients with Compensated Cirrhosis.
    Hepatology. 2017 Oct 12. doi: 10.1002/hep.29594.
    PubMed     Abstract available


  1091. EHRLICH L, Glaser SS
    Novel beta-catenin/FXR Interaction Regulates Hepatic Bile Acid Metabolism During Cholestasis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29584.
    PubMed    


  1092. RAMMOHAN A, Reddy MS, Farouk M, Vargese J, et al
    Pembrolizumab for Metastatic Hepatocellular Carcinoma Following Live Donor Liver Transplantation: The Silver Bullet?
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29575.
    PubMed     Abstract available


  1093. SIDHU SS, Sharma BC, Goyal O, Kishore H, et al
    Reply: Terminating an episode of overt hepatic encephalopathy - L - ornithine L-aspartate may have some role.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29571.
    PubMed    


  1094. WANG F, Hongwei T, Li L, Piontek K, et al
    Exosome - miR-335 as a novel therapeutic strategy in hepatocellular carcinoma.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29586.
    PubMed     Abstract available


  1095. ZHAO J, Adams A, Roberts B, O'Neil M, et al
    PRMT1 and JMJD6 dependent arginine methylation regulate HNF4alpha expression and hepatocyte proliferation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29587.
    PubMed     Abstract available


  1096. RATHI S, Taneja S
    Terminating an episode of overt hepatic encephalopathy- Lornithine L-aspartate may have some role.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29570.
    PubMed    


  1097. MONTANO-LOZA AJ, Mazurak VC, Ebadi M, Meza-Junco J, et al
    Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29578.
    PubMed     Abstract available


  1098. MURPHY AG, Selaru F
    Extracellular vesicles as novel therapeutics in hepatic failure.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29576.
    PubMed    


  1099. MACDONALD S, Andreola F, Bachtiger P, Amoros A, et al
    Cell death markers in cirrhotic patients with acute decompensation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29581.
    PubMed     Abstract available


  1100. MASYUK AI, Masyuk TV, Lorenzo Pisarello MJ, Ding JF, et al
    Cholangiocyte Autophagy Contributes to Hepatic Cystogenesis in Polycystic Liver Disease and Represents a Potential Therapeutic Target.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29577.
    PubMed     Abstract available


  1101. PRADHAN-SUNDD T, Zhou L, Vats R, Jiang A, et al
    Dual catenin loss in murine liver causes tight junctional deregulation and progressive intrahepatic cholestasis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29585.
    PubMed     Abstract available


  1102. BARBIER L, Ronot M, Aussilhou B, Cauchy F, et al
    Polycystic liver disease: Hepatic venous outflow obstruction lesions of the non-cystic parenchyma have major consequences.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29582.
    PubMed     Abstract available


  1103. RAEVENS S, Geerts A, Paridaens A, Lefere S, et al
    Placental growth factor inhibition targets pulmonary angiogenesis and represents a novel therapy for hepatopulmonary syndrome in mice.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29579.
    PubMed     Abstract available


  1104. KOWDLEY KV, Luketic V, Chapman R, Hirschfield GM, et al
    A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29569.
    PubMed     Abstract available


  1105. RUSSO N, Brown RS Jr, Schwartz RE, Rosenblatt R, et al
    Hepatology Highlights.
    Hepatology. 2017;66:1013-1015.
    PubMed    


  1106. ALBILLOS A, Zamora J, Martinez J, Arroyo D, et al
    Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.
    Hepatology. 2017;66:1219-1231.
    PubMed     Abstract available


  1107. SO-ARMAH KA, Lim JK, Lo Re V, Tate JP, et al
    FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.
    Hepatology. 2017;66:1286-1295.
    PubMed     Abstract available


  1108. KOLACHALA VL, Palle S, Shen M, Feng A, et al
    Loss of L-selectin-guided CD8+ , but not CD4+ , cells protects against ischemia reperfusion injury in a steatotic liver.
    Hepatology. 2017;66:1258-1274.
    PubMed     Abstract available


  1109. BASURAY S, Smagris E, Cohen JC, Hobbs HH, et al
    The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation.
    Hepatology. 2017;66:1111-1124.
    PubMed     Abstract available


  1110. BANGEN JM, Hammerich L, Sonntag R, Baues M, et al
    Targeting CCl4 -induced liver fibrosis by RNA interference-mediated inhibition of cyclin E1 in mice.
    Hepatology. 2017;66:1242-1257.
    PubMed     Abstract available


  1111. LIU Z, Que S, Mardinoglu A
    Rediscussion on linearity between fibrosis stages and mortality risk in nonalcoholic fatty liver disease patients.
    Hepatology. 2017;66:1357-1358.
    PubMed    


  1112. SAFIRI S, Khazaei S, Mansori K, Ayubi E, et al
    Comments on "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis".
    Hepatology. 2017;66:1358-1359.
    PubMed    


  1113. VALENTI L, Dongiovanni P
    Mutant PNPLA3 I148M protein as pharmacological target for liver disease.
    Hepatology. 2017;66:1026-1028.
    PubMed    


    September 2017
  1114. KAKAR S, Ferrell LD
    Glutamine synthetase staining and CTTNB1 mutation in hepatocellular adenomas.
    Hepatology. 2017 Sep 29. doi: 10.1002/hep.29567.
    PubMed    


  1115. RIORDAN JD, Feddersen CR, Tschida BR, Jackson P, et al
    Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma.
    Hepatology. 2017 Sep 29. doi: 10.1002/hep.29565.
    PubMed     Abstract available


  1116. REBOUISSOU S, Bioulac-Sage P, Nault JC, Calderaro J, et al
    Reply to << Glutamine synthetase staining and CTNNB1 mutation in hepatocellular adenomas >>.
    Hepatology. 2017 Sep 29. doi: 10.1002/hep.29563.
    PubMed    


  1117. OU-YANG Q, Lin XM, Zhu YJ, Zheng B, et al
    Distinct Role of Nuclear Receptor Corepressor 1 Regulated de novo Fatty Acids Synthesis in Liver Regeneration and Hepatocarcinogenesis.
    Hepatology. 2017 Sep 28. doi: 10.1002/hep.29562.
    PubMed     Abstract available


  1118. TIMCHENKO NA
    Mitochondrial and anabolic pathways in hepatocellular carcinoma.
    Hepatology. 2017 Sep 28. doi: 10.1002/hep.29559.
    PubMed    


  1119. LUO P, Yin P, Hua R, Tan Y, et al
    A large-scale, multi-center serum metabolite biomarkers identification study for the early detection of hepatocellular carcinoma.
    Hepatology. 2017 Sep 28. doi: 10.1002/hep.29561.
    PubMed     Abstract available


  1120. CHTIOUI H
    OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29556.
    PubMed    


  1121. SORIA A, Lapadula G, Fabbiani M, Gori A, et al
    Treatment failure with DAA in hepatocellular carcinoma: More than one explanation?
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29553.
    PubMed    


  1122. KRENKEL O, Puengel T, Govaere O, Abdallah AT, et al
    Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis.
    Hepatology. 2017 Sep 21. doi: 10.1002/hep.29544.
    PubMed     Abstract available


  1123. WYLES D, Poordad F, Wang S, Alric L, et al
    Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.
    PubMed     Abstract available


  1124. LIU R, Li X, Huang Z, Zhao D, et al
    CHOP-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29540.
    PubMed     Abstract available


  1125. JAHN D, Geier A
    Bile acids in NASH: pathophysiological driving force or innocent bystanders?
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29543.
    PubMed    


  1126. ERICE O, Munoz-Garrido P, Vaquero J, Perugorria MJ, et al
    MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.
    Hepatology. 2017 Sep 18. doi: 10.1002/hep.29533.
    PubMed     Abstract available


  1127. LEE MH, Huang YH, Chen HY, Khor CS, et al
    Human Leukocyte Antigen Variants and Risk of Hepatocellular Carcinoma Modified by HCV Genotypes: A Genome-wide Association Study.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29531.
    PubMed     Abstract available


  1128. LO RE O, Fusilli C, Rappa F, Van Haele M, et al
    Induction of cancer cell stemness by depletion of macrohistone H2A1 in hepatocellular carcinoma.
    Hepatology. 2017 Sep 15. doi: 10.1002/hep.29519.
    PubMed     Abstract available


  1129. CESARI M, Frigo AC, Tonon M, Angeli P, et al
    Cardiovascular predictors of death in patients with cirrhosis.
    Hepatology. 2017 Sep 13. doi: 10.1002/hep.29520.
    PubMed     Abstract available


  1130. WINTERS AC, Tremblay D, Arinsburg S, Mascarenhas J, et al
    Reassessing the Safety Concerns of Utilizing Blood Donations from Patients with Hemochromatosis.
    Hepatology. 2017 Sep 13. doi: 10.1002/hep.29521.
    PubMed     Abstract available


  1131. PISCAGLIA F, Tovoli F, Pini P, Salvatore V, et al
    A new horizon in the prevention of the postembolization syndrome after Transcatheter Arterial Chemioembolization for hepatocellular carcinoma.
    Hepatology. 2017 Sep 13. doi: 10.1002/hep.29517.
    PubMed    


  1132. RIMOLA J, Diaz-Gonzalez A, Darnell A, Varela M, et al
    Complete response under sorafenib in patients with hepatocellular carcinoma. Relationship with dermatologic adverse events.
    Hepatology. 2017 Sep 12. doi: 10.1002/hep.29515.
    PubMed     Abstract available


  1133. WANG B, Fu J, Yu T, Xu A, et al
    Contradictory Effects of Mitochondria- and Non-mitochondria-targeted Antioxidants on Hepatocarcinogenesis by Altering DNA Repair.
    Hepatology. 2017 Sep 12. doi: 10.1002/hep.29518.
    PubMed     Abstract available


  1134. LOOMBA R, Lawitz E, Mantry PS, Jayakumar S, et al
    The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial.
    Hepatology. 2017 Sep 11. doi: 10.1002/hep.29514.
    PubMed     Abstract available


  1135. LIU CH, Chern GG, Hsu FF, Huang KW, et al
    A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia.
    Hepatology. 2017 Sep 8. doi: 10.1002/hep.29513.
    PubMed     Abstract available


  1136. FINN RS, Zhu AX, Wigdan F, Almasri J, et al
    Therapies for Advanced Stage Hepatocellular Carcinoma with Macrovascular invasion or Metastatic Disease: a Systematic Review and Meta-analysis.
    Hepatology. 2017 Sep 7. doi: 10.1002/hep.29486.
    PubMed     Abstract available


  1137. MARSHALL K, Jin J, Atkinson C, Alawieh A, et al
    Natural IgM initiates an inflammatory response important for both hepatic ischemia reperfusion injury and regeneration.
    Hepatology. 2017 Sep 7. doi: 10.1002/hep.29512.
    PubMed     Abstract available


  1138. BORENTAIN P, Colson P, Bolon E, Gauchez P, et al
    Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29508.
    PubMed    



  1139. ERRATUM for Beta-blockers in 2016: Still the safest and most useful drugs for portal hypertension?
    Hepatology. 2017 Sep 4. doi: 10.1002/hep.29171.
    PubMed    


  1140. SCHWARTZ RE, Batisti J, Brown RS Jr, Tafesh Z, et al
    Hepatology Highlights.
    Hepatology. 2017;66:683-685.
    PubMed    


  1141. BOUATTOUR M, Raymond E, Qin S, Cheng AL, et al
    Recent Developments of c-Met as a Therapeutic Target in Hepatocellular Carcinoma.
    Hepatology. 2017 Sep 1. doi: 10.1002/hep.29496.
    PubMed     Abstract available


  1142. TAKYAR V, Nath A, Beri A, Gharib AM, et al
    How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool.
    Hepatology. 2017;66:825-833.
    PubMed     Abstract available


  1143. KACHAYLO E, Tschuor C, Calo N, Borgeaud N, et al
    PTEN Down-Regulation Promotes beta-Oxidation to Fuel Hypertrophic Liver Growth After Hepatectomy in Mice.
    Hepatology. 2017;66:908-921.
    PubMed     Abstract available


  1144. PEREA L, Coll M, Sanjurjo L, Blaya D, et al
    Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury.
    Hepatology. 2017;66:953-968.
    PubMed     Abstract available


  1145. SANGRO B, Martinez-Urbistondo D, Bester L, Bilbao JI, et al
    Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review.
    Hepatology. 2017;66:969-982.
    PubMed     Abstract available


  1146. PANDEY S
    Healthy controls in nonalcoholic fatty liver disease management: A biomedical research perspective.
    Hepatology. 2017;66:1006-1007.
    PubMed    


  1147. LO GH
    Do we need vasoconstrictors up to 5 days after successful hemostasis by ligation of bleeding varices?
    Hepatology. 2017;66:1009.
    PubMed    


  1148. DELLAVANCE A, Ferraz MLG, Cancado ELR, Andrade LEC, et al
    Expansion and intensification of humoral autoimmune response in the transition from preclinical to full-blown primary biliary cholangitis.
    Hepatology. 2017;66:997.
    PubMed    


    August 2017
  1149. ROBERTS LR, Sirlin CB, Zaiem F, Almasri J, et al
    Imaging for the Diagnosis of Hepatocellular Carcinoma: a Systematic Review and Meta-analysis.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29487.
    PubMed     Abstract available


  1150. KULIK L, Heimbach JK, Zaiem F, Almasri J, et al
    Therapies for Patients with Hepatocellular Carcinoma Awaiting for Liver Transplantation: a Systematic Review and Meta-analysis.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29485.
    PubMed     Abstract available


  1151. PICCININ E, Peres C, Bellafante E, Ducheix S, et al
    Hepatic PPARgamma coactivator 1beta drives mitochondrial and anabolic signatures that contribute to hepatocellular carcinoma progression.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29484.
    PubMed     Abstract available


  1152. VYAS D, Baptista PM, Brovold M, Moran E, et al
    Self-assembled liver organoids recapitulate hepato-biliary organogenesis in vitro.
    Hepatology. 2017 Aug 23. doi: 10.1002/hep.29483.
    PubMed     Abstract available


  1153. YANG JD, Malhi H
    Green Tea Consumption - A Potential Chemopreventive Measure for Hepatocellular Carcinoma?
    Hepatology. 2017 Aug 21. doi: 10.1002/hep.29481.
    PubMed    


  1154. KABIR TD, Ganda C, Brown RM, Beveridge DJ, et al
    A miR-7/GAS6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
    Hepatology. 2017 Aug 18. doi: 10.1002/hep.29478.
    PubMed     Abstract available


  1155. RIAZ A, Gabr A, Abouchaleh N, Ali R, et al
    Radioembolization for Hepatocellular Carcinoma: Statistical Confirmation of Improved Survival in Responders by Landmark Analyses.
    Hepatology. 2017 Aug 18. doi: 10.1002/hep.29480.
    PubMed     Abstract available


  1156. WARD ES, Ober RJ
    Hepatic function of FcRn revealed: Implications for overcoming drug-mediated hepatotoxicity.
    Hepatology. 2017 Aug 17. doi: 10.1002/hep.29476.
    PubMed    


  1157. FRIEDMAN SL, Ratziu V, Harrison SA, Abdelmalek MF, et al
    A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis.
    Hepatology. 2017 Aug 17. doi: 10.1002/hep.29477.
    PubMed     Abstract available


  1158. PARIKH ND, Marrero WJ, Wang J, Steuer J, et al
    Projected increase in obesity and non-alcoholic steatohepatitis-related liver transplantation waitlist additions in the United States.
    Hepatology. 2017 Aug 17. doi: 10.1002/hep.29473.
    PubMed     Abstract available


  1159. DEMAREZ C, Gerard C, Cordi S, Poncy A, et al
    MiR-337-3p controls hepatobiliary gene expression and transcriptional dynamics during hepatic cell differentiation.
    Hepatology. 2017 Aug 17. doi: 10.1002/hep.29475.
    PubMed     Abstract available


  1160. DE HAAS RJ, Lim C, Bhangui P, Salloum C, et al
    Curative Salvage Liver Transplantation in Cirrhotic patients with Hepatocellular Carcinoma: An intention-to-treat analysis.
    Hepatology. 2017 Aug 14. doi: 10.1002/hep.29468.
    PubMed     Abstract available


  1161. HALGAND B, Desterke C, Riviere L, Fallot G, et al
    Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: A nosological and prognostic determinant.
    Hepatology. 2017 Aug 12. doi: 10.1002/hep.29463.
    PubMed     Abstract available


  1162. LIN YH, Wu MH, Huang YH, Yeh CT, et al
    Taurine upregulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma.
    Hepatology. 2017 Aug 12. doi: 10.1002/hep.29462.
    PubMed     Abstract available


  1163. MATSUDA M, Tsurusaki S, Miyata N, Saijou E, et al
    Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice.
    Hepatology. 2017 Aug 5. doi: 10.1002/hep.29421.
    PubMed     Abstract available


  1164. KRISS M, Burchill M
    HCV and non-hepatic malignancy: Is pre-emptive DAA therapy indicated prior to treatment?
    Hepatology. 2017 Aug 2. doi: 10.1002/hep.29414.
    PubMed    


  1165. SCHNEIDER Y, Brown RS, Saumoy M, Schwartz RE, et al
    Hepatology Highlights - August 2017.
    Hepatology. 2017;66:309-311.
    PubMed    


  1166. STIEDE K, Miao W, Blanchette HS, Beysen C, et al
    Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study.
    Hepatology. 2017;66:324-334.
    PubMed     Abstract available


  1167. KOH C, Sakiani S, Surana P, Zhao X, et al
    Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity.
    Hepatology. 2017;66:591-601.
    PubMed     Abstract available


  1168. LAI JC, Covinsky KE, Dodge JL, Boscardin WJ, et al
    Development of a novel frailty index to predict mortality in patients with end-stage liver disease.
    Hepatology. 2017;66:564-574.
    PubMed     Abstract available


  1169. LIU S, Sun Y, Jiang M, Li Y, et al
    Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase.
    Hepatology. 2017;66:631-645.
    PubMed     Abstract available


  1170. HUNT CM, Papay JI, Stanulovic V, Regev A, et al
    Drug rechallenge following drug-induced liver injury.
    Hepatology. 2017;66:646-654.
    PubMed     Abstract available


  1171. SAIKIA P, Bellos D, McMullen MR, Pollard KA, et al
    MicroRNA 181b-3p and its target importin alpha5 regulate toll-like receptor 4 signaling in Kupffer cells and liver injury in mice in response to ethanol.
    Hepatology. 2017;66:602-615.
    PubMed     Abstract available


  1172. SANOFF HK, Chang Y, Lund JL, O'Neil BH, et al
    Immortal time bias or sorafenib effect in elderly patients with HCC?
    Hepatology. 2017;66:678-679.
    PubMed    


  1173. PONZETTO A, Perez-Perez GI, Figura N
    Alpha1-antitrypsin deficiency and c-JUN.
    Hepatology. 2017;66:677.
    PubMed    


  1174. HE Y, Gao B
    A small specific-sized hyaluronic acid ameliorates alcoholic liver disease by targeting a small RNA: New hope for therapy?
    Hepatology. 2017;66:321-323.
    PubMed    


  1175. FAN H, Zhu JH
    FABP1 as a novel potential biomarker for predicting mortality in acetaminophen-induced acute liver failure.
    Hepatology. 2017;66:670.
    PubMed    


  1176. GEIER A, Jahn D, Hermanns HM
    Interleukin-6: The dark side of liver regeneration in chronic liver disease.
    Hepatology. 2017;66:667-668.
    PubMed    


  1177. ICHIKAWA S, Motosugi U, Oguri M, Onishi H, et al
    Magnetic resonance elastography for prediction of radiation-induced liver disease after stereotactic body radiation therapy.
    Hepatology. 2017;66:664-665.
    PubMed    


  1178. AZOULAY D, Lahat E, Salloum C, Compagnon P, et al
    Heterotopic liver retransplantation for impossible former graft explantation.
    Hepatology. 2017;66:655-657.
    PubMed    


    July 2017
  1179. GU J, Jeong S, Xia Q
    Intrahepatic cholangiocarcinoma arising from HBV Infection may be a highly selected population for liver transplantation.
    Hepatology. 2017 Jul 31. doi: 10.1002/hep.29413.
    PubMed    


  1180. SIDHU SS, Sharma BC, Goyal O, Kishore H, et al
    L-ornithine L-aspartate in bouts of overt hepatic encephalopathy.
    Hepatology. 2017 Jul 27. doi: 10.1002/hep.29410.
    PubMed     Abstract available


  1181. COBB DA, Golden-Mason L, Rosen HR, Hahn YS, et al
    Hepatocyte-derived exosomes promote T follicular regulatory cell expansion during HCV infection.
    Hepatology. 2017 Jul 27. doi: 10.1002/hep.29409.
    PubMed     Abstract available


  1182. TANDON P, Madsen K, Kao D
    Fecal microbiota transplantation for hepatic encephalopathy - ready for prime time?
    Hepatology. 2017 Jul 22. doi: 10.1002/hep.29396.
    PubMed    


  1183. SAUERBRUCH T
    Continuation of non-selective beta-blockers for patients with liver cirrhosis and hemodynamic non-response?
    Hepatology. 2017 Jul 22. doi: 10.1002/hep.29394.
    PubMed    


  1184. ZHU L, Baker RD, Zhu R, Baker SS, et al
    Sequencing the gut metagenome as a non-invasive diagnosis for advanced nonalcoholic steatohepatitis.
    Hepatology. 2017 Jul 21. doi: 10.1002/hep.29387.
    PubMed    


  1185. LI H, Li X, Liu S, Guo L, et al
    PD-1 Checkpoint Blockade in Combination with an mTOR Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1.
    Hepatology. 2017 Jul 21. doi: 10.1002/hep.29360.
    PubMed     Abstract available


  1186. PEDERSEN JS, Kimer N, Henriksen JH, Bendtsen F, et al
    The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort.
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29386.
    PubMed    


  1187. HIJMANS BS, Boss A, van Dijk TH, Soty M, et al
    Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia.
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29389.
    PubMed     Abstract available


  1188. KALAFATELI M, Tsochatzis EA
    Reply to "The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort."
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29391.
    PubMed    


  1189. FU Y, Silverstein S, McCutcheon JN, Dyba M, et al
    An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice.
    Hepatology. 2017 Jul 18. doi: 10.1002/hep.29380.
    PubMed     Abstract available


  1190. AN S, Zhao LP, Shen LJ, Wang S, et al
    USP18 protects against hepatic steatosis and insulin resistance via its DUB activity.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29375.
    PubMed     Abstract available


  1191. MULLISH BH, McDonald JAK, Thursz MR, Marchesi JR, et al
    Correspondence: Fecal Microbiota Transplant from a Rational Stool Donor Improves Hepatic Encephalopathy: A Randomized Clinical Trial.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29369.
    PubMed    


  1192. ARDEVOL A, Ibanez-Sanz G, Profitos J, Aracil C, et al
    Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29370.
    PubMed     Abstract available


  1193. WU H, Tao J, Li X, Zhang T, et al
    MicroRNA-206 Prevents the Pathogenesis of Hepatocellular Carcinoma Via Modulating Expression of cMet and Cdk6.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29374.
    PubMed     Abstract available


  1194. PURI P, Daita K, Joyce A, Mirshahi F, et al
    The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Hepatology. 2017 Jul 11. doi: 10.1002/hep.29359.
    PubMed     Abstract available


  1195. SARWAR A, Zhou L, Novack V, Tapper EB, et al
    Hospital volume and mortality after trans-jugular intrahepatic portosystemic shunt creation in the United States.
    Hepatology. 2017 Jul 6. doi: 10.1002/hep.29354.
    PubMed     Abstract available


  1196. YANG L, Wang WH, Qiu WL, Guo Z, et al
    A single-cell transcriptomic analysis reveals precise pathways and regulatory mechanisms underlying hepatoblast differentiation.
    Hepatology. 2017 Jul 6. doi: 10.1002/hep.29353.
    PubMed     Abstract available



  1197. Hepatology Highlights.
    Hepatology. 2017;66:1-3.
    PubMed    


  1198. CASSANO M, Offner S, Planet E, Piersigilli A, et al
    Polyphenic trait promotes liver cancer in a model of epigenetic instability in mice.
    Hepatology. 2017;66:235-251.
    PubMed     Abstract available


  1199. PICCOLO P, Annunziata P, Soria LR, Attanasio S, et al
    Down-regulation of hepatocyte nuclear factor-4alpha and defective zonation in livers expressing mutant Z alpha1-antitrypsin.
    Hepatology. 2017;66:124-135.
    PubMed     Abstract available


  1200. UNALP-ARIDA A, Ruhl CE
    Liver fibrosis scores predict liver disease mortality in the United States population.
    Hepatology. 2017;66:84-95.
    PubMed     Abstract available


  1201. MUELLER S, Nahon P, Rausch V, Peccerella T, et al
    Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.
    Hepatology. 2017;66:96-107.
    PubMed     Abstract available


  1202. YI S, Sahni N
    Regulome networks and mutational landscape in liver cancer: An informative path to precision medicine.
    Hepatology. 2017;66:280-282.
    PubMed    


  1203. YIP TC, Wong VW
    How to identify patients with advanced liver disease in the community?
    Hepatology. 2017;66:7-9.
    PubMed    


  1204. CARDOSO FS, Pereira R, Alexandrino G, Bagulho L, et al
    Futility of care in patients with acute-on-chronic liver failure.
    Hepatology. 2017;66:292-294.
    PubMed    


    June 2017
  1205. CHENG X, Xia Y, Serti E, Block PD, et al
    Hepatitis B virus evades innate immunity of hepatocytes but activates macrophages during infection.
    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.
    PubMed     Abstract available


  1206. LIU J, Hu X, Chen J, Li X, et al
    Pericentral hepatocytes produce IGF-2 to promote liver regeneration during special injuries.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29340.
    PubMed     Abstract available


  1207. LAI Q, Vitale A, Iesari S, Finkenstedt A, et al
    Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29342.
    PubMed     Abstract available


  1208. HENRIET E, Hammoud AA, Dupuy JW, Dartigues B, et al
    Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29336.
    PubMed     Abstract available


  1209. TSAI CL, Liu WL, Hsu FM, Yang PS, et al
    Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29328.
    PubMed     Abstract available


  1210. LIU Y, Zhang Y, Wang S, Dong QZ, et al
    Prospero-related homeobox 1 drives angiogenesis of hepatocellular carcinoma through selectively activating IL-8 expression.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29337.
    PubMed     Abstract available


  1211. DAWSON PA
    Hepatic bile acid uptake in humans and mice: Multiple pathways and expanding potential role for gut-liver signaling.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29325.
    PubMed    


  1212. ZHANG C, Huang J, An W
    Hepatic stimulator substance resists hepatic ischemia-reperfusion injury by regulating Drp1 translocation and activation.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29326.
    PubMed     Abstract available


  1213. YIP LY, Aw CC, Lee SH, Hong YS, et al
    The Liver-Gut Microbiota Axis Modulates Hepatotoxicity of Tacrine in the Rat.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29327.
    PubMed     Abstract available


  1214. KIM DS, Ryu JW, Son MY, Oh JH, et al
    A Liver-specific Gene Expression Panel Predicts the Differentiation Status of in vitro Hepatocyte Models.
    Hepatology. 2017 Jun 22. doi: 10.1002/hep.29324.
    PubMed     Abstract available


  1215. PAPATHEODORIDIS GV, Idilman R, Dalekos GN, Buti M, et al
    The risk of hepatocellular carcinoma is decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29320.
    PubMed     Abstract available


  1216. CHIDA T, Ito M, Nakashima K, Kanegae Y, et al
    Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.
    PubMed     Abstract available


  1217. LEE M, Chung GE, Lee JH, Oh S, et al
    Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.
    Hepatology. 2017 Jun 15. doi: 10.1002/hep.29318.
    PubMed     Abstract available


  1218. GAO Y, Feng J, Yang G, Zhang S, et al
    HBx-elevated MSL2 Modulates HBV cccDNA through Inducing Degradation of APOBEC3B to Enhance Hepatocarcinogenesis.
    Hepatology. 2017 Jun 13. doi: 10.1002/hep.29316.
    PubMed     Abstract available


  1219. TAYLOR EJ, Jones RL, Guthrie JA, Rowe IA, et al
    Modelling the benefits and harms of surveillance for hepatocellular carcinoma: information to support informed choices.
    Hepatology. 2017 Jun 12. doi: 10.1002/hep.29315.
    PubMed     Abstract available


  1220. JIANG L, Yan Q, Fang S, Liu M, et al
    Calcium binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating ERK signaling pathway.
    Hepatology. 2017 Jun 12. doi: 10.1002/hep.29312.
    PubMed     Abstract available


  1221. BALWANI M, Wang B, Anderson KE, Bloomer JR, et al
    Acute Hepatic Porphyrias: Recommendations for Evaluation and Long Term Management.
    Hepatology. 2017 Jun 12. doi: 10.1002/hep.29313.
    PubMed     Abstract available


  1222. ZHENG C, Zeng H, Lin H, Wang J, et al
    Serum microcystins level positively linked with risk of hepatocellular carcinoma: a case-control study in Southwest China.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29310.
    PubMed     Abstract available


  1223. NG CKY, Piscuoglio S, Terracciano LM
    Molecular classification of hepatocellular carcinoma: The view from metabolic zonation.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29311.
    PubMed    


  1224. AKINROTIMI O, Riessen R, VanDuyne P, Park JE, et al
    Shp deletion prevents hepatic steatosis and when combined with Fxr loss protects against type 2 diabetes.
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29305.
    PubMed     Abstract available


  1225. BAJAJ JS, Kassam Z, Fagan A, Gavis EA, et al
    Fecal Microbiota Transplant from a Rational Stool Donor Improves Hepatic Encephalopathy: A Randomized Clinical Trial.
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29306.
    PubMed     Abstract available


  1226. KWONG AJ, Goel A, Mannalithara A, Kim WR, et al
    Improved Post-Transplant Mortality After Share 35 for Liver Transplantation.
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29301.
    PubMed     Abstract available


  1227. DUFOUR JF
    Hepatology Highlights.
    Hepatology. 2017;65:1783-1784.
    PubMed    


  1228. DOYCHEVA I, Watt KD, Alkhouri N
    Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic.
    Hepatology. 2017;65:2100-2109.
    PubMed     Abstract available


  1229. AJMERA VH, Terrault NA, Harrison SA
    Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review.
    Hepatology. 2017;65:2090-2099.
    PubMed     Abstract available


  1230. GIANNINI EG, Savarino V
    Noninvasive assessment of varices needing treatment in patients with advanced chronic liver disease: No one should be left behind.
    Hepatology. 2017;65:2131.
    PubMed    


  1231. KARLAS T, Beer S, Babel J, Busse H, et al
    Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease patients?
    Hepatology. 2017;65:2126-2128.
    PubMed    


  1232. GUNDLING F, Tiller M, Schepp W
    Comment on "esophageal balloon tamponade vs. esophageal stent in controlling acute refractory variceal bleeding: A multicenter RCT".
    Hepatology. 2017;65:2120-2121.
    PubMed    


  1233. ARIAS IM
    Coming of age and building of bridges ... reflections on the past, present, and, hesitatingly, future.
    Hepatology. 2017;65:1785-1788.
    PubMed    


    May 2017
  1234. MARKWARDT D, Holdt L, Steib C, Benesic A, et al
    Plasma Cystatin C is a predictor of renal dysfunction, ACLF and mortality in patients with acutely decompensated liver cirrhosis.
    Hepatology. 2017 May 25. doi: 10.1002/hep.29290.
    PubMed     Abstract available


  1235. WANG Z, Han J, Zhang H, Wu MC, et al
    Emphasis on Harms of Hepatocellular Carcinoma Surveillance: Just Pretending Innocent After Taking Advantages?
    Hepatology. 2017 May 24. doi: 10.1002/hep.29288.
    PubMed    


  1236. CHIANG JYL
    Linking long non-coding RNA to control bile acid signaling and cholestatic liver fibrosis.
    Hepatology. 2017 May 24. doi: 10.1002/hep.29289.
    PubMed    


  1237. MASYUK TV, Masyuk AI, Lorenzo Pisarello M, Howard BN, et al
    TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases via cAMP/Galphas signaling.
    Hepatology. 2017 May 23. doi: 10.1002/hep.29284.
    PubMed     Abstract available


  1238. HAYASHI PH, Rockey D, Fontana RJ, Tillmann HL, et al
    Death and Liver Transplantation within Two Years of Onset of Drug-Induced Liver Injury.
    Hepatology. 2017 May 23. doi: 10.1002/hep.29283.
    PubMed     Abstract available


  1239. TSOCHATZIS EA, Bosch J
    Statins in cirrhosis - ready for prime time.
    Hepatology. 2017 May 22. doi: 10.1002/hep.29277.
    PubMed    


  1240. POSSO-OSORIO I, Mendez-Rayo T, Andres Jimenez C, Escobar D, et al
    Hepatic infiltration by silicone in a patient with asia syndrome.
    Hepatology. 2017 May 18. doi: 10.1002/hep.29274.
    PubMed    


  1241. CHO CS, Lombard DB, Lee JH
    SIRT3 as a Regulator of Hepatic Autophagy.
    Hepatology. 2017 May 18. doi: 10.1002/hep.29271.
    PubMed    


  1242. HAN D, Li J, Wang H, Su X, et al
    Circular RNA MTO1 acts as the sponge of miR-9 to suppress hepatocellular carcinoma progression.
    Hepatology. 2017 May 18. doi: 10.1002/hep.29270.
    PubMed     Abstract available


  1243. SAMOYLOVA ML, Nigrini MJ, Dodge JL, Roberts JP, et al
    Biases in the reporting of hcc tumor sizes on the liver transplant waiting list.
    Hepatology. 2017 May 18. doi: 10.1002/hep.29269.
    PubMed     Abstract available


  1244. BUENDIA MA, Armengol C, Cairo S
    Molecular classification of hepatoblastoma and prognostic value of the HB 16-gene signature.
    Hepatology. 2017 May 16. doi: 10.1002/hep.29262.
    PubMed    


  1245. SAFIRI S, Ayubi E
    Dual photon microscopy based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis: Methodological issues.
    Hepatology. 2017 May 16. doi: 10.1002/hep.29261.
    PubMed    


  1246. ZHANG QY, Zhao LP, Tian XX, Yan CH, et al
    The novel intracellular protein CREG inhibits hepatic steatosis, obesity and insulin resistance.
    Hepatology. 2017 May 15. doi: 10.1002/hep.29257.
    PubMed     Abstract available


  1247. SLIJEPCEVIC D, Roscam Abbing RLP, Katafuchi T, Blank A, et al
    Hepatic uptake of conjugated bile acids is mediated by both NTCP and OATPs and modulated by intestinal sensing of plasma bile acid levels in mice.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29251.
    PubMed     Abstract available


  1248. DESERT R, Rohart F, Canal F, Sicard M, et al
    Human Hepatocellular Carcinomas with a Periportal Phenotype Have the Lowest Potential for Early Recurrence after Curative Resection.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29254.
    PubMed     Abstract available


  1249. ZHAO E, Ilyas G, Cingolani F, Choi JH, et al
    Pentamidine Blocks Hepatotoxic Injury in Mice.
    Hepatology. 2017 May 3. doi: 10.1002/hep.29244.
    PubMed     Abstract available


  1250. O'HARA SP, LaRusso NF
    Cellular Senescence, Neuropeptides and Hepatic Fibrosis: Additional Insights into Increasing Complexity.
    Hepatology. 2017 May 2. doi: 10.1002/hep.29243.
    PubMed    


  1251. DUFOUR JF
    Hepatology Highlights.
    Hepatology. 2017;65:1429-1431.
    PubMed    


  1252. DULAI PS, Singh S, Patel J, Soni M, et al
    Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
    Hepatology. 2017;65:1557-1565.
    PubMed     Abstract available


  1253. PARK JK, Shao M, Kim MY, Baik SK, et al
    An endoplasmic reticulum protein, Nogo-B, facilitates alcoholic liver disease through regulation of kupffer cell polarization.
    Hepatology. 2017;65:1720-1734.
    PubMed     Abstract available


  1254. XIANG D, Cheng Z, Liu H, Wang X, et al
    Shp2 promotes liver cancer stem cell expansion by augmenting beta-catenin signaling and predicts chemotherapeutic response of patients.
    Hepatology. 2017;65:1566-1580.
    PubMed     Abstract available


  1255. O'HARE EA, Yang R, Yerges-Armstrong LM, Sreenivasan U, et al
    TM6SF2 rs58542926 impacts lipid processing in liver and small intestine.
    Hepatology. 2017;65:1526-1542.
    PubMed     Abstract available


  1256. HOU G, Chen L, Liu G, Li L, et al
    Aldehyde dehydrogenase-2 (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP-activated protein kinase signaling in mice.
    Hepatology. 2017;65:1628-1644.
    PubMed     Abstract available


  1257. RAVA M, D'Andrea A, Doni M, Kress TR, et al
    Mutual epithelium-macrophage dependency in liver carcinogenesis mediated by ST18.
    Hepatology. 2017;65:1708-1719.
    PubMed     Abstract available


  1258. WALESKY C, Goessling W
    WNTing no RASt for hepatocellular carcinoma.
    Hepatology. 2017;65:1435-1437.
    PubMed    


  1259. LACKNER C, Bataller R, Burt A, Miquel R, et al
    Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?
    Hepatology. 2017;65:1758-1761.
    PubMed    


  1260. LING Z, Liu X, Cheng Y, Shao L, et al
    Blood microbiota as a potential noninvasive diagnostic biomarker for liver fibrosis in severely obese patients: Choose carefully.
    Hepatology. 2017;65:1775-1776.
    PubMed    


  1261. MARTINEZ J, Tellez L, Albillos A
    Acute variceal bleeding in patients on primary prophylaxis with nonselective beta-blockers: A poor prognosis factor?
    Hepatology. 2017;65:1774.
    PubMed    


  1262. VUPPALANCHI R, Saxena R, Storniolo AMV, Chalasani N, et al
    Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib.
    Hepatology. 2017;65:1762-1764.
    PubMed    


    April 2017
  1263. WON JK, Yu SJ, Hwang CY, Cho SH, et al
    Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
    Hepatology. 2017 Apr 25. doi: 10.1002/hep.29237.
    PubMed     Abstract available


  1264. ZHENG X, Xu F, Liang H, Cao H, et al
    SIRT1/HSF1/HSPs Pathway is Essential for Exenatide-alleviated Lipid-induced Hepatic Endoplasmic Reticulum Stress.
    Hepatology. 2017 Apr 25. doi: 10.1002/hep.29238.
    PubMed     Abstract available


  1265. SRIVASTAVA J, Robertson CL, Ebeid K, Dozmorov M, et al
    A Novel Role of Astrocyte Elevated Gene-1 (AEG-1) in Regulating Non-alcoholic Steatohepatitis (NASH).
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29230.
    PubMed     Abstract available


  1266. LI S, Dou X, Ning H, Song Q, et al
    SIRT3 Acts As a Negative Regulator of Autophagy Dictating Hepatocyte Susceptibility to Lipotoxicity.
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29229.
    PubMed     Abstract available


  1267. KOKUDO T, Hasegawa K, Matsuyama Y, Takayama T, et al
    Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey.
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29225.
    PubMed     Abstract available


  1268. BARGE S, Ziol M, Nault JC
    Autoimmune-like chronic hepatitis induced by olmesartan.
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29228.
    PubMed     Abstract available


  1269. PEMBROKE T, Sebastiani G
    Hepatic steatosis, hepatitis C and human immunodeficiency viruses: A complex interplay.
    Hepatology. 2017 Apr 19. doi: 10.1002/hep.29218.
    PubMed    


  1270. KUO F, Park J, Chen A
    Coil Assisted Retrograde Transvenous Obliteration and Partial Splenic Artery Embolization for Hepatic Encephalopathy.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29212.
    PubMed    


  1271. SONG Y, Liu C, Liu X, Trottier J, et al
    H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29209.
    PubMed     Abstract available


  1272. LI Y, Song Y, Zhao M, Guo Y, et al
    A Novel Role for CRTC2 in Hepatic Cholesterol Synthesis via SREBP-2.
    Hepatology. 2017 Apr 10. doi: 10.1002/hep.29206.
    PubMed     Abstract available


  1273. ONO A, Goossens N, Finn RS, Schmidt WN, et al
    Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203.
    PubMed    


  1274. ZHANG H, Li ZL, Xing H, Wu MC, et al
    Hepatocellular Carcinoma Surveillance: Sometimes Just Specialists' Incidental Behavior?
    Hepatology. 2017 Apr 7. doi: 10.1002/hep.29200.
    PubMed    


  1275. KIM KH, Choi S, Zhou Y, Kim EY, et al
    Hepatic FXR/SHP Axis Modulates Systemic Glucose and Fatty Acid Homeostasis in Aged Mice.
    Hepatology. 2017 Apr 5. doi: 10.1002/hep.29199.
    PubMed     Abstract available


  1276. DUFOUR JF
    Hepatology Highlights.
    Hepatology. 2017;65:1081-1083.
    PubMed    


  1277. HADJIHAMBI A, De Chiara F, Hosford PS, Habtetion A, et al
    Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease.
    Hepatology. 2017;65:1306-1318.
    PubMed     Abstract available


  1278. BALIGAR P, Kochat V, Arindkar SK, Equbal Z, et al
    Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human alpha1-antitrypsin.
    Hepatology. 2017;65:1319-1335.
    PubMed     Abstract available


  1279. SEBODE M, Weidemann S, Wehmeyer M, Lohse AW, et al
    Anti-TNF-alpha for necrotizing sarcoid granulomatosis of the liver.
    Hepatology. 2017;65:1410-1412.
    PubMed     Abstract available


  1280. MITRA A, Yan J, Xia X, Zhou S, et al
    IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition+ metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient beta2-spectrin+/- mice.
    Hepatology. 2017;65:1222-1236.
    PubMed     Abstract available


  1281. HALL Z, Bond NJ, Ashmore T, Sanders F, et al
    Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
    Hepatology. 2017;65:1165-1180.
    PubMed     Abstract available


  1282. PETTA S, Wong VW, Camma C, Hiriart JB, et al
    Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
    Hepatology. 2017;65:1145-1155.
    PubMed     Abstract available


  1283. LO GH
    The interval of endoscopic variceal ligation: The shorter the better?
    Hepatology. 2017;65:1414-1415.
    PubMed    


  1284. SARITAS U, Ustundag Y
    One- or two-week interval for variceal banding after bleeding: Which one to choose?
    Hepatology. 2017;65:1415-1416.
    PubMed    


  1285. SOOKOIAN S, Pirola CJ
    Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention.
    Hepatology. 2017;65:1417-1419.
    PubMed    


    March 2017
  1286. TOHME S, Yazdani HO, Liu Y, Loughran P, et al
    Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth via HMGB1 and TLR9 interaction.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29184.
    PubMed     Abstract available


  1287. LIU P, Ge M, Hu J, Li X, et al
    A functional mTORC1 signaling is indispensable for c-Myc driven hepatocarcinogenesis.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29183.
    PubMed     Abstract available


  1288. SORIA A, Fabbiani M, Lapadula G, Gori A, et al
    Unexpected viral relapses in HCV-infected patients diagnosed with hepatocellular carcinoma during treatment with DAAs.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29181.
    PubMed    


  1289. SORIANO G, Bajaj JS
    Grading the range of hepatic encephalopathy from overt to covert: Animals to the Rescue!
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29186.
    PubMed    


  1290. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Abstract available


  1291. SASAKI R, Devhare PB, Steele R, Ray R, et al
    Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29170.
    PubMed     Abstract available


  1292. NAHON P, Seror O, Durand-Zaleski I
    Reply to: <<Screening for Hepatocellular carcinoma: A drug safety issue>>.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29174.
    PubMed    


  1293. BRAILLON A
    Screening for hepatocellular carcinoma: A drug safety issue.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29173.
    PubMed    


  1294. DE MATTOS AZ, Miozzo SA, Tovo CV, de Mattos AA, et al
    Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29132.
    PubMed    


  1295. MOLLER S, Hove JD
    Assessment of systolic function in the evaluation of patients with cirrhosis.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29163.
    PubMed    


  1296. LI X, Liu R, Yang J, Sun L, et al
    The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2-/- mice.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29145.
    PubMed     Abstract available


  1297. MAIERS JL, Kostallari E, Mushref M, deAssuncao TM, et al
    The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice.
    Hepatology. 2017;65:983-998.
    PubMed     Abstract available


  1298. ZHU B, Wei L, Rotile N, Day H, et al
    Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model.
    Hepatology. 2017;65:1015-1025.
    PubMed     Abstract available


  1299. ALONSO EM, Horslen SP, Behrens EM, Doo E, et al
    Pediatric acute liver failure of undetermined cause: A research workshop.
    Hepatology. 2017;65:1026-1037.
    PubMed     Abstract available


  1300. KISSELEVA T
    The origin of fibrogenic myofibroblasts in fibrotic liver.
    Hepatology. 2017;65:1039-1043.
    PubMed     Abstract available


  1301. KARVELLAS CJ, Speiser JL, Tremblay M, Lee WM, et al
    Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure.
    Hepatology. 2017;65:938-949.
    PubMed     Abstract available


  1302. MUSSO G, Cassader M, Paschetta E, Gambino R, et al
    Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges.
    Hepatology. 2017;65:1058-1061.
    PubMed    


  1303. ESHRAGHIAN A
    High prevalence of nonalcoholic fatty liver disease in the middle east: Lifestyle and dietary habits.
    Hepatology. 2017;65:1077.
    PubMed    


    February 2017
  1304. ZUBIETE-FRANCO I, Fernandez-Tussy P, Barbier-Torres L, Simon J, et al
    Deregulated neddylation in liver fibrosis.
    Hepatology. 2017;65:694-709.
    PubMed     Abstract available


  1305. KAIKKONEN JE, Wurtz P, Suomela E, Lehtovirta M, et al
    Metabolic profiling of fatty liver in young and middle-aged adults: Cross-sectional and prospective analyses of the Young Finns Study.
    Hepatology. 2017;65:491-500.
    PubMed     Abstract available


  1306. GOLDRING C, Antoine DJ, Bonner F, Crozier J, et al
    Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury.
    Hepatology. 2017;65:710-721.
    PubMed     Abstract available


  1307. HU H, Zhu W, Qin J, Chen M, et al
    Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis.
    Hepatology. 2017;65:515-528.
    PubMed     Abstract available


  1308. MA JZ, Yang F, Zhou CC, Liu F, et al
    METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6 -methyladenosine-dependent primary MicroRNA processing.
    Hepatology. 2017;65:529-543.
    PubMed     Abstract available


  1309. DEL CHIERICO F, Nobili V, Vernocchi P, Russo A, et al
    Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.
    Hepatology. 2017;65:451-464.
    PubMed     Abstract available


  1310. HATTING M, Tacke F
    From NAFLD to HCC: Is IL-17 the crucial link?
    Hepatology. 2017;65:739-741.
    PubMed    


  1311. SINTUSEK P, Dhawan A
    Lipid and copper metabolism in humans with wilson disease: Enigmatic relationship.
    Hepatology. 2017;65:753-755.
    PubMed    


  1312. THIELE M, Madsen BS, Krag A
    Is liver stiffness equal to liver fibrosis?
    Hepatology. 2017;65:749.
    PubMed    


    January 2017
  1313. WANG Y, Aoki H, Yang J, Peng K, et al
    The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29076.
    PubMed     Abstract available


  1314. ARORA P, Basu A, Schmidt ML, Clark GJ, et al
    NS5B Promotes Degradation of the NORE1A Tumor Suppressor to Facilitate Hepatitis C Virus Replication.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29049.
    PubMed     Abstract available


  1315. BJORNSSON ES, Jonasson JG
    Idiosyncratic drug-induced liver injury associated with bile duct loss and vanishing bile duct syndrome: Rare but has severe consequences.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29040.
    PubMed    


  1316. MARONI L, Hohenester SD, van de Graaf SF, Tolenaars D, et al
    Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice.
    Hepatology. 2017 Jan 5. doi: 10.1002/hep.29029.
    PubMed     Abstract available


  1317. ALCARAZ-QUILES J, Titos E, Casulleras M, Pavesi M, et al
    Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure.
    Hepatology. 2017;65:202-216.
    PubMed     Abstract available


  1318. DECARIS ML, Li KW, Emson CL, Gatmaitan M, et al
    Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.
    Hepatology. 2017;65:78-88.
    PubMed     Abstract available


  1319. NAVARRO VJ, Khan I, Bjornsson E, Seeff LB, et al
    Liver injury from herbal and dietary supplements.
    Hepatology. 2017;65:363-373.
    PubMed     Abstract available


  1320. WANG J, Koh HW, Zhou L, Bae UJ, et al
    Sirtuin 2 aggravates postischemic liver injury by deacetylating mitogen-activated protein kinase phosphatase-1.
    Hepatology. 2017;65:225-236.
    PubMed     Abstract available


  1321. AJMERA V, Perito ER, Bass NM, Terrault NA, et al
    Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.
    Hepatology. 2017;65:65-77.
    PubMed     Abstract available


  1322. LEUNG JC, Loong TC, Wei JL, Wong GL, et al
    Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.
    Hepatology. 2017;65:54-64.
    PubMed     Abstract available


  1323. MEDINA-CALIZ I, Robles-Diaz M, Lucena MI, Andrade RJ, et al
    Drug-induced liver and skin reactions: In need of a consensus definition.
    Hepatology. 2017;65:391.
    PubMed    


  1324. LIU K, Xu W, Wong VW
    Serum biomarkers for nonalcoholic fatty liver disease: Are we there yet?
    Hepatology. 2017;65:8-11.
    PubMed    


  1325. LO GH
    The use of esophageal stent in controlling acute refractory variceal bleeding.
    Hepatology. 2017;65:385-386.
    PubMed    


    December 2016
  1326. WANG KS, Tiao G, Bass LM, Hertel PM, et al
    Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29019.
    PubMed     Abstract available


  1327. QIU YL, Gong JY, Feng JY, Wang RX, et al
    Defects in MYO5B are associated with a spectrum of previously undiagnosed low gamma-glutamyltransferase cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29020.
    PubMed     Abstract available


  1328. SAVALE L, Sattler C, Coilly A, Conti F, et al
    Long-term outcome in liver transplantation candidates with portopulmonary hypertension.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28990.
    PubMed     Abstract available


  1329. BONKOVSKY HL, Kleiner DE, Gu J, Odin JA, et al
    Clinical Presentations and Outcomes of Bile Duct Loss caused by Drugs and Herbal and Dietary Supplements.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28967.
    PubMed     Abstract available


  1330. JANSEN PL, Ghallab A, Vartak N, Reif R, et al
    The ascending pathophysiology of cholestatic liver disease.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28965.
    PubMed     Abstract available


    September 2016
  1331. KULKARNI SR, Soroka CJ, Hagey LR, Boyer JL, et al
    Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid fed mouse model of cholestasis.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28826.
    PubMed     Abstract available


    August 2016
  1332. GONZALES E, Taylor SA, Davit-Spraul A, Thebaut A, et al
    MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28779.
    PubMed     Abstract available


    July 2016
  1333. VERGANI D, Mieli-Vergani G
    Mouse model of primary biliary cholangitis with a striking female predominance: A new powerful research tool.
    Hepatology. 2016 Jul 7. doi: 10.1002/hep.28718.
    PubMed    


    June 2016
  1334. ARAB JP, Karpen SJ, Dawson PA, Arrese M, et al
    Bile acids & nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
    Hepatology. 2016 Jun 30. doi: 10.1002/hep.28709.
    PubMed     Abstract available


  1335. SPENGLER EK, Kleiner DE, Fontana RJ
    Vemurafenib-induced Granulomatous hepatitis.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28692.
    PubMed    


  1336. FENG S, Demetris AJ, Spain KM, Kanaparthi S, et al
    Five year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R.
    Hepatology. 2016 Jun 15. doi: 10.1002/hep.28681.
    PubMed     Abstract available


    April 2016
  1337. WU N, Meng F, Invernizzi P, Bernuzzi F, et al
    The secretin/secretin receptor axis modulates liver fibrosis through changes in TGF-beta1 biliary secretion.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28622.
    PubMed     Abstract available


    March 2016
  1338. ALVARO D, Gaudio E
    Biliary tree stem cell subpopulations.
    Hepatology. 2016 Mar 12. doi: 10.1002/hep.28546.
    PubMed    


    February 2016
  1339. WU W, Patel A, Kyostila K, Lohi H, et al
    Genome-wide Association Study in Mice Identifies Loci Affecting Liver-related Phenotypes Including Sel1l Influencing Serum Bile Acids.
    Hepatology. 2016 Feb 9. doi: 10.1002/hep.28495.
    PubMed     Abstract available


  1340. OIKAWA T
    Cancer Stem Cells and Their Cellular Origins in Primary Liver and Biliary Tract Cancers.
    Hepatology. 2016 Feb 5. doi: 10.1002/hep.28485.
    PubMed     Abstract available


    November 2015
  1341. FERNANDEZ J, Tandon P, Mensa J, Garcia-Tsao G, et al
    Antibiotic prophylaxis in cirrhosis: Good and bad.
    Hepatology. 2015 Nov 3. doi: 10.1002/hep.28330.
    PubMed     Abstract available


    July 2015
  1342. HENRY ZH, Northup PG
    Baclofen for the treatment of muscle cramps in patients with cirrhosis: A new alternative.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27988.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: